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Summary
Anthrax is a disease of animals and man caused by Bacillus anthracis. The 
Protective Antigen (PA) of B. anthracis can induce protective immunity and is a candidate 
vaccine antigen, but current vaccines are not ideal. Live vaccine vectors, such as the 
aromatic amino acid Salmonella mutants, are capable of delivering anugens to the immune 
system and stimulating immune responses. The aim of this project was to develop a 
recombinants, ryphimurium expressing PA and to evaluate the protective immune responses 
generated in mice.
Native PA was expressed at low levels in S. typhimurium. Various approaches to 
increasing expression were tried including changing the promoter, expressing the 63 kDa 
C-tcrminal fragment of PA as a fusion protein and expressing this fragment after a signal 
sequence. Altering the B. anthracis PA promoter to the E. coli lac promoter increased 
expression of PA which was exported with the B. anthracis signal sequence. The 
cytoplasmically located PA fragment was unstable and was not successfully exported by the 
signal sequence.
The recombinant organisms were evaluated to select one for in vivo study. Many 
phagemids were unstable without ampicillin selection and an attempt to stabilise one with 
the cer region was not successful. Two constructs were chosen for animal work.
Recombinant PA was shown to induce partial protection, comparable to native PA, 
when both were purified and administered with adjuvant. Mice were vaccinated 
intravenously with the live S. typhimurium constructs and subsequent challenged with 
virulent B. anthracis spores. The PA-expressing-5. typhimuruon only colonised at low levels 
but induced partial protective responses. These protective responses occurred without 
detectable anti-PA antibodv
This work showed that PA expressed by S. typhimurium can induce protective 
responses even when only low colonisation occurs. It shows the potential for this approach 
and suggests that further work to stabilise and increase the expression of PA would be 
worthwhile.
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Chapter 1. Introduction
1.1 Anthrax
Anthrax is an infectious disease known since antiquity. It is thought to be 
responsible for the fifth plague o f Egypt and more recently in 1613 the 'Black bain' plague 
in Europe in which 60,000 people are believed to have died (Whitford, 1979). It is nearly 
universal in its geographic distribution and, although primarily a disease of herbivores, it can 
affect many species including man (Christie, 1987). Accurate figures on the incidence are 
hard to obtain as most cases occur in under-developed regions (Fujikura, 1990). In 1985, 
of 168 countries supplying data to the Food and Agriculture Organization, 83 reported 
bovine anthrax. 56 ovine, 25 equine and 21 porcine (Turnbull, 1990). Comprehensive recent 
global figures on human cases are not available (Fujikura, 1990). World Health Organisation 
(WHO) reports use the estimates o f Glassman (cited in Whitford, 1979) o f 20,000 to 100,000 
human cases per year. In Zimbabwe a massive outbreak occurred during 1978-80 with 9711 
human cases and 151 deaths. Even in Europe there was an average o f 429 human cases per 
annum during the period 1979-84 (Turnbull, 1990). Anthrax can now be controlled in man 
and domesticated animals by the use of vaccines, but in wild herbivores it still causes major 
epidemics. In endangered species anthrax can have a significant effect. In the Etosha 
National Park, Namibia, anthrax was thought to be responsible for the decline in numbers 
of the blue wildebeest from 30,000 in 1965 to 2,500 in 1978. Between 1959 and 1962 
approximately 25% o f the South African population o f roan antelopes (estimated at 320) 
were killed by anthrax (Turnbull, 1990). The WHO have a Working Group monitoring 
anthrax disease control worldwide.
1.1.1 Bacillus aruhracis
Anthrax is caused by Bacillus anthracis, a Gram positive, non-motile, facultatively 
anaerobic spore-forming organism. The vegetative bacteria, when recovered from infected 
animals, are rod-shaped 3-8 fim long and enclosed by a thick polypeptide capsule visible 
under the microscope with certain stains (Christie, 1987). In the presence of oxygen  
sp o lia tion  occurs. The spores arc ellipsoid, non-bulging and central. There is a considerable 
difference between the resistance o f the vegetative and spore forms. The vegetative cells arc 
easily killed by heating to 55°C for 1 hour, and by most disinfectants and antibiotics. In an 
unopened carcase the vegetative cells arc destroyed during putrefaction within 80 hours at 
summer temperatures (Christie, 1987). On the other hand the spores o f B. anthracis are
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extremely resistant to heat, cold, ultraviolet light, desiccation, high and low pH, chemical 
disinfectants and the products of other bacteria (Turnbull, 1990). For instance, they can 
survive 160“C dry heal for one hour, 68 years in the dry state and up to 60 years in soil. 
Moist heat is more effective and autoclaving at 121°C for 15 mins will kill all spores 
(Christie, 1987).
1.1.2 Anthrax in Animals
Herbivores usually acquire the disease by ingesting spores from contaminated soil. 
This leads to the gastro-intestinal form of the disease where the spores germinate within a 
few hours and the bacteria rapidly develop a capsule (Turnbull, 1990). A local lesion forms 
with considerable oedema. In susceptible animals the bacteria multiply and invade the blood 
leading to bacteraemia, toxaemia and death. The bacilli are found in large numbers in the 
blood and tissues o f the animals and, if the bacteria become exposed to the air (in discharges 
from the animal or due to scavenger attack), they sporulate and contaminate the local area 
(Turnbull, 1990). In herbivores the disease is often hyperacute and the animals may be 
found dead. Animals may also be infected through the skin via wounds or by biting insects.
Other species are more resistant to anthrax, the course o f  infection may be longer 
and oedema may be more pronounced. Carnivores are particularly resistant and may often 
have antibody to anthrax toxin suggesting recovery following infection (Turnbull, 1990).
Contaminated feedstuffs or fertilizers and industrial waste from the wool and leather 
industries are also important in the epizootiology of the disease (Christie, 1987).
1.1-3 Anthrax in Man
Anthrax in man is often classified as either industrial or non-industrial. Industrial 
anthrax arises from contact with contaminated animal products. Hides, skins, wool, hair, 
bones, hooves and horn arc all implicated. Non-industrial anthrax occurs in farmers, 
pathologists and veterinarians as a result o f close contact with infected animals
(Christie. 1987).
The disease takes one of three forms (Knudson, 1986). Most human cases are of 
cutaneous anthrax contracted from direct contact with infected material and show the 
development of the characteristic black eschar or carbuncle. The word anthrax is derived 
from a Greek word meaning charcoal (Whitford. 1979). With treatment most cutaneous
3
Chapter 1. Introduction
cases survive. Pulmonary anthrax is usually caused by industrial exposure to aerosolized 
spores. The spores are aerosolized dunng handling o f contaminated material such as hides 
and hair. Illness begins 2-5 days after exposure and within hours the patient is acutely ill. 
Death occurs in 2-3 days and treatment is usually unrewarding once clinical signs develop 
(Hamblcton el al., 1984). The third form is intestinal anthrax and this is very rare. It 
usually results from eating meat from anthrax carcases (Lakshmi & Kumar. 1992). The 
eschar develops within the gastrointestinal tract and, if diagnosed early enough, treatment can 
be successful (Knudson, 1986).
1.1.4 Anthrax Virulence
The virulence of B. anthracis is attributed to two factors, the polypeptide capsule and 
a tripartite exotoxin. Virulent strains contain two large plasmids pXOl (170-185 kbp) and 
pX 02 (90-95 kbp) (Leppla, 1991). The genes for the toxin components (see Section 1.1.5) 
arc found on pXOl and the capsular genes (capA,B and Q  are on pX 02. B. anthracis 
strains vary in their virulence not only based on the presence o f these plasmids but also 
between strains containing both plasmids. It is not clear if the difference is due to genetic 
variation between the plasmids, or if the strains have chromosomal differences. 
Chromosomal elements can affect virulence, possibly by regulating toxin or capsule 
expression from the plasmids (Wclkos. 1991).
The gamma-linked poly-D-glutamic acid capsule is thought to play a role in the 
establishment o f the infection. Capsulated strains resist phagocytosis in vitro (Whitford, 
1979) and inscrtional inactivation of the cap  genes increases the ability o f neutrophils to 
phagocytosc the bacilli (Wclkos, 1991). Regulation of the expression of the capsule is 
complex and affected by regions both on the plasmid containing the cap genes and the 
chromosome (W clkos, 1991). Capsule production is influenced by the medium composition 
and C 0 2 level that the culture is grown in (Bartkus & leppla, 1989). Encapsulated, non- 
toxigenic strains arc attenuated but do not induce protective immune responses, whereas non- 
cncapsulalcd, toxigenic strains arc also attenuated but do induce protective responses (Ivins 
et al., 1986). Therefore the capsule is not considered an important protective antigen.
The role o f anthrax toxin is less clear but is generally accepted to be the cause o f 
death (Lcppla, 1991). The pioneering work in this field was carried out during the 1950s 
and 60s. It was shown that if  one administered streptomycin to guinea pigs infected with
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B. anihracis, the animals could be saved if the antibiotic was given early enough. If the 
antibiotic was given later in infection, even though the blood could be sterilized , the animals 
would still die (Smith & Keppie, 1954). Smith also showed that sterile plasma obtained 
from animals dying of anthrax was lethal when injected into mice and guinea pigs- It was 
then shown that the bacteria-frce extracellular products o f B. anihracis were immunogenic 
(Gladstone, 1946). Over the next 10-15 years the complex nature of the toxin was identified, 
although many questions were raised as to the mechanism of action (Smith & Stoner, 1967). 
Even after 30 years, the answers to som e of these questions is still awaited (Leppla, 1991).
As the toxin plays a central role in both virulence and protection it is discussed in 
more detail.
1-1-5 Anthrax Toxin
The anthrax toxin is composed o f three proteins. Protective Antigen (PA), Lethal 
Factor (LF) and Oedema Factor (also spelt Edema Factor, EF). The genes for all three have 
been cloned and sequenced (Welkos et al. , 1988; Bragg & Robertson, 1989; Escuyer el al.,
1988). PA is the cell binding component which promotes the internalization of either LF 
or EF. The combination of PA and LF is referred to as Lethal Toxin, and PA and EF is 
called Edema Toxin. Edema Toxin causes oedema when injected intradermally in animals 
and EF is a calmodulin dependent adenylate cyclase (Leppla, 1982). Edema toxin has an 
obvious role in creating the extensive oedema seen in some manifestations o f the disease and 
also has a direct effect on neutrophils and this may inhibit the mobilization and activation 
of phagocytes critical for the clearance o f the bacteria (Leppla. 1991). When injected 
intravenously in susceptible animals Lethal Toxin causes rapid death but its mechanism of 
action is unknown although it is assumed to have an enzymatic action within the cytosol 
(Lcppla, 1991; Fricdlander et al., 1993). LF has been reported to have an homologous 
region to the zinc-binding site o f mctalloprotcascs (KJimpel el al., 1993). Lethal toxin may 
help to establish the infection by incapacitating phagocytes and causing cell death and is 
considered responsible for the lethal action of anthrax toxin (Leppla, 1991).
B. anthracis produces low yields of toxin in most rich media, whereas bacteria 
grown in certain minimal media produce increased levels o f toxin if bicarbonate is added and 
the culture is grown under C 0 2 (Bartkus & Leppla, 1989). Trans-acting factors on plasmid 
pXOl arc required for regulation o f  the transcription o f the PA gene (Bartkus & Leppla,
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1989) and maximal production occurs in early stationary phase (Calaldi et al., 1992). Lethal 
toxin is produced from early logarithmic through stationary phases when cultured in vitro 
(Ezzell et al., 1984).
A model for the action o f anthrax toxin has been proposed (Leppla, 1991) and is 
illustrated in Figure 1.1. PA is secreted from B. anthracis as an 83 kDa protein (PA-83). 
PA-83 binds to a specific cell surface receptor where it is cleaved by a trypsin-like protease 
into 63 and 20 kDa fragments (PA-6.3 and PA-20). PA-63 remains bound to the receptor 
and loss o f PA-20 reveals a specific binding site for which the secreted EF and LF compete. 
The PA-63 in a complex with either EF or LF is internalized by endocytosis and LF or EF 
is transferred into the cytosol where they have their toxic action. Although this model may 
be applicable to some tissue areas, evidence exists that the PA-83 becomes cleaved by a 
serum protease and can form complexes o f PA-63 and LF prior to cell binding. It is 
suggested that a penlam erof PA-63 may complex with each LF molecule (Ezzell & Abshire, 
1992).
Owing to the central role o f PA in the toxic action, and the fact that it is non-toxic 
itself, PA is recognised as an important antigen in vaccine production.
1.1.6 Physical Control Methods
Apart from vaccination, anthrax cases in both animals and man can be reduced by 
minimising exposure to B. anthracis spores (Christie, 1987). The carcases o f animals which 
have died o f anthrax arc the main sources o f spores and disposal o f carcases is defined by 
law in many countries. As long as the carcase is unopened the B. anthracis will not 
sporulate thus post-mortems should not be carried out. The carcase should be buried with 
quicklime or incinerated. Proper carcase disposal is expensive and may not be practical in 
developing countries. It is also difficult to arrange for wild animal populations. Once a 
pasture is contaminated, it is time-consuming to decontaminate it. Chemicals such as 
formaldehyde have been used for this purpose (Manchec et al., 1983), but in general 
susceptible animals should be kept from grazing on contaminated pasture.
For man, infection is usually acquired from contaminated animal by-products. 
Reducing exposure to spores has led to a decrease in human cases. This is usually 
accomplished by sterilising contaminated products such as raw bones, hair and wool. 
Disinfection o f imported wool was carried out at a Government Wool Disinfection Station
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Figure 1.1 Model for the action o f anthrax toxin on cells
The diagrams show one model for the binding and internalization o f anthrax toxin
into a cell. From Leppla (1991).
A. PA is secreted from B. anthracis as an 83 kDa protein. PA binds to a 
specific cell-surface receptor.
B. One model has 83 kDa PA cleaved on the cell surface by a trypsin-like 
protease into 63 and 20 kDa fragments. Cleavage of the 20 kDa fragment 
reveals a specific binding site for which the secreted EF and LF compete.
C. LF or EF binds to 63 kDa PA and then it is internalized by endocytosis and 
LF or EF is transferred into the cytosol.
/
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Figure 1.1 Model for the action o f anthrax toxin on cells
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in Liverpool from 1921 and credited with a large reduction in human cases (Whitford, 1979). 
Meat from infected animals should not be consumed although this often occurs in third 
world countries (Turnbull, 1990; Lakshmi & Kumar, 1992).
Physical control methods are expensive to implement and so may not be practical 
in developing countries. The cost-benefit o f large scale disinfection of bulk raw materials 
must be carefully assessed (Christie. 1987). Wild animal populations cannot be protected 
by proper carcase disposal and much of the pasture used by animals in Africa is 
contaminated (Turnbull, 1990). In these circumstances other methods of control, such as 
vaccination, may provide a better solution.
1.1.7 Anthrax Treatment
Penicillin is the drug o f choice and most isolates o f B. anthracis are susceptible to 
this antibiotic (Turnbull, 1990). As cutaneous anthrax has a chronic course, oral treatment 
is usually successful. In pulmonary anthrax more aggressive therapy must be given as, once 
symptoms develop, treatment is often unsuccessful (Knudson, 1986). Successful 
management o f intestinal anthrax depends on early diagnosis. If for any reason penicillin 
is not indicated, then tetracyclines, erythromycin or streptomycin can be used. Anti-anthrax 
serum was advocated before antibiotics became available. The serum was raised in horses, 
goats, donkeys, cattle and sheep (Knudson. 1986). Up to 1 litre of anti-anthrax serum was 
given and anaphylactic reactions were common.
1.1-9 Anthrax Vaccines
Animal anthrax vaccines were first introduced on a wide scale by Pasteur in 1881 
(Turnbull, 1991). His vaccine consisted of live spores, partially attenuated by culture at 
elevated temperatures. This cures a proportion o f the bacteria of plasmid pXOl, although 
it is now believed that the immunogenicity of this vaccine is attributable to the small number 
of toxigenic bacteria which were not cured of plasmid pXOl (Whilford, 1979). Saponin was 
added to provoke a violent immune response. These early vaccines still retained some 
virulence and varied from batch to batch. In 1937 Sterne developed an attenuated live spore 
vaccine which still remains in use today (Hamblcton el al., 1984). His strain (34F2) had 
been cured of the pX 02 plasmid and so did not produce a capsule but was still toxigenic. 
Its wide veterinary use throughout the world has dramatically reduced outbreaks o f anthrax
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in domesticated animals and contributed to a reduction in human cases by reducing human 
contact with contaminated animal products (Tunbull, 1991).
In Russia a live spore vaccine derived from Sterne's strain has been used in man, but 
live spore vaccines are not considered safe enough for human use in the West. Live spore 
vaccines can vary from batch to batch, are contraindicated in many medical conditions and 
require careful use (Turnbull, 1991). In the 1950s the UK developed an alum-precipitated 
cell-free filtrate o f Sterne strain cultures grown so as to maximise the PA coatent. In the 
1960s the US developed a similar aluminium-hydroxide adsorbed vaccine (Hambielon et al.. 
I9K4). The PA is considered to be the major antigen in these vaccines. These vaccines are 
administered by multiple parenteral vaccinations and cause side-effects ranging from local 
to systemic reactions. It is difficult to assess the impact of these human vaccines on the 
reduction of anthrax cases as they were introduced at the same time as improved industrial 
practices were reducing the level o f anthrax cases. One study did find the alum precipitated 
vaccine to be 92.5% effective in an industrial setting (Brachman et al., 1962). Animal 
studies have however suggested that these vaccines arc not fully effective against challenge 
with large doses of virulent organisms, particularly by the aerosol route (Turnbull, 1991).
Satisfaction with the current veterinary vaccine used in domesticated animals is not 
matched with regard to the human vaccine. The long course o f  primary injections, need for 
annual boosters, side-effects and concerns about the protective efficacy o f  the vaccine have 
all encouraged research into new vaccines (Hamblcton et aL, 1984; Turnbull. 1991). There 
is also a need for an alternative vaccine for use in wild animals, particularly in Africa, where 
anthrax is a major problem in some areas and a significant killer of endangered species. 
Although it is possible to administer the current veterinary vaccine by darting individual 
animals with a syringe projectile containing vaccine, this is costly and can only be used in 
certain restricted areas. Ideally, a cheap oral vaccine which can be administered in food bait 
is required (Turnbull, 1991).
L 2  Vaccine Requirements
The ideal vaccine would be a single dose oral vaccine giving life-long protective 
immunity without side-effects. It should be cheap to produce and stable in storage. 
Originally there was little pressure to develop a new human vaccine. The current vaccines 
arc adequate in controlling industrial anthrax when improved industrial safety measures are
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also in cffccl. The level o f  anthrax in domesticated animals is controlled by the live spore 
vaccine and so  reduces the infectious burden in animal products and thus the exposure risk 
to man. Although it is considered unsatisfactory to administer crude and undefined 
preparations such as the culture supernatant used in the human vaccines, there was little 
pressure to develop a new vaccine until, in the 1980s, Western countries became concerned 
about the potential use o f an aerosol o f virulent anthrax spores as a Biological Warfare 
weapon. Concerns about the efficacy o f the current vaccines against such challenges and the 
other problems associated with the current vaccines led to much research on anthrax and 
potential replacement vaccines. The increasing interest in wild life conservation also directed 
funding towards a vaccine solution for African wildlife.
1.2.1 Experimental Work
During the 1980s the toxin components were cloned and sequenced (Welkos et al., 
1988; Bragg & Robertson, 1989; Escuyer et a!., 1988). The genetics o f B. anthracis were 
clarified and a number o f  conclusions reached. It was shown that the toxin, or part of the 
toxin, was required for protective immunity. The Sterne strain does not possess the capsule 
but can induce high levels o f protective immunity (Turnbull, 1991). If strains of non- 
toxigenic B. anthracis were used as live vaccines they conferred no protection (Ivins & 
Welkos, 1988). PA was found to be the main immunogen and animal data has shown that 
a strong immune response to PA alone can protect against challenge with even the most 
virulent strains (Ivins & Welkos, 1988). Finally, it has been shown that protective immunity 
is not solely a function o f  anti-PA antibody levels as immunity to anthrax, following Sterne 
spore vaccination, can occur in the presence of low anti-PA titres (Ivins et al., 1990; 
Turnbull, 1991). Two possibilities for the protective mechanism have been suggested. 
Firstly cell-mediated immunity (CMI) may be important as adjuvants that are known to 
stimulate CMI enhance the protective effect o f PA vaccines (Ivins et al., 1992). The 
aluminum compound adjuvants used in the human PA vaccines arc known to augment the 
humoral response and not the CMI (Gupta et al.. 1993) and this failure to stimulate CMI 
may be responsible for their lack o f  effectiveness. Secondly, current PA vaccines may not 
stimulate the protective class o f antibodies produced by the Sterne strain. The UK and US 
vaccines may not present PA to the immune system in the native conformation. The work 
of Ezzcll & Abshirc (1992) has suggested that PA may be complexed to LF in the scrum.
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The epitopes expressed by this complex may be quite different to that of adsorbed or 
precipitated PA. Thus, although the anti-PA antibody litre may be lower following live 
strain vaccination, the antibodies present may have a higher affinity for the natural toxin 
complex. This possibility is considered less likely as strongly adjuvanted PA alone can be
protective.
The work described above suggests that a suitable vaccine could be made using PA 
alone, but it must be presented to the immune system such that protective responses are 
stimulated.
1.2.2 A pproaches to new vaccines
There are three main approaches to developing a new vaccine.
Firstly there is the possibility o f a subunit vaccine based around PA. Some o f the 
unpleasant side-effects o f the current vaccine may be attributable to components other than 
PA in the vaccine and so a purified PA vaccine may be less reactogenic. Strongly 
adjuvanted PA has been shown to confer protective immunity in animals but the adjuvants 
used are not suitable for humans and produce severe side-effects. Various novel adjuvants 
have been tried such as TriMix or Detox (Ribi Immunochcm Research Inc.. Hamilton, 
Montana, USA) and these have produced good immunity but there are still concerns about 
their toxicity (Turnbull, 1991). It may prove difficult to separate the strong adjuvanting 
effects o f these compounds from their toxic effects. Much research is taking place in this 
area and a suitable novel adjuvant may become available. PA subunit vaccines may give 
better protection if the PA is configured in the native form. If, as suggested by Ezzcll & 
Abshire (1992), this is as pentamers with a single LF molecule, it may be possible to 
genetically engineer LF so that it is non-toxic but can still bind to PA stably and form the 
naturally configured complex. This complex may stimulate a more protective class o f anti- 
PA antibody than PA alone. A subunit vaccine o f this type might also have the advantage 
that it would be simpler to licence than a live vaccine.
The second approach is to rationally attenuate B. anthracis so as to benefit from the 
success o f the Stcmc animal vaccine, but with a higher degree of safety that is required for 
a human vaccine. An auxotrophic mutant o f the Sterne strain has been constructed and 
tested in animals and found to confer strong protective immunity (Ivins et al., 1990). Such 
an approach has the advantage o f  presenting the full range of the anthrax antigens (less the
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capsule and p X 02  associated proteins) to the immune system. Although PA has been shown 
to induce protective immunity under the right circumstances, other antigens may contribute 
to immunity although efforts to identify such antigens have failed (Ezzell & Abshire, 1988). 
It would o f course be necessary to ensure that the mutant selected could not revert to 
virulence by using several deletions that attenuate independently. Such a mutant might not 
be orally active as the rarity o f the intestinal form o f anthrax is probably related to its low 
infectivity by this route. Therefore a rationally attenuated B. anthracis vaccine might have 
to be administered by injection or scarification.
A  third approach, suggested by Winthcr & Dougan (1984), is to use a live carrier 
vector to target PA to the immune system. Vaccine vectors are used to express heterologous 
gene products. When the vector is administered, not only is there the possibility o f  an 
immune response to the vector, but also to the heterologous protein. As it is known that 
strongly adjuvanted PA alone can protect against anthrax, and the gene for PA is available, 
this approach is practical. PA has been expressed in the related bacterium B. subrilis and 
101“ live spores were able to protect guinea pigs against IM challenge with Ames strain 
B. anthracis (Ivins et al., 1990). This result illustrates the potential for a vector approach. 
If the vector was active orally then this means o f  administration becomes practical. The 
vector used could have important consequences for the nature o f the immune response 
generated. The vector should be chosen to stimulate those arms o f the immune system that 
arc required for protective immunity.
Although subunit vaccines have many advantages over live vaccines, a suitable 
adjuvant has not been identified that can stimulate a strong enough response to PA. An 
attenuated B. anthracis might induce protective immunity but is unlikely to be orally active. 
As PA has been identified as the only antigen needed for protection, it is a candidate antigen 
for expression from a vaccine vector. Living vectors can stimulate strong immune responses 
and some vectors are orally active and so might case vaccine administration. Therefore the 
last approach offers the best potential o f  achieving the ideal vaccine requirements.
U  Vaccine Vectors
The suitability o f many bacteria and viruses as vaccine vectors has been investigated 
over the past decade. In many cases organisms have been considered as vaccine vectors on 
the basis o f the case with which genetic manipulations could be carried out. Other factors
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arc important and include: a full understanding of the organism so that rational decisions can 
be taken over its attenuation and use. its ability to cam  and express foreign genes and 
configure and present the protein antigens appropriately, the safety of the constructs in 
relation to side-effects and reversion to virulence, and the ability o f  the organism to induce 
appropriate protective immune responses.
Some of the organisms that have been considered as vaccine vectors are shown in 
Table 1.1. One of the desirable features of a new vaccine is oral administration. As PA is 
a bacterial antigen it may be more logical to select a bacterial vector. The most promising 
orally active bacterial vector is attenuated Salmonella.
1,3.1 Attenuated Salmonella
When administered orally to mice S. typhimurium invade via the M cells of the 
Pevers patches before moving to the Mediastinal Lymph nodes and then to the liver and 
spleen where they can establish an infection in the reticuloendothelial system (RES) (Carter 
& Collins, 1974). If an attenuated strain is used, then this infection is cleared after several 
weeks, and the animals remain immune to infection with wild type strains (Killar & 
Eisenstein, 1985; Dougan ei a i ,  1988).
In the search for safe live vaccines against Salmonellosis, attention has focused on 
mutant strains which have decreased virulence. The decreased virulence can often be 
associated with the loss of a plasmid or a defective gene. There are two approaches to the 
development of attenuated organisms with defective genes. Firstly it is possible to generate 
random mutations, select for reduced virulence and then investigate the nature of the 
mutation (Edwards & Stocker, 1988; Finlay et al.. 1988). A second approach is to construct 
organisms with specific defects in their genetic material and evaluate the effect. These two 
approaches have identified potential vaccine candidates and some arc listed in Table 1.2.
Plasmidlcss mutants of som e Salmonella strains may have reduced virulence, but 
other strains, such as S. typhi, do not have a virulence plasmid. Auxotrophic mutants arc 
of varying virulence. This allows the degree of attenuation to be selected as required. The 
aromatic amino acid mutants have been extensively studied and are promising candidate 
strains. This class o f mutants is discussed in detail below. Invasion/survival in eukaryotic 
cell mutants have yet to be fully characterised, but have the potential to allow a precise 
degree of invasion before the mutation prevents further steps in the normal invasion cycle.
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|| Organism Comments Reference
Vaccina virus Extensively studied, may 
lead to generalised 
infection in 
immunocompromised 
individuals.
Moss. (1991)
Avipox viruses Cannot replicate in 
mammalian cells. 
Potentially safer than 
Vaccinia.
Anon. (1992)
Adenovirus Administered orally to US 
Army recruits.
WHO. (1990)
Poliovirus Only short epitopes 
expressed.
WHO. (1990)
E. coli Stimulate surface 
immunity unless invasion 
competent.
WHO. (1990); Guzman, 
(1991)
S. typhimurium Animal model for S. typhi 
in humans, orally active, 
extensively studied.
Formal et al., (1981); 
Curtiss. (1990); 
Hormaeche (1991)
S. typhi Attenuated strains as 
vectors for humans.
Cryz. (1992)
Listeria monocytogenes Intracellular pathogen, 
attenuated strains being 
developed, /3-galaclosidasc 
expressed and induces 
weak responses.
Schafer el al., (1992)
Yersinia enterocolitica Orally active, poor 
protection against Yersinia 
challenge but induce 
antibody to expressed 
I.T-B.
O'Gaora, (1990)
BCG Stable, safe, low-cost and 
good cellular immunity, 
difficult to manipulate.
Stover el al., (1991)
Streptococcus gordonii Commensal organism of 
the oral cavity.
Pozzi et al., (1992)
Corynebacterium
pseudotuberculosis
Attenuated strain proposed 
as live vector.
Hodgson et al., (1992)
Tabic 1.1 Candidate vaccine vectors
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C la s s A t te n u a tio n C o m m e n ts  i
P la s m id le s s  m u ta n ts V iru le n c e  p la s m id  c u r e d I la v e  d e c re a s e d  v iru le n c e  b u t  c a n  s t i l l  c a u s e  d i s e a s e  ( J o n e s  e l  1
a t . ,  1 9 8 2 ) . j
A u x o t r o p h ic  m u ta n ts a s d  ( a s p a r ta te  /9 -s e m ia ld e h y d e  
d e h y d r o g e n a s e )  m u ta t io n s
R e q u i r e  d ia m in o p im e lic  a c i d  a n d  a r e  a v i ru le n t  b u t  o n ly  in d u c e  a  
g e n e r a l iz e d  s e c re to ry  im m u n e  re s p o n s e  a n d  li t t le  o r  n o  h u m o ra l  
o r  c e l lu la r  im m u n ity  (C u r t i s s  e l  a t . ,  1 9 8 7 ) .
I 'h y  m in e -d e p e n d e n t  m u ta t io n s O f  r e d u c e d  v iru le n c e  o n ly  ( C u r t i s s .  1 9 9 0 ).
P u r in e  m u ta n ts I^eve l o f  a t te n u a t io n  d e p e n d s  o n  w h e re  in  th e  p a th w a y  th e  
m u ta t io n  is  lo c a te d . M u ta t io n s  b e f o re  th e  in o s in e  
m o n o p h o s p h a te  b r a n c h  p o in t  a r e  o n ly  p a r tia lly  a t te n u a te d ,  a n d  
th o s e  a f te r  m a y  b e  h y p e r a t te n u a te d .  (S ig w a r t  e l a t . ,  1 9 8 9 ; 
( X 'a l l a g h a n  e l  a t . ,  1 9 8 8 ).
A r o m a tic  a m in o  a c id  m u ta n ts M u ta t io n s  in  th e  a r o m a t ic  a m in o  a c id  b io s y n th e s i s  p a th w a y . 
T h e s e  a r e  d is c u s s e d  b e lo w  in  d e ta il .
O th e r s  i n c lu d in g  h is , c y s , p n c B O f  l im i te d  u s e  (C u r t i s s ,  1 9 9 0 )
In v a s io n /s u rv iv a l  in  
e u k a r y o t i c  c e l ls
M u ta n ts  d e f e c t iv e  in  t ra n s c y to s is  
o r  c e l l  a t ta c h m e n t
T n p h o A  m u ta n ts , s e v e ra l  g r o u p s ,  a t te n u a te d  to  v a r y in g  d e g r e e s  
( F in la y  e l  a t . .  1 9 8 8 )
M a c ro p h a g e  c e l l - l i n e  s u rv iv a l M u ta t io n s  a f f e c t in g  s u rv iv a l  w i th in  th e  m a c ro p h a g e  (F i e ld s  e l
a t . ,  1 9 8 6 ) .
A n t ib io t i c  a s s o c ia te d  
m u ta t io n s
S tr e p to m y c in -d e p e n d e n t H ig h  re v e r s io n  f r e q u e n c y ,  p o o r ly  im m u n o g e n ic ,  s e n s i t iv e  to  
ly o p h i l iz a t io n  ( D u P o n t  e l  a t . ,  1 9 7 0 , L e v in e  e l  a t . ,  1 9 7 6 ) .
M e ta b o l ic - d r i f t  m u ta t io n s N a l/R i f /H s t  s ta b le  s t r a in  u s e d  a s  a  R u s s ia n  s h e e p  v a c c in e  ( L in d e  
e l  a t . .  1 9 9 2 )
T e m p e r a tu r e - s e n s i t iv e
m u ta n ts
T s ’ c o a s te r  m u ta n ts H ig h  re v e r s io n  f r e q u e n c y  a n d  n o t fu l ly  c h a r a c te r i s e d  ( O h ta  e l
a t . .  1 9 8 7 ) .
C a r b o h y d r a t e  m e ta b o l is m  
m u ta n ts
g a lE  m u ta t io n s . G a la c to s e  e p im e r a s e le s s  m u ta n ts  w h ic h  fo r m  b a s is  o f  S . ty p h i  
T y 2 1 a  v a c c in e  s t r a in .  A  c o m p le x  a n d  u n d e f in e d  m u ta t io n  
w h o s e  a t te n u a t io n  m a y  n o t  b e  d u e  to  th e  g a lE  d e f e c t  (G e r m a n ie r  
A  F u re r ,  1 9 7 5 ; H o n e  e l  a t . ,  1 9 8 8 a ) .
G lo b a l  r e g u la to r  m u ta n ts c y a ,  c r p  m u ta n ts M u ta t io n s  in  th e  c y c l ic  A M P  p a th w a y , a  k e y  re g u la to ry  s y s te m  
n e c e s s a r y  fo r  th e  t r a n s c r ip t io n  o f  m a n y  g e n e s .  T h e  d o u b le  
m u ta t io n  p ro v id e s  s e c u r i ty  a g a in s t  s p o n ta n e o u s  re v e r s io n .  A  
p ro m is in g  s y s te m  o f  a t te n u a t io n .  (C u r t is s  A  K e lly ,  1 9 8 7 )
o m p R o m p R  r e g u la te s  e x p r e s s io n  o f  g e n e s  in c lu d in g  o u te r  m e m b ra n e  
p ro te in s  O m p C  a n d  O m p F . o m p R  m u ta n ts  a r e  a t te n u a te d  
(D o r m a n  e l  a t . ,  1 9 8 9 ) . L a c k  o f  th e s e  O M P s  is n o t  re s p o n s ib le  
fo r  th e  a t te n u a t io n  ( C h a t f ie ld  e l  a t . ,  1 9 9 1 ) .
p h o P T w o - c o m p o n e n t  s y s te m  r e s p o n s iv e  to  p h o s p h a te  le v e ls ,  r e g u la te s  
s e v e ra l  v iru le n c e -a s s o c ia te d  g e n e s ,  a t te n u a te d  in  m ic e  ( M i l l e r  e l  
a t . .  1 9 8 9 a ; M ille r  A  M e k a la n o s ,  1 9 9 0 ).
O t h e r  v i ru le n c e  a s s o c ia te d  
m u ta n ts
h lr A S e r in e - p ro te a s e  h o m o lo g o u s  t o  E . c o t i  h e a t  s h o c k  p ro te in , 
a t te n u a te d  in  m ic e  ( J o h n s o n  e l  a t . ,  1 9 9 1 ; C h a t f ie ld  e l  a t . ,  1 9 9 2 )
h e m A M u ta n ts  u n a b le  t o  c a n y  o u t  o x id a t iv e  r e s p ir a t io n ,  a t te n u a te d  a n d  
im m u n o g e n ic  in  m ic e  ( B e n ja m in  e l  a t . ,  1 9 9 1 )
Table 1.2 Potential Salmonella vaccine candidates. 
Based on Curtiss, (1990) and Chatficld et al., (1992)
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The antibiotic-associated mutants are often point mutations which can revert at high 
frequencies. Although they may be suitable as animal vaccines, this method of attenuation 
is unlikely to be approved for human use. The temperature-sensitive mutants also revert at 
high frequencies and the mutations are not fully characterised. The carbohydrate metabolism 
mutants have an extensive history. The galE mutation was thought to be responsible for the 
attenuation of the S. typhi vaccine strain Ty21a. Subsequent work has shown that other 
mutations in this strain are responsible for the attenuation. Global regulator mutants can be 
highly attenuated as the organism is unable to respond effectively to changes in its 
environment as it invades the body. There is some concern that, as the actual gene 
responsible for virulence is not deleted, escape mutants could occur which could revert to 
virulence. A safer approach is to identify the virulence-associated gene and delete all or part 
of the gene. Promising candidates include the htrA mutants. It may be possible to delete 
several virulence-associated genes to achieve the desired level o f attenuation.
1.3.2 Aromatic Amino Acid Mutants
In 1950 Bacon and co-workers (Bacon et al., 1950a; Bacon et al., 1950b) showed 
that some mutant strains of 5. typhi, induced by chemicals and radiation, had reduced 
virulence for mice and would only grow in the presence o f particular substrates. One of 
these auxotrophs required p-aminobenzoic acid (PABA). Subsequently the aromatic 
biosynthesis pathway has been elucidated. Mutations in this pathway lead to a requirement 
for aromatic compounds and reduced virulence. The pathway is shown in Figure 1.2 (from 
Stocker, 1988). Evaluation of aro mutants as possible candidates for attenuated live 
Salmonella vaccine strains has been undertaken.
The first aro mutation constructed using modem genetic techniques was in the araA 
gene in S. typhimurium (Hoiseth & Stocker, 1981). 2,3-dihydroxybenzoic acid (DHA), 
PABA, and the three aromatic amino acids, are required for growth o f aro mutants. The 
three aromatic amino acids arc available in the host tissues, but PABA and DHA are not 
available. PABA is required for folate production and DHA for enterochelin. Although an 
cntcrochelin mutant alone causes some attenuation (Yancey et al., 1979), the folate 
deficiency is thought to be more important. The mechanism by which this deficiency causes 
attenuation is not clear but it has been proposed that the lack o f  folic acid leads to a 
depletion o f  formyl-methionine and thus an inability to initiate new protein chains (Stocker,
16
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Figure 1.2 Aromatic Amino acid pathway
The diagram shows the main components o f the aromatic amino acid pathway. The 
genes which code for enzymes involved in each step are shown. Chorismic acid is required 
for many synthetic products. For the purposes of in vivo attenuation all except PABA and 
DHB are available from the host and so it is the depletion of these compounds, and their 
derivatives, that is held responsible for attenuation.
PEP P-enolpyruvate
EP Erythrose-4-P
DAHP 3-deoxy-D-arabino-hcptulosonic acid 7-P
DHQ Dchydroquinatc
DHS Dchydroshikimate
SAP Shikimatc-3-P
EPSAP Shikimatc-5 enolpyruvate 3-P
PABA Para-aminobenzoic acid
DHB 2-3 dihydroxybcnzoic acid
Facing page 17
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AROMATIC BIOSYNTHESIS PATHWAY
PEP + EP
aroFGH
D A H P
1 aroB
DHQ
1 aroD
DHS
■
aroE
SHIKIMIC ACID
1 aroL
SAP
1 aroA
EPSAP
CHORISMIC ACID PABA 
DHB '
TRYPTOPHAN/TYROSINE
PHENYLALANINE
FOLIC ACID 
ENTEROCHELIN
UBIQUINONE
MENAQUINONE
Figure 1.2 Aromatic Amino acid pathway
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1990). The doubling lime in the mouse spleen for a S. ryphimurium aroA mutant is 3.4 days 
as compared to 9.9 hours for a virulent strain (Killar & Eisenstein. 1985). Initially the aroA 
gene was only inactivated by the insertion of the tetracycline resistant transpuson TnlO but, 
in order to limit reversions by clean excision, deletion mutants were constructed (Hoiseth & 
Stocker, 1981). A deletion mutant o f aroA was constructed in the mouse virulent 
5. typhimurium strain SL 1344 and designated SL 3261. This strain has been used to 
evaluate immune responses in mice.
For additional safety from reversions to virulence, it is possible to add a second or 
third mutation in the aromatic amino acid pathway. aroC (Dougan et al., 1988) and aroD 
(Miller et al., 1989) mutations have been tried alone and in combination with an aroA 
deletion. The aroC and aroD  mutations seem to have the same level o f attenuation as the 
aroA deletion yet are still immunogenic (Miller et al.. 1989), thus when two aro deletions 
are combined in one organism the attenuating effect is not addinve. The araA, aroC  and 
aroD genes are at 19, 47 and 36 mins respectively on the S. typhimurium chromosome 
(Sanderson & Hurley. 1987). Thus construction of Salmonella strains with multiple deletions 
in the aromatic amino acid pathway would not have an additional effect on attenuation but 
would contribute a greater degree o f  safety (Dougan et al., 1988).
Aro mutants of several Salmonella strains have been shown to be effective oral 
vaccines in different species including mice (Killar & Eisenstein, 1985), calves (Smith et al., 
1984), sheep (Mukkur et al., 1987), chickens (Cooper et al., 1990) and preliminary data is 
available for humans (Hone et al., 1992).
1-3,3 Immunological Response to Live Attenuated Salmonella Vaccines
Live attenuated strains of Salmonella have been given to animals by many different 
routes such as IV, IP. IM, SC and oral. The oral route has produced the most wide ranging 
immunological responses, presumably because the other methods (except possibly IP) may 
bypass the gut associated lymphoid tissue ■ GALT). Delivery o f  an antigen in S. typhimurium 
via the GALT elicits generalized secretory. humoral and cellular immune responses (Curtiss 
& Kelly, 1987). Different routes o f  administration can stimulate different arms of the 
immune system (Mukkur et al.. 1987; Wu et al., 1989). IM vaccination with an attenuated 
5. dublin expressing an epitope of the Hepatitis B surface antigen was compared to oral
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vaccination. With the same number of viable attenuated bacteria, IM vaccination induced 
higher serum antibody levels (Wu et al., 1989). This may be due to the large percentage of 
an oral dose that is excreted but it is known that oral antigen presentation may suppress the 
systemic response (Wu et al., 1989). However, effective and protective mucosal and cellular 
immunity, without delectable serum antibody, has been found in mice vaccinated orally with 
attenuated S. typhimurium expressing a malaria antigen (Sadoff et al., 1988). The 
development of the full immune response appears to require presentation of the antigen to 
the GALT and then limited replication in the RES. However, persistence in the RES is not 
in itself enough to establish immunity as purA strains persist for several weeks but fail to 
induce significant protective immunity (O'Callaghan et al., 1988).
It has been known for some time that clinical enteric infection with S. typhimurium 
in pregnant women can induce high colostrum levels of specific IgA (Allardyce et al., 1974). 
The mechanism for this generalised secretion of mucosal IgA following stimulation at one 
mucosal surface has now been extensively studied. Delivery o f antigen to the GALT (or 
bronchial associated lymphoid tissue - BALT) stimulates a generalized mucosal response 
involving the bronchus, breast, genitourinary tract, lacrimal glands and bowel - the 
"Common Mucosal Immune System" (Bienenstock et al., 1978). Oral administration of 
attenuated 5. typhimurium expressing the M protein of Streptococcus pyogenes invokes 
specific salivary antibodies and can protect against intranasal challenge with either wild type 
S. typhimurium or virulent Streptococcus pyogenes (Poirier et al., 1988).
Serum responses are generally good, but vary as a consequence of the route of 
administration (Mukkur et al., 1987) and probably require more antigen to be present than 
is needed for purely T-cell responses. Antibody also has a role in antibody-dependent 
cellular cytotoxicity which has been proposed as important in protection against Salmonella 
infection (Tagliabue et al., 1986). Scrum responses can be absent even when protection is 
demonstrated (Aggarwal et al., 1991; Strugncll et al.. 1992).
Cellular immune responses have been detected after Salmonella vaccination (Killar 
& Eisenstcin, 1985; Stocker, 1988) of both a specific and non-specific nature. Protection, 
consistent with non-specific activation o f  macrophages, was shown to begin as early as 3 
days following oral vaccination and specific immunity to last for at least 7 months (Killar 
& Eisenstcin, 1985). CD4* virus-specific T-cells (but not CDS’ T-cells) have been induced 
by vaccination with S. typhimurium aroA SL 3261 expressing the nucleoprotein o f Influenza
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virus (Tile et al., 1990). Yang el al. (1990) showed that T-helpcr subsets can be 
preferentially stimulated by oral vaccination with aroA S. typhimurium expressing a 
Leishmanial surface protein. CDS* cytotoxic T-cells have been identified following  
vaccination with a Salmonella vaccine expressing the circumsporozoite antigen o f 
Plasmodium berghei (Sadoff et al.. 1988; Aggarwal el al.. 1991) and the CS of Plasmodium 
yoelii (Flynn el al., 1990) although the mechanism by which the antigen was able to become 
G ass 1 MHC restricted is only now being elucidated (Pfeifer et al., 1993). Oral or 
intravenous vaccination with a aro S. typhimurium strain expressing the P.69 antigen o f 
Bordetella pertussis showed significant protection against an aerosol challenge with virulent 
B. pertussis without antibody being detected (Strugnell et al., 1992). The reasons why 
different antigens give rise to different types of immune responses is unknown but may be 
due to variations in cytokine production and antigen processing (Strugnell et al., 1992).
1.3.4 Expression o f  Heterologous Antigens
It was perceived that attenuated Salmonella had potential as expression vectors for 
antigens from other pathogens (Formal et al.. 1981). Antigens which are presented to the 
GALT and RES can stimulate generalized secretory, humoral and cellular immune 
mechanisms. This oral vaccination system offers the opportunity to deliver appropriate 
antigens by an etiective route and to stimulate protective immunity. Side effects should be 
minimal and oral vaccination would be cost effective (Gements, 1987). Many heterologous 
antigeas have been expressed in attenuated strains o f  Salmonella and those of bacterial origin 
arc shown in Table 1.3, antigens of viral and eukaryotic origin are shown in Table 1.4. The 
expression of biologically active human Intcrlcukin-I/3 from S. typhimurium has been shown  
and offers a means to deliver therapeutic proteins in vivo (Carrier et al., 1992). Several 
recent reviews have been published describing these recombinant organisms (Curtiss, 1990; 
Hormacchc. 1991; Cardenas & Gcm cnls. 1992). Protective immunity induced by 
heterologous antigens expressed from attenuated Salmonella has been demonstrated for the 
following antigens: Shigella flexneri antigens in mice (Baron et al., 1987) and Shigella 
sonnei in humans (Black et al., 1987), Streptococcus pyogenes M protein (Poirier et al.,
1988), Malarial sporozoites (Sadoff et al., 1988), tetanus toxin (Fairwcather et al., 1990), 
Influenza virus (Titc et al., 1990) and P.69 antigen o f Bordetella pertussis (Strugncl! et al., 
1992). Partial protection was demonstrated with expression o f Influenza virus
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A n t ig e n
i|
C o m m e n t s  a n d  r e f e r e n c e s
E . c o l i  a n t i g e n s C F A  I f i m b r i a e  a n d  h e a t - s t a b l e  t o x i n  e x p r e s s e d  in  a  g a l l ,  s t r a i n  o f  S .  t y p h i .  N o t  t e s t e d  i n  a n i m a l s  
( Y a m a m o t o  e t  a l . ,  1 9 8 5 ) .
E . c o l i  L T - B B  s u b u n i t  o f  h e a t - l a b i l e  e n t e r o t o x in  e x p r e s s e d  in  a r o m a t i c - d e p e n d e n t  S .  d u b l i n  p r o d u c in g  
n e u t r a l i s i n g  a n t i b o d y  ( ( D e m e n t s  e t  a l . ,  1 9 8 6 ) .  L T - B  h a s  a l s o  b e e n  e x p r e s s e d  in  a n  a r o A  
S . t y p h i m u r i u m  s t r a i n  ( M a s k c l l  e t  a l . ,  1 9 8 7 )  a n d  a  g a l E  S . t y p h i  ( C l e m e n t s  &  H l - M o r s h id y ,  1 9 8 4 ) .
S h i g e l l a  a n t i g e n s S h i g e l l a  f l e x n e r i  2 a  t y p e  a n d  g r o u p  a n t i g e n s  i n t o  g a l E  S .  t y p h i .  M i c e  p r o t e c t e d  a g a i n s t  c h a l l e n g e  
w i th  v i r u l e n t  S .  f l e x n e r i .  ( B a r o n  e t  a l . ,  1 9 8 7 ) .  S h i g e l l a  s o n n e i  f o r m  I a n t i g e n  p l a s m id  w a s  
e x p r e s s e d  in  S .  t y p h i  a n d  p r o t e c t e d  m i c e  ( F o r m a l  e t  a l . ,  1 9 8 1 )  a n d  m a n  ( B l a c k  e t  a l . ,  1 9 8 7 ) .  A  
I a m B - S h i g a  t o x i n  f u s i o n  i n d u c e d  a n  a n t i b o d y  r e s p o n s e  ( S u  e t  a l . ,  1 9 9 2 )
S t r e p t o c o c c u s  
m u t a n s  a n t i g e n s
A s  a n t i - c a r i e s  v a c c i n e  t h e  s u r f a c e  p r o t e i n  a n t i g e n  S p a A  w a s  e x p r e s s e d  i n  t h e  c A M P  m u t a n t s  o f  
S . t y p h i m u r i u m  ( C u r t i s s  e t  a l . ,  1 9 8 8 ) .  A  g l u c o s y l t r a n s f e r a .s e  G t f A  h a s  a l s o  b e e n  e x p r e s s e d  ( C a r d e n a s  
&  C l e m e n t e ,  1 9 9 2 )
M  p r o t e in S t r e p ,  p y o g e n e s  M  p r o t e i n  e x p r e s s e d  in  a r o  S .  t y p h i m u r i u m .  T h e  M  p r o t e i n  w a s  n o t  d e t e c t a b l e  o n  
th e  s u r f a c e  o f  t h e  v a c c i n e  s t r a i n  y e t  p r o d u c e d  a  s t r o n g  p r o t e c t iv e  i m m u n e  r e s p o n s e .  T h e  m ic e  w e r e  
a l s o  p r o t e c t e d  a g a i n s t  i n t r a n a s a l  c h a l l e n g e  a f t e r  o r a l  v a c c i n a t i o n  a n d  s p e c i f i c  I g A  w a s  f o u n d  in  t h e  
s a l i v a  ( P o i r i e r  e t  a l . ,  1 9 8 8 ) .
E .  c o l i  K 8 8 K 8 8  a d h e r e n c e  a n t i g e n  e x p r e s s e d  in  g a l E  a n d  a r o A  S .  t y p h i m u r i u m .  A n t i - K 8 8  a n t i b o d i e s  w e r e  
d e t e c t e d  ( D o u g a n  e t  a l . ,  1 9 8 6 ) .
/ 9 - g a l a c to s id a s e / 3 - g a l a c t o s i d a s e  w a s  e x p r e s s e d  i n t r a c c l l u l a r l y  in  a r o A  S . t y p h i m u r i u m .  I t  e l i c i t e d  b o th  h u m o r a l  a n d  
c e l lu l a r  i m m u n i t y  i n  m i c e .  ( B r o w n  e t  a l . ,  1 9 8 7 ) .
B r u c e l l a  a b o r t u s  3 1  
IcD a p r o t e in
O r a l  v a c c i n a t i o n  w i t h  A c y a  A c r p  S .  t y p h i m u r i u m  e x p r e s s i n g  t h i s  p r o t e i n  i n d u c e d  m u c o s a l  a n d  
s y s t e m i c  a n t i b o d y  r e s p o n s e s ,  b u t  n o t  d e l a y e d  t y p e  h y p e r s e n s i t i v i t y  ( S t a b c l  e t  a l . ,  1 9 9 1 ) .
F la g e l l a  e x p r e s s i o n  
s y s t e m  f o r  e p i t o p e s .
A n t i g e n  e p i t o p e s  t e s t e d  i n c l u d e  C h o l e r a  t o x in  ( S a l e t c  e t  a l . ,  1 9 8 9 ) ,  a n d  S t r e p ,  p y o g e n e s  M  p r o t e in  
e p i t o p e  ( S t o c k e r ,  1 9 9 0 ) .  A n t i b o d i e s  a g a i n s t  t h e  e p i t o p e s  a r e  p r o d u c e d .
V ib r io  c h o l e r a e  
a n t i g e n s
5 .  t y p h i  T y 2 1 a  e x p r e s s i n g  O - a n t i g c n s  p r o d u c e d  a n t i b o d y  r e s p o n s e s  a n d  p a r t i a l  p r o t e c t io n  in  h u m a n s  
( T a c k e t  e t  a ! . ,  1 9 9 0 ) .
M y c o b a c t e r iu m  
l e p r a e  a n t i g e n s
M y c o b a c t e r i u m  l e p r a e  p r o t e i n  a n t i g e n s  h a v e  b e e n  e x p r e s s e d  in  S c y a  A c r p  A a s d  S . t y p h i m u r i u m  
( C l a r k - C u r t iM  e t  a l . ,  1 9 9 0 ) .
( ' - f r a g m e n t  o f  
t e t a n u s  t o x i n
O r a l  v a c c i n a t i o n  p r o t e c t s  m i c e  a g a i n s t  t o x in  c h a l l e n g e  ( F a i r w e a t h e r  e t  a l . ,  1 9 9 0 ;  S t r u g n e l l  e t  a l . ,  
1 9 9 0 )
T r e p t m e m a  p a l l i d u m  
a n t i g e n
l i p o p r o t e i n  e x p r e s s e d  f r o m  c h r o m o s o m a l l y  i n t e g r a te d  g e n e  a n d  e x p r e s s i o n  d e t e c t e d  b y  W e s te r n  
b l o t t i n g  ( S t r u g n c l l  e t  a l . ,  1 9 9 0 )
F r a n c i s e l l a  
t u l a r e n s i s  p r o t e i n
A  1 7  k D a  l i p o p r o t e i n  e x p r e s s e d  in  A c r p  A c y a  S .  t y p h i m u r i u m  i n d u c e d  a n t i b o d y  a n d  r e d u c e d  
b a c t e r i a l  c o u n t s  o f  a  c h a l l e n g e  s t r a i n  ( S j o s t e d t  e t  a l . ,  1 9 9 2 ) .
B o r d e t e l l a  p e r t u s s i s  
a n t i g e n s
P .6 9  a n t i g e n  e x p r e s s e d  o n  S .  t y p h i m u r i u m  s u r f a c e  i n d u c e d  p r o t e c t iv e  i m m u n i t y  w i t h o u t  d e t e c t i o n  o f  
P .6 9  a n t i b o d y  ( S t r u g n c l l  e t  a l . ,  1 9 9 2 ) .  P e r t u s s i s  to x in  S I  s u b u n i t  w a s  e x p r e s s e d  in  5 . t y p h i m u r i u m  
S L  3 2 6 1  a n d  i n d u c e d  s c r u m  a n d  m u c o s a l  a n t i b o d y  ( W a l k e r  e t  a l . ,  1 9 9 2 ) .  F i l a m e n t o u s  
H e m a g g l u t i n i n  a n t i g e n  e x p r e s s e d  in  a r o A  S . d u b l i n  s t i m u l a t e d  Ig G ,  Ig M  a n d  I g A  a n t i b o d y  in  m ic e  
( M o l i n a  A  P a r k e r ,  1 9 9 0 ) .
N e i s s e r i a  
m e n in g i t i d i s  O M P
O u t e r  M e m b r a n e  P r o t e i n  e x p r e s s e d  in  5 .  t y p h i m u r i u m  S L  3 2 6 1  in  o u t e r  m e m b r a n e  in d u c e d  a n  
a n t i b o d y  r e s p o n s e  b u t  n o t  s h o w n  t o  b e  p r o t e c t iv e  ( T a r k k a  e l  a t . ,  1 9 8 9 ) .
C h la m y d i a  
t r a c h o m a t i s  M O M P
F p i t o p c s  o f  t h e  m a j o r  o u t e r  m e m b r a n e  p r o t e i n  e x p r e s s e d  a s  I . a m B  f u s i o n s  w h i c h  w e r e  l o c a t e d  in  
th e  o u t e r - m e m b r a n e .  I n d u c e d  a  w e a k  s e r u m  Ig G  r e s p o n s e  ( H a y e s  e t  a l . ,  1 9 9 1 ) .
Table 1.3 Bacterial heterologous antigens which have been expressed in Salmonella
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Antigen Comments and references
Dengue virus envelope antigen 76% of E gene stahly expressed but problems with animal 
model (Cohen er aL. 1990)
Rotavirus glycoprotein VP7-0-gal fusion expressed in 5. typhi murium SL 3261 induced 
anti-/3-gal antibodies but not anti-VP7 (Salas-Vidal et aL, 1990)
Influenza virus nucleoprotein Expressed in S. typhimurium SL 3261 (Tite et aL, 1988) and 
used to induce protective immunity in mice (Tite et aL, 1990)
Herpes simplex virus 
glycoprotein
Glycoprotein D expressed in S. typhimurium aroA for use in 
Guinea pig model Bowen et aL, 1990).
Hepatitis B virus surface and 
nucleocapsid antigens
Expressed as fusions with E. coli LT-B or as pre-S2 B-cell 
epitopes fused to the nucleocapsid protein. Elicit high-titre 
antibody responses (Schodcl & Will, 1989; Schodel et aL, 1991)
HIV-1 envelope protein Using a two plasmd system and fusing an epitope of HIV-1 env 
gene to gene 10 ex' phage T7. Animal studies reported in 
progress (Tijtiaar e t aL, 1992)
SIV P27 gag Expression varies -s:tween different Salmonella strains (Stratum 
et aL. 1992)
OmpA expression system Influenza virus haerrtagglutinin expressed as fusion with OmpA 
partially protected mice against virus challenge (Pistor & 
Hobom, 1990). P-ismodium falciparum antigens (730 amino 
acids) expressed as OmpA protein fusions are locaied on Ihe 
surface of S. typhimurium (Schorr et aL, 1991).
Flagella expression system for 
epitopes
Epitopes (approximately 20 amino acids) can be expressed in 
functional flagella and include ones from the Hepatitis B surface 
protein, the HIV g?l60 surface protein and the murine 
cytomegalovirus immediate-early protein, pp89 (Stocker. 1990).
Circumsporozoite proteins (CS) Plasmodium berghei CS expressed by S. typhimurium induced 
cell-mediated protection to sporozoites in the absence of 
antibcvly (Sadoff et aL, 1988; Aggarwal et aL, 1991). The 
Plasmodium yoehi CS gene was chromosomally integrated and 
induced cytotoxic T-oells (Flynn et aL, 1990).
Trypanosoma cruzi 
neuraminidase
Salmonella expressing the protein elicited a strong antibody 
response to the amigen (Flynn et aL, 1990).
leishmanial surface protein Preferentially induced Th, cells and antibody and partially 
protected mioe ap  nsl challenge (Yang et aL, 1990).
Schistosome surface antigen Expressed in 5. nrhimurium hut no further reports of use 
(Taylor et aL. 19$r>).
Human Respiratory Syncytial 
Virus Glycoprotein
Expressed in S. nphimurium and recombinant protein shown to 
induce neutralising antibodies when given to Cotton rats 
(Manin-Gallardo <t aL, 1993)
Tabic 1.4 Antigens o f  Viral and Eukaryotic origin which have been expressed in Salmonella
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haemagglutinin (Pistor & Hobom, 1990), a Leishmanial surface protein (Yang et al., 1990) 
and a membrane protein o f Francisella tularensis (Sjostedt et a!., 1992).
The cellular location of the antigen can affect the immune response. Although it was 
felt that surface expression would be desirable, many workers have found that immune 
responses are generated by cytoplasmic antigens such as /3-galactosidasc (Brown et al., 
1987). It is difficult to design controlled studies to evaluate the immune responses to 
cytoplasmic and surface antigens as the immunological character of the antigen will alter 
depending on its cellular processing and locanon. Various systems arc available to express 
antigens or epitopes on the surface o f the bacteria (Stocker, 1990) but surface expression is 
not a prerequisite for an immune response. Probably the main problem found has been to 
stably express the antigens in sufficient quantity (Hormaeche, 1991). Potential ways to 
overcome these problems have been reviewed by Charles & Dougan (1990). Thus it can be 
seen that a range o f antigens have been successfully expressed in Salmonella and protective 
responses have been elicited in some cases.
1.4 Aim o f the project
Anthrax is an important disease for which an adequate vaccine does not exist. A  
new vaccine is needed and a vaccine vector expressing PA offers many possible advantages. 
Rationally attenuated Salmonella were the most suitable vaccine vector for the expression 
of PA for the following reasons. A  bacterial vector might be expected to express a bacterial 
protein to higher levels than might a eukaryotic system, in terms of the regulatory regions 
of the gene and the codon usage, although there are differences between Bacillus and 
Salmonella in these areas. Salmonella are orally active yet can generate a range o f immune 
responses. It is known that anti-PA antibody alone is not correlated with protection against 
B. anthracis challenge and so other immune responses need to be generated (probably CMI). 
Clinical trials arc underway to evaluate the use o f aro S. typhi as human typhoid vaccines, 
and if this becomes approved it should facilitate its use as a vaccine vector. Bacterial 
vaccines arc cheap to produce and can be lyophilised to ease and prolong their storage. Oral 
vaccines can be administered by non-mcdically trained personnel, without the need for sterile 
equipment. Salmonella are related to E. coli and this will facilitate genetic manipulation 
techniques.
Chapier 1. Introduction
The Bacillus gene for PA was available on a plasmid, pPA26. Initial reports have 
suggested that PA was poorly expressed from plasmid pPA26 in E. coli (Vodkin & Leppla, 
1983). It was decided to address these problems in a rational manner in order to produce 
stable high level expression of PA in Salmonella. The constructs that were made are shown 
in a fold-out page at Annex A. The most suitable construct developed would be expressed 
in an aroA S. typhimurium strain designated SL 3261 and tested in animals for the induction 
of protective immune response against B. anthracis challenge. This would demonstrate the 
suitability of this approach in developing a new vaccine.
Therefore, the aim of this project is to produce an attenuated S. typhimurium strain 
which stably expresses PA and induces protective immune responses against B. anthracis 
when given to mice.
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2J. Materials
Inorganic chemicals and solvents were obtained mainly from Sigma Chemical Co. 
Ltd (Poole, Dorset), BDH Ltd. (Poole, Dorset) or Boehringer Mannheim UK Ltd. (Lewes, 
East Sussex).
Tryptonc, yeast extract and "Bacto" agar were obtained from Difco Laboratories 
(West Mosely, Surrey) or Oxoid Ltd. (Basingstoke, Hants).
The majority of biochemicals were from Sigma, Boehringer or Bio-Rad (Hemel 
Hempstead, Herts).
Anti-PA mouse monoclonal antibodies (designated 14C7, 2D3 and 3B6) were 
produced by Dr D Williamson, CBDE, from cell lines provided by USAMRI1D (Little et al., 
1988). The horse polyclonal antisera was raised against the spore vaccine at CBDE. 
Enzyme labelled antibodies were from Sigma or Bio-Rad.
Restriction endonucleases and most other DNA modifying enzymes were from 
Boehringer or CP Laboratories (Bishop's Stortford, Herts).
Plasmids and phagemids were from Pharmacia LKB Biotechnology Ltd. (Milton 
Keynes, Bucks), Stratagene Ltd. (Cambridge) or Boehringer.
Unless otherwise stated, the water used was distilled water.
2:1,1 Strains
The strains used in this study arc described in Table 2.1
2.1.2 Plasmids
The plasmids and phagemids used in this study are described in Table 2.2
2 2  General Methods
2.2.1 Centrifugation
Small samples were centrifuged in a bench top Hermle Z-230M microfugc 
(Andaman and Co. Ltd., Kingston-upon-Thamcs. Surrey). Larger volumes were centrifuged 
in either a Sorval RT-6000or a Beckman J2-20 centrifuge (Beckman Instruments, Inc., High 
Wycombe, Bucks) using a JA-10 or JA-20 rotor. Ultracentrifugation was performed in a 
Beckman 70.1Ti rotor in an L8-M centrifuge.
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Escherichia coli
Strain Relevant Genotype Comments Source Reference
HB 101 supE44 hsdS20(rB'mB') 
ree Al 3 a ral 4 proA2 
lacYl galK2 rpsL20 
xyl-5 mtl-1
Transformable strain. 
Host for plasmids 
with lacl and for cell 
fractionation 
experiments
Laboratory
stocks
Bolivar & 
Backman 
(1979)
JM 101 supE thi A(lac-proAB) 
F[traD36 proAB* lacl’ 
lacZAmlS]
Host for pUC and 
pBluescript plasmids
Stratagene
Ltd.,
Cambridge
Messing
(1979)
JM 109 recAl supE44 endAl 
hsdR17 gyrA96 relAl 
thi A(lac-proAB) 
F[traD36 proAB* lacl" 
lacZAmlS]
Recombination 
deficient derivative. 
Host for pUC and 
pBluescript
Stratagene
Ltd.
Yanisch- 
Perron et aL 
(1985)
Salmonella typhimurium
Strain Relevant Genotype Comments Source Reference
LB 5010 rm* galE PI* Used to modify 
E. coli plasmid DNA 
for electroporation 
into SL 3261
Prof G 
Dougan, 
Wellcome 
Labs,
Beckenham
Bullas & 
Ryu (1983)
SL 1344 hisG46 WRAY lineage, calf 
isolated, mouse 
virulent
Dr BAD 
Stocker, 
Stanford, 
USA
Smith el aL 
(1984)
SL 3261 aro A DEL406, hisG46 Derived from 
SL 1344; a vaccine 
strain
Dr BAD 
Stocker
Hoiseth &
Stocker
(1981)
Bacillus anthracit
Vollum
IB
Toxigenic and 
encapsulated
Isolated from a cow, 
Oxford , 1944. 
Virulent. NCTC 
10340.
CBDE Turnbull et 
aL, (1992)
Tabic 2.1 Bacterial strains used in this study
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Vectors
I Designation Marker Promoter Comments Reference
pUC18/19 Amp' lac laeZ' cloning vector Yanisch-Perron a  al. 
(1985) ,
pBR322 Amp',
Tet'
cloning vector Bolivar et al (1977)
pBluescript II 
KS+
Amp' lac laeZ' phagemid Alting-Mees & Short 
(1989)
pTrc99A Amp' tre high expression 
plasmid
Pharmacia LKB Ltd., 
Milton Keynes, | 
Bucks j
Recombinant Plasmids
Designation Vector Comments Reference
pPA26 pBR322 Plasmid with B. anthracis DNA containing 
the PA gene
Vodkin &
Leppla
(1983)
pFS2.2 pUC19 Plasmid expressing LT-B from lac 
promoter. Used in the construction of 
pSIG13
Schodel & 
Will (1989)
pKS492 pUC18 Contains cer locus Prof. D 
Sherratt, 
Univ. of 
Glasgow
pCBl pBluescript Recombinant expressing full-length PA This study
pORFl pBluescript Recombinant expressing full-length PA This study
pORFlc pBluescript Recombinant as for pORFl with cer locus This study
pVET4m pBluescript Recombinant expressing 63 kDa PA, lac This study
pVET4n pBluescript Recombinant expressing 63 kDa PA, lac This study
pNIKln pTrc99A Recombinant expressing 63 kDa PA, ire This study
pNIKlm pTrc99A Recombinant expressing 63 kDa PA, tre This stud)
pSIG13 pUC19 Recombinant expressing 63 kDa PA, lac This study
pBPA9 pBluc script Recombinant phagemid containing the 
sequence for the PA-63 with an unmodified 
C-terminus. Used in construction of 
pNIKln.
This study
Table 2.2. Plasmids and Phagemids used in this study
28
Chapter 2. Materials and Methods
2.2.2 Sterilisation
Heat stable solutions were sterilised in an autoclave on a liquid cycle. Other 
solutions were sterilized by passing through a 0.22ftm pore size membrane. Pipette tips and 
instruments were sterilized in an autoclave on a steam cycle.
2 J  Microbiological Methods
2.3.1 Preparation o f  Culture Media
2.3.1.1 Routine Media 
LB-rnedjum (L-broth or L-agar)
L-broth and L-agar were used for all routine cultures of both E. coli and 
5. typhimurium.
L-Medium
Tryptone 10 g
Yeast extract 10 g
NaCl 5 g
Make to one litre and adjust pH to 7.0 with 5N  NaOH; for L-agar add 15 g Bacto- 
agar before autoclaving.
Glucose Minimal Agar
Glucose minimal agar (GMA) was used for maintaining the F  episomc in certain 
strains o f  E. coli.
GMA
lOx M9 salts 100 ml 
20% Glucose 20 ml 
Minimal agar 15 g
Make to 1 litre and before use supplement with ImM M gS04, O.lmM CaCI2 and 
ImM thiamine.
lOx M9 Salts
NajHP04-7h20
k h 2p o 4
12« g
30 g 
5 gNaCl
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NH,C1 10 g
Dissolve in water to 1 litre. Divide into aliquots and autoclave 15 mins at 15 lb/sq 
inch liquid cycle.
2xTY Medium
This medium was used in the preparation of ssDNA from phagemids.
Tryptone 16 g
Yeast extract 10 g
NaCl 5 g
Add to 900 ml water, adjust to pH 7.0 with 5N NaOH and make to 1 litre.
SOC Medium
This medium was used to recover bacteria after electroporation.
Tryptone 20 g
Yeast extract 5 g
NaCl 0.5 g
Add to 950 ml water and shake to dissolve. Add 10 ml o f 250mM KC1 and adjust 
to pH 7.0 with 5N NaOH. Make to 1000 ml and autoclave. Before use add 20 ml 
of a Alter sterilized 1M glucose solution and 5 ml of a Alter sterilized 2M MgCl2 
solution.
Minimal M edia for pro  mympis
aro and his mutants were identified by growing on minimal media supplemented as 
required with aromix and/or histidine.
Minimal medium
170 ml 2% noble agar (Difco)
20 ml lOx M9 Salts 
10 ml 20% Glucose 
2 ml Ca/Mg Salts 
1% v/v Aromix (if required)
1% v/v Histidine -4mg/ml slock ( if  required)
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Ca/Mg Salts 
lOmM CaCl2 
KK)mM MgSO,
Make separately, autoclave, mix in 1:1 ratio before use.
Aromix
Phenylalanine 4mg/ml
Tryptophan 4mg/ml
Para-aminobcnzoic acid lmg/ml
Dihydroxybenzoic acid lmg/ml
Filter sterile. Make Tyrosine (4mg/ml) separately and add to medium at 1% v/v 
before use.
Phosphate-buffered saline (PBS)
NaCI K g
KQ 0.2 g
N a,H P04 1.44 g
k h , p o 4 0.24 g
Make to 800 ml and adjust pH to 7.4 with H Q , make to I litre and autoclave.
2.3.1.2 Media supplements
Media was supplemented as required with:
S to c k  s o lu t io n A m o u n t  / 1 0 0  m l  m e d ia W o r k i n g  c o n c e n t r a t i o n
A m p i c i l l i n 2 5  m g /m l 0 .4  m l 1 0 0  ¿4g/m l
C h l o r a m p h e n ic o l 3 4  m g /m l  in  e th a n o l 0 .5  m l 1 7 0  /¿ g /m l
K a n a m y c i n 1 0  m g /m l 1 0 0  /<! 1 0  /4 g /m l
T h i a m i n e 0 .1 % 1 m l 0 . 0 0 1 %
I P T O I M 1 0 0  /at I m M
X - g a l 2 0  m g /m l  in  N ,N -  
d i m e t h y l  f o r m a m i d c
1 .6  m l 3 2 0  / ig / r n l
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2.3.1.3 Culture conditions
Cultures were grown at 37°C under aerobic conditions. Small volumes were grown 
in 20 ml Universal tubes and larger volumes in 250 ml flasks. Cultures were routinely 
incubated in an orbital shaker except for animal inoculation cultures which were grown 
statically.
2-3.2 Plate counts
Plate counts were used to determine the number of viable bacteria in cultures and 
tissue homogenates and to assess the ratio of antibiotic resistant to sensitive cells. Two 
methods were used.
Manual counting. Serial 10 fold dilutions in PBS were made and 100 /¿I of 
appropriate dilutions plated out on L-agar plates with antibiotic supplementation if  required. 
For cultures the Abs,„KI was used to estimate the cell density; it was found that for 
5. lyphimurium an Abs**, o f  1 equated to 2 x l0 9 bacteria. For tissue homogenates, a wider 
range o f dilutions were plated out as an estimate of the bacterial count was not available. 
The plates were incubated overnight at 37°C. Colonies on the plates were counted manually.
Automated method. From an estimate of the cell density, the culture was diluted 
with ice-cold PBS to produce approximately a 10* to 106 cfu/ml culture. 50 p\ of this 
dilution were plated out using a Spiral Plater Model D (Spiral Systems Inc., Cincinnati, 
USA). After overnight incubation at 37°C, the plates were placed in a Laser Colony Counter 
Model 500A (Spiral System Instruments Inc., Bethesda, USA) and the cfu/ml count 
determined from the distribution o f colonics along the spiral track using Bacterial 
Enumeration Software BEN CASBA II (Spiral System Instruments Inc., Bethesda, USA).
2.4 DNA Methods
2,4,1 Phenol extraction and ethanol precipitation of DNA
DNA in aqueous solution was extracted with an equal volume of Tris-buffcrcd 
phcnol/chlorolorm followed by an equal volume of chloroform. DNA was precipitated from 
aqueous solution by adjusting the salt concentration to cither 0.3M sodium acetate (using 3M 
sodium acetate pH 5.5) or 2M ammonium acetate (using 10M ammonium acetate) and 
adding 2 volumes o f absolute ethanol and storing at -20°C for 10 mins to overnight and 
centrifuging in a microfugc for 10 mins. When necessary, salt was removed from the pellet
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by washing in 70% ethanol. Pellets were air dried and resuspended in an appropriate volume 
of distilled water or TE buffer.
Tris buffered phcnol/chloroform 
100 ml phenol (melted at 65°C)
96 ml chloroform 
4 ml isoamyl alcohol 
200 fig 8-hydroxyquinoline
Equilibrate with 1M Tris pH 8.0, cover with 0.1M Tris pH 8.0.
2.4.2 Plasmid preparations
2.4.2.1 Small-scale plasmid preparations
The protocol used was a modification o f the Bimboim & Doly (1979) alkaline lysis 
method as amended in Sambrook et al. (1989). Basically l.S  ml of culture were pelleted and 
resuspended in 100 fil o f Buffer A (50mM glucose, 25mM Tris pH 8.0, lOmM EDTA). 
After 5 mins on ice 200 fi\ o f  Buffer B (0.2M  NaoH, 1% SDS) were added and after a 
further 5 mins on ice ISO /al o f  Buffer C (2M sodium acetate) were added and the precipitate 
spun down after 3-5 mins. The supernatant was phenolxhloroform extracted and the DNA 
precipitated with ethanol.
2.4.2.2 Large-scale plasmid preparations 
Two methods were used:
a. Chloramphenicol amplification followed by SDS lysis and purification by 
equilibrium centrifugation in CsCl-elhidium bromide gradients (Sambrook et al., 1989)
b. Use o f the Qiagcn >plasmid<maxi kit for culture volumes o f 150 ml (for high copy 
number vectors) as directed by the manufacturer (Qiagen, FRG)
2-4.3 Restriction Digests
Restriction endonucleases were obtained from Boehringcr Mannheim UK Ltd. and 
CP Laboratories and were used with the supplied buffers and in accordance with the 
manufacturer's directions.
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2.4.4 DNA electrophoresis and fragment purification
DNA in final sample buffer was clcctrophoresed in horizontal agarose gels consisting 
of from 0.7% to 1.5% (w/v) agarose (Gibco Ltd., Uxbridge, Middlesex) in TBE containing 
0.5 ng/m\ cthidium bromide. Bands were visualised under UV light.
Sample Buffer (x6)
50% (v/v) Glycerol 
0.25% (w/v) Bromophenol blue 
0.1M EDTA 
in distilled water
TBE buffer(xlO)
54.5 g Tris
27.5 g Boric Acid
4.2 g Disodium EDTA
make to 500 ml with distilled water
DNA fragments were purified from gels by one of three methods:
2,4.4.1 PEAE Çellulosç
The method of Dretzen et al. (1981) as modified by Sambrook el al. (1989) was 
used. DEAE membranes (NA45 membranes, Schleicher-Scheull) were activated by soaking 
for 5 mins in lOmM EDTA, pH 8.0 followed by 5 mins in 0.5N NaOH, washed six times 
in water and stored in water at 4°C. The appropriate band was run onto the membrane, the 
membrane was washed in 10 ml of low salt buffer (50mM Tris pH 8, 0.15M NaG and 
lOmM EDTA) and placed into an eppendorf tube. The membrane was covered in high salt 
buffer (HSB - 50mM Tris pH 8, 1M NaCl and lOmM EDTA) and incubated at 65°C for 30 
mins. The HSB was removed and a second aliquot added for a 15 min incubation. Both 
aliquots were combined, the D N A  purified by phenol extraction and ethanol precipitated in 
the presence o f 2M ammonium acetate. The DNA was resuspended in distilled water.
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2.4.4.2 Qiacx
Qiacx silica gel (Oiagcn, PRO) was used according to the manufacturer's instructions 
and with the buffers provided in the Qiacx >gcl extraction« kit. This method o f fragment 
purification was found to give the best results.
2.4.4.3 Agarase
Agarase was purchased from Bochnngcr Mannheim and used according to the 
manufacturer's instructions and the modified method of Maulé (1992). The DNA samples 
were electrophorcsed on a 0.8% LMP agarose gel. The band was excised and an equal 
volume of TAE buffer added and the gel melted at 65°C for 10 mins. The solution was 
cooled to 45°C and 1 Unit of agarasc/100 u\ of solution added. The mixture was incubated 
at 45°C for 60 mins and then cooled and 1/10 volume of 3M sodium acetate added and the 
tube stored on ice for 10 mins. The undigested agarose was pelleted and the supernatant 
carefully removed. .3 volumes of ethanol was added and the tube held at -20°C for 60 mins 
before the DNA was pelleted in a microfugc. The pellet was dried and resuspended in an 
appropriate volume of water or TE buffer.
2.4.5 Ligation reactions
Bacteriophage T4 DNA Ligase was purchased from Bochringcr Mannheim and 
ligations were performed in the manufacturer's buffer at 15°C overnight for sticky-cndcd 
ligations. Blunt-ended ligations were performed according to the method of Sambrook el 
al. (1989) using 0.5mM ATP, 15% PEG 8000 and 0.5 Weiss Units o f T4 Ligase per 10 fA 
reaction mix.
2.4,5.1 O P  treatment
Calf Intestinal Phosphatase (CIP) was used to dcphosphorylatc vector DNA to reduce 
rccircularizaiion of vector DNA without incorporation of an insert. Purified DNA was 
treated in CIP dcphosphorylation buffer with CIP at a concentration o f  1 unit/100 pmolcs 
of DNA. Restricted DNA was CIP treated in the restriction buffer by adding ZnCl, to a 
concentration of ImM and then the appropriate amount of Q P. The reaction mix was 
incubated at 37°C for 30 mins. EDTA was added to 5mM and the O P  inactivated at 75°C 
for 10 mias.
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CIP dephosphorvlation buffer (IQx) 
lOmM ZnCI, 
lOmM MgCl, 
lOOmM Tris (pH 8.3)
2.4.6 Oligonucleotide synthesis
Oligonucleotides were used as sequencing primers, PCR primers and for the 
construction of DNA linkers in plasmid construction. They were synthesised by Dr. D 
Anderson (CBDE, Porton Down) on a 200A DNA synthesizer (Beckman) using cyanoethyl- 
phosphoramiditc chemistry. Oligonucleotides were supplied in the dcprotected form, cleaved 
from the phosphoramidite column and dried from the Anal ammonium solution. Rouunely 
primers were dissolved in water, ethanol precipitated, resuspended in distilled water and 
quantified by spccirophotometric methods.
2.4.7 Sequencing Methods 
2.4.7.1 Template preparation
Four types o f template were used in sequencing:
a. Phagemid ssDNA. The pBluescript II vectors can be rescued as single stranded 
DNA as they contain an M13-related f l ,  filamentous phage, intergenic region. The 
phagemid must be present in an F' bearing plasmid and so for ssDNA preparation the 
plasmids were electroplated into E. coli JM 109 which had been maintained on a glucose 
minimal agar plate. The recombinant bacteria were grown on an L-agar plate supplemented 
with ampicillin and a colony was inoculated into 2 ml o f 2xTY broth supplemented with 
ampicillin and thiamine. This was grown to an Abs^,, o f 0.S to 0.8. The culture was 
infected with the helper phage MI3K07 at a multiplicity of infection o f 10 phagc/bacteria 
and incubated for 1 hour. 100 ml o f 2xTY were supplemented with ampicillin and 
kanamycin and inoculated with the phage infected culture and incubated overnight. The cells 
were pelleted and the phage precipitated from the supernatant with 20% PEG8000 in 2.5M  
NaCI at a ratio o f  1 ml PEG to 5 ml o f supernatant. The phage was pelleted by 
centrifugation and resuspended in 5 ml of water. The phage coat was removed by 
phcnol/chloroform extraction and the ssDNA precipitated with ethanol and resuspended in 
a final volume o f 200^1 of water.
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b. Dynabcad ssDNA. The Dynabcad Template Preparation kit (Dynal (UK) Ltd. 
Wirral) was used to prepare ssDNA according to the manufacturer's instructions except for 
the following modifications. The non-biotinylatcd strand was removed with 1(K)/¿I of 0.15M  
NaOH and the Dynabcads were resuspended in 15 fA o f water so that they could be used for 
2 sequencing reactions (7 [A per reaction). In some eases the PCR primers used were 
biotinylated-T3 and T7 primers (see Table 2.4) which correspond to these regions in 
pBlucscript. For long inserts, higher primer concentrations were used in the PCR reaction 
than is recommended. As the unused primers would block streptavidin sites on the beads, 
the PCR product was precipitated with Ammonium acetate and ethanol before binding to the 
beads.
c. Denatured dsDNA. Purified plasmid DN A or PCR product was sequenced following 
alkaline denaturation as described in the 'Sequenase Version 2' kit (United States 
Biochemical Corp., Cleveland, Ohio). 3-5 fig o f plasmid DNA were denatured in 0.2M 
NaOH, 0.2mM EDTA for 30 min at 37°C. 0.1 volumes of 3M sodium acetate were added 
and the DNA precipitated with 3 volumes of ethanol. The pellet was resuspended in 7 fA 
o f water and sequenced as for ssDNA.
d. dsDNA. Cycle sequencing can function with a dsDNA template as the template is 
denatured during the heating cycles. Plasmid DNA was purified using Qiagen columns.
2-4.7.2 Sequencing reactions
Except for cycle sequencing, DNA sequencing reactions were performed using the 
didcoxy chain termination method of Sanger el al. (1977) using cloned T7 DNA polymerase 
supplied in a sequencing kit form (Sequenase Version 2, United States Biochemical Corp.). 
Sequencing primers were synthesised at CBDE. Primers used are listed in Table 2.3. The 
manufacturer's instructions were followed with the labelling mix diluted 1:3 in water. 
Routinely labelling was carried out for 5 mins at room temperature and termination reactions 
were incubated at 37°C for 5 mins. Before the stop solution was added a "Taq chase" was 
usually used. dlTPs and dl labelling mix were used to resolve areas of CG compressions 
according to the manufacturer's instructions.
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| Name 5 '  t o  3 '  s e q u e n c e C om m en ts
PAS1 ATA GTG TTT TOT TTA GTA PA s e q u e n c i n g  p r i m e r  (4 0 0 0  
i n  pP A 26 i n s e r t )
PAS 2 TGA TAA TAT TTT TOT TAT PA s e q u e n c i n g  p r i m e r  (3 8 0 0 )
PAS 3 TGT TAG TTG CGT TTA ATT PA s e q u e n c i n g  p r i m e r  (3 6 0 0 )
PAS 4 GCC GCT ATC CGC CTT TCT PA s e q u e n c i n g  p r i m e r  (3 4 0 0 )
PAS5 AAG AAA TTG ATT GTA ATT C PA s e q u e n c i n g  p r i m e r  (3 2 0 0 )
PAS 6 TTG GAG CCG TCC CAG TAT PA s e q u e n c i n g  p r i m e r  (3 0 0 0 )
PAS 7 GCA TTT CCA TGT ACT TCA PA s e q u e n c i n g  p r i m e r  (2 8 0 0 )
PAS 8 TGT AAC CTT TTC GAA ATC ACT 
GTA
PA s e q u e n c i n g  p r i m e r  (2 6 0 0 )
PAS 9 TAG GTC CAG CAC TTG TAC PA s e q u e n c i n g  p r i m e r  (2 4 0 0 )
PAS 10 CTA AAA AAG GCT ATG AGA PA s e q u e n c i n g  p r i m e r  (4 0 7 3 )
P A S H CTT CTC TCA TCC GCC AAA p T rc 9 9 A  ( 3 5 0 )  PCS 
s e q u e n c i n g  i n t o  i n s e r t
PAS 12 CTG ATT TTG TTA GAA TTA PA s e q u e n c i n g  p r i m e r  ( 2 2 0 0 )  ||
PAS 13 TGT AGT AGA AGA GGT AAC PA s e q u e n c i n g  p r i m e r  ( 2 0 0 0 )  ||
PAS 14 GTT TAA CTT CTG CCT GAA PA s e q u e n c i n g  p r i m e r  ( 1 9 0 0 )  ||
PAS7R ACA TGT AGA TAT GGA GAA PA s e q u e n c i n g  p r i m e r  f o r  
c o m p l e m e n t a r y  s t r a n d  ( 2 6 8 0 )  1
U n i v e r s a l
P r i m e r
GTA AAA CGA CGG CCA GT M13 - 2 0  P r i m e r
SK P r i m e r TCT AGA ACT AGT GGA TC p B l u e s c r i p t  s e q u e n c i n g  
p r i m e r  |
Table 2.3 Sequencing primers used in this study. Sequences are shown 5' to 3'. The figure 
in brackets in the 'Comments' column refers to the site that the primer binds at within the 
gene or plasmid.
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Cycle sequencing was performed using a Circumvent kit (New England Btolabs, 
Bishop's Stortford) according to the manufacturer's instructions. 200 ng of dsDNA template 
were used and approximately 10 pmol of primer. The manufacturer recommends 1.2 pmol 
of primer, but excess primer was found to improve the sequence ladder. ” SdATP was 
incorporated into the sequence products by cycling the reactions on a PCR machine (PREM 
111, LEP Scientific, Milton Keynes) for 30 cycles o f 95°C for 30  secs, 55°C for 30 secs. 72°C 
for 30 secs.
2.4.7.3 "Tag chase"
To help resolve areas of G/C compressions and sequence over other regions 
containing secondary structure during non-cycle sequencing, a "Taq chase" step was added 
to the standard method. Taq polymerase enzyme was diluted in the manufacturer's buffer 
to give a concentration o f  1 unit/;d. Before the addition o f stop solution. 1 /d o f  the diluted 
Taq polymerase enzyme was added to each tube and the tubes incubated at 72°C for 2 mins.
2.4.7.4 Denaturing PAGE separation
Denaturing PAGE was used to separate the extension products. Sequencing plates 
(Sequigcn sequencing apparatus, Bio-Rad) were cleaned and silanised as required. Either 
21x40 cm or .38x50 cm plates were used, and gel components arc listed for each size of 
plates. lxTBE gel mix was made using 6% acrylamide mix and lOxTBE. The plates were 
scaled with 25-50 ml o f  gel mix after the addition o f 170-350 fi\ of both 10% (w/v) 
ammonium persulfate (APS) and TEMED. Once set, the rest o f the gel was poured after 
adding 1-2/d/m l of gel mix o f APS and TEMED to the remaining lxTBE gel mix. A comb 
was inserted upside down in the top o f  the gel to form a well. The upper and lower buffer 
chambers contained 0.5xTBE and lxTBE respectively. The gel was pre-run at 60-140W  
until it reached 50°C. The well was irrigated to remove urea, the comb inserted and the 
samples loaded in the order GATC. The gel was run at a wattage designed to maintain the 
temperature at 50°C. The plates were split and the gel covered in gel fixer (10% methanol 
10% acetic acid) for 15 mins. The gel was transferred to filter paper, covered in Saran wrap 
and dried under vacuum at 80°C. After removal o f the Saran wrap, the dried gel was 
exposed to hyperfilm-/3-max (Amcrsham) overnight in a film cassette.
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TBE (10x1
54.5 g Tris
27.5 g Boric Acid
4.2 g Disodium EDTA
make to 500 ml with distilled water
6% acrylamide gel mix
215 g Urea
75 ml 40% acrylamide/bis-acrylamidc gel mix (Boehringer)
make to 450 ml, stir till dissolved and make to final volume o f 475 ml. Store 4°C.
2.4.8 Polymerase Chain Reactions
The Polymerase Chain Reaction (PCR) was used for several applications. Gene 
fragments produced during PCR were cloned with either blunt-ends or by the incorporation 
of 'tails' containing restriction enzyme sites. PCR was also used to detect recombinant clones 
and to prepare ssDNA for sequencing.
The primers used are shown in Table 2.4. Primers were designed according to 
standard criteria where possible although the choice was limited where they were needed to 
span particular regions for cloning purposes. Primers were synthesised in-house and diluted 
to give a working strength solution o f 1/igul.
A reaction mix was prepared using methods to prevent contamination. The Taq 
polymerase manufacturer's lOx buffer was used (500mM KC1, lOOmM Tns-HCl (pH 8.3) 
15mM MgCI2 and 0.1% gelatin). The MgCI, concentration is critical and was usually 
optimised. This lOx buffer gives a Final molarity o f 1.5mM which is at the low end of the 
normal range used of 1.5 to 4mM. Therefore additional MgCI. was added to identify the 
best concentration for a particular reaction mix. A  typical reaction mix would be:
2 n\ lOmM dATP 
2 nI lOmM dTTP 
2 n\ lOmM dGTP 
2 fi\ lOmM dCTP
10 fi\ lOx Buffer (supplied with the enzyme)
2 fi\ primer 1 (1 ,«g//il for a 20mer)
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Name S '  t o  3 '  s e q u e n c e C om m ents [
UFB B io t in - G C T  TCC GGC TCG TAT 
GTT GTG TG
D yn& bead u n i v e r s a l  p r i x e r
UF GOT TCC GGC TCG TAT GTT GTG 
TG
D y n a b e a d  u n i v e r s a l  p r i s e r  |
URB B io t in - A A A  GGG GGA TGT GCT 
GCA AGG CG
D y n a b e a d  u n i v e r s a l  p r i x e r
UR AAA GGG GGA TGT GCT GCA AGG 
CG
D y n a b e a d  u n i v e r s a l  p r i x e r
T3 ATT AAC CCT CAC TAA AG p B l u e s c r i p t  p r i m e r  ||
T7 AAT ACG ACT CAC TAT AG p B l u e s c r i p t  p r i m e r  {
PA 1 2 2 2 AAT TCA AGT ACG GTC GCA AT I n t e r n a l  PA p r i m e r s  ||
PA 1 2 1 9 CTT TAA TTG TCG CGA GTG TT I n t e r n a l  PA p r i m e r s  ||
ANTHPR3 ATC CGG AGC TCA GAT CTC GAA 
CTC AAG AAA AAA GCG A
C l o n i n g  p r i m e r  f o r  63 icDa 
f r a g m e n t  ||
ANTHPR4 ATC TAG AGA GCT CCT AGG TAT 
CCT ATC TCA TAG CCT TTT TT
C l o n i n g  p r i m e r  f o r  63 JcDa | 
f r a g m e n t
ANPR3S TCG AAC TCA AGA AAA AAG CGA C o m p l im e n ta r y  r e g i o n  c f  
ANTHRR3 |
ANPR4S TAT CCT ATC TCA TAG CCT TTT 
TTA
C o m p l im e n ta r y  r e g i o n  o f  j 
ANTHPR4
BPA3 ATC GGA GCT CCG TCG AAC TCA 
AGA AAA AAG CGA
C l o n i n g  p r i m e r  f o r  63 icDa 
r e g i o n
BPA4 ATC ACT ATC CTA TCT CAT AGC 
CTT TTT T
C l o n i n g  p r i m e r  f o r  63 icDa 
r e g i o n
PAALL5 ACA AAA GCT GGG TAC CTT TTA 
TAC AAA AAG GAG AAC G
C l o n i n g  p r i m e r  f o r  pO R Jl
PAALL3 GGT CGA CTC TAG AGG ATC CTA 
CAA ACA ATC TCA AAG GAT
C l o n i n g  p r i m e r  f o r  p O R fl
Table 2.4 PCR Primers used in this study. Sequences are shown 5' to 3'.
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2 /il primer 2 (1 ,ug/fil for a 20mer)
0.5 /A o f Taq DNA polymerase - 5U/ml (Boehringer) 
x f.rl of DNA template solution 
y fA of H20  to make total to 100 /d
The mixture was pipetted into a 0.6 ml eppendorf tube and placed in the heating 
block o f a PREM 111 (LEP Scientific. Milton Keynes. Bucks) PCR machine. This machine 
automatically allows an equilibration period between temperature points to allow the tube 
contents to stabilize at that temperature. A typical cycle for a 1 kbp fragment would consist
of:
a. 95°C for 5 mins - to completely denature the template DNA for the
first cycle and inactivate any proteases or nucleases 
present.
b. 95°C for 30 secs - to denature the DNA
40°C for 30 secs - to anneal the primers
72°C for 1 min - to elongate the strands
repeat for 30 cycles
c. 72°C for 5 mins - to finish elongating all strands, for cloning
d. refrigerate 4CC - until ready to use product
2.4.8.1 Blunting of PCR products with Klenow
Taq polymerase is able to add a non-template-dependent base to the 3' end of 
extended chains. It is necessary to remove this addition in order to blunt-end clone PCR 
fragments. This was done using the method described by Sardelli (1991). The PCR 
products were gel purified and resuspended in lx  buffer or the Taq enzyme was heat 
inactivated (10 mins at 99°C). The MgCl. concentration was adjusted to 5mM and 1-2U 
Klcnow enzyme added. This was incubated at room temperature for 30 mins and the 
Klcnow inactivated at 95°C for 5 mins. The DNA was either ammonium acetate precipitated 
(PCR mix) or used directly (gel purified DNA).
2.4.9 Electroporation
Electroporation was used in preference to transformation of competent cells because 
of its ease of use and because it was also needed to move plasmids into vaccine strains, as
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the competent cell transformation method selects for rough mutants. The only alternative 
to electroporation was P22 transduction which can be less successful than electroporation 
when plasmids expressing toxic proteins are transformed.
2.4.9.1 Preparation of cells
Stocks o f bacteria for electroporation were prepared in advance and stored at -70°C. 
The cells were grown in 500 ml o f L-broth to mid-log phase (A b s^  of 0.5-0.8). The cells 
were chilled on ice and harvested by centrifugation. They were washed in 500 ml of cold 
10% glycerol and pelleted by centrifugation. This was repeated 3 times with the cells being 
resuspended in 250 ml, 50 ml and 10 ml o f 10% glycerol. The cells were finally 
resuspended in 1 ml and divided into 50 /A aliquots and stored at -70°C.
2.4.9.2 Pulsing cells
An aliquot of cells was thawed on ice. A pulsing cuvette (Bio-Rad) was chilled and 
40 p\ o f cells pipetted into a chilled eppendorf tube. 1-2 /A of the ligation mix or plasmid 
preparation were added, mixed and left on ice for 1 min. The mixture was transferred to the 
cuvette and placed in the pulsing chamber (Gene Pulser, Bio-Rad, Hemel Hempstead). 
£. coli were pulsed at 2.5 KV, 25 pF and 200 ohms. S. typhimurium were pulsed at 1.25 
KV, 25 pF and 800 ohms. The pulse voltage and time constant were checked to ensure that 
a short circuit had not occurred. The time constant for £. coli should be 5 msec and for 
S. typhimurium 20 msec. After the pulse the cuvette was removed and 1 ml of SOC medium 
ased to flash out the cells from the cusette. The SOC was placed in a tube and incubated 
at 37°C for 1 hour. Aliquots o f the SOC were plated out onto selective media plates and 
incubated overnight.
2AAQ Computer analysis o f nucleotide and amino acid data
Nucleotide and amino acid sequence were analyzed using the DNASTAR software 
on a IBM compatible PC. The CLONE programme was used to construct the nucleotide 
sequences from the vector sequence files, PA sequence file - ANTH_PA.SEQ and PCR 
primer sequence entered directly into the CLONE statement. The MAPSE0 programme was 
used to generate the complimentary sequence, identify restriction sites and translate the 
appropriate reading frame into corresponding amino acids.
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mRNA secondary structure was predicted using the algorithm of Zuker & Slieglcr 
(1981) which is implemented within the computer programme Genmon 4.3 (GBF. 
Braunschweig) on a Vax computer. The structure was predicted at a temperature o f 37°C.
2.5 Protein Methods
2.5.1 Preparation of cell lysates
2.5.1.1 Whole cell - routine
Cell lysates were prepared by growing the cells in the appropriate conditions, with 
IPTG induction as required. For quantitative results, the Absw„, was measured and the 
cultures diluted with medium to give the same cell densities. 1.5 ml of culture were 
centrifuged in an eppendorf tube and the supernatant discarded. The pellet was resuspended 
in 100 fi\ of water and 100fi\ of 2xLoading Buffer (2xLB - 62.5 mM Tris pH 6.8, 10% (v/v) 
glycerol, 0.01% (w/v) bromophcnol blue, 3% (w/v) SDS, 5% (v/v) 2-mcrcaptoethanol) was 
added and boiled for 3 mins.
2-5.1.2 Whole cell - chloramphenicol amplification
A modification o f the method o f Little & Lowe (1991) was used to maximise 
plasmid copy number so as to enhance the ratio between cell proteins and recombinant 
proteins. This method was used to show expression of plasmid proteins which could not be 
detected by routine methods. 100 (A o f an overnight culture were added to 30 ml o f L-broth 
supplemented with ampicillin. The culture was grown to an A b s^  of 0 .8  to 1.0 and 
chloramphenicol was added to 170/tg/ml and the culture grown overnight. The cells were 
pelleted and washed in L-broth. The washed cells were resuspended in 30 ml L-broth 
supplemented with ampicillin and incubated for 1 hour. If comparisons were to be made 
between cultures, the Abs„K) was measured and the denser cultures diluted with L-broth to 
give the same A b s^  readings. A set amount of the cultures was then treated as for routine 
whole cell lysates.
2 5.1,3 Cell fractionation
E. coli HB 101 cells were fractionated into pcriplasmic and cytoplasmic fractions by 
a modification of the method of Sambrook et al. (1989). Normally the bacteria were grown
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overnight in 100 ml of modified M9 media to enhance production of alkaline phosphatase, 
but if this media inhibited expression of the recombinant protein then L-broth and any 
necessary inducer was used. After measuring the A bs^ , 40  ml of cells were pelleted and 
resuspended in 1.5 ml of TES (20% sucrose (w/v), 30mM Tris (pH 8.0), ImM EDTA (pH 
8.0)), and fresh lysozyme added (1 mg/ml), and placed on ice for 10-30 mins. The 
sphcroplasts were recovered and the supernatant stored as the periplasmic fraction. The 
spheroplasts were washed in TES buffer and resuspended in 1.5 ml of 100 mM Tris (pH 8.0) 
and ruptured by three cycles of frecze/thawing (dry ice/ethanol to 37°C) and the cell 
membranes and insoluble proteins pelleted to leave the soluble cytoplasmic fraction. The 
pellet was solubilized in 1.5 ml of 1% Triton X-100.
2.5.1.4 Recovery o f periplasmic proteins
This method was used to prepare periplasmically located recombinant PA (rPA) from 
E. coli JM 109 bacteria containing phagemid pORFl. The rPA was used as an immunogen 
in animal experiments.
10 ml of L-broth supplemented with ampicillin were inoculated with E. coli JM 109 
/  pORFl and grown for 6 hours, shaking at 37°C. 1 ml o f this culture was inoculated into 
10 flasks containing 100 ml L-broth supplemented with ampicillin. The flasks were 
incubated overnight at 37°C in a shaking incubator. rPA production was induced with ImM 
IPTG for 4 hours. The cells were pelleted by centrifuging at 5000 rpm at 4°C for 10 
minutes in a Beckman centrifuge. The pellet was resuspended in 300 ml cold lOmM Tris, 
pH 7.4 and repellcted. The cells were resuspended in 100 ml 10 mM Tris, 0.58M sucrose, 
pH 8.0 at room temperature. 2.2 ml o f  2mg/ml lysozyme were added followed 15 sec later 
by 4.5 ml o .lM  EGTA. This was incubated for 10 min at room temperature. 1.1 ml of 
UKlmM Phcnylmclhylsulphonyl Fluoride (PMSF) were added and the spheroplasts pelleted 
by centrifugation at 10,000 rpm for 20 min at 4°C in the Beckman centrifuge. The 
supernatant was recovered (approx 100 ml). The protein was precipitated with 70% 
ammonium sulphate (47.2 gm ammonium sulphate per 100 ml) added slowly to the stirred 
supernatant which was maintained at 0-4°C. The precipitate was left at 4°C overnight and 
then centrifuged at 14,000 rpm for 6 0  min at 4°C. The supernatant was removed and the 
precipitated proteins resuspended in 5 ml cold PBS and dialysed against 4x one litre changes 
of PBS at 4°C. The solution was spun in an ultracentrifuge using a swing out rotor (55Ti)
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ai 32.000 rpm for 30 min to pellet contaminating LPS and other solid material. The 
supernatant was niter sterilized through a 0.22/tm filter and stored in aliquots at -20°C.
2.5.2 Enzyme assays
Enzyme assays were used to show the accuracy of the cell fractionation method. 
E. coll HB 101 was used as this has the appropriate enzymes present.
2.5.2.1 Alkaline phosphatase enzyme assay
Cell fractions were assayed for the presence of alkaline phosphatase which is present 
in the periplasm in large amounts when the cells arc cultured in low phosphate conditions. 
The assay is as described by Tomani (1967). Samples were diluted in 0.6M Tris pH 8.2 to 
give a volume of 0.9 ml. The substrate was p-nitrophenolphosphale (PNPP) at a 
concentration of 0.0066M (17.4 mg in 10 ml o f 0.6M Tns buffer). The samples were placed 
in cuvettes and maintained at 28°C in a water bath. 100 fil of the substrate were added to 
each cuvette and the increase in absorption at 414nm. due to the formation of yellow p- 
mtrophcnol. was monitored at several time points. Values were compared to a blank 
containing buffer and substrate. Enzyme units/ml of sample were calculated as:
Enzyme units------- ¿«to x  factQr
ml time (mins)
2.5.2.2 fl-galactosidasc enzyme assay
Cell fractions of HB 101, which carries the laeZ gene on the chromosome, were 
assayed for /3-galactosidasc activity, an enzyme that is found cytoplasmically. The assay was 
described by Miller (1972). The samples were diluted in Z buffer to a final volume o f 0.8 
ml. placed in capped cuvettes and maintained at 28°C in a water bath. The substrate was 
4 mg/ml o-nitrophcnyl-/3-D-galactosidc (ONPG) in 0 .1M phosphate buffer pH 7.0 (61 ml 
0.1M Na?H P 04 and 39 ml of 0 .1M NaHjPOJ. 0 .2 ml of substrate was added to each cuvette 
and the increase in absorbance at 420nm monitored as this represented the formation of 
yellow 0-mtrophcnol. The values were compared to a blank containing only buffer and 
substrate. The absorbance at 550nm was also monitored as this represented the light 
scattering due to debris and was used as a correction factor. The enzyme units /ml of 
sample were calculated as:
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Enzyme units ^ 420~l-75X/4si0 
mi firn« (mins)
X dilution factor X 1000
Z Buffer
NajHPO.THX)
NaH2PO4.H ,0
KCI
0.06M
0.04M
0.01M
M gS0,.7H ,0
/3-mcrcaptoethanol
0.001M
0.05M
adjust pH to 7 with orthophosphoric acid.
2.5.3 Proteolytic cleavage of PA - Trypsin digests
Full length PA was treated with trypsin to cleave the 83 kDa protein into 63 kDa and 
20 kDa fragments. These could he used as markers on Western blots. Agarose beads coated 
with N-tosyl-L-phenylalanine chloromethy! ketone (TPCK) treated insoluble trypsin (Sigma) 
were washed in Tris/Glycinc (25mM Tris pH 8.0, 0.2M Glycine) buffer and resuspended in 
buffer to give 38 Units activity/ml. Freeze-dried PA was reconstituted with water to give 
a concentration o f 1.75 mg/ml. 50 ft I of this PA solution were mixed with 60 ft\ o f  the 
washed trypsin beads and incubated for 30 mins at room temperature. The tube was spun 
to pellet the beads and the supernatant removed and 50 ft\ o f 2xLB added. This was boiled 
for 2 mins. For SDS-PAGE this was diluted 1 in 10 in lxLB and 20 ft\ loaded per well. 
Unclcavcd PA was diluted to the same extent and run separately.
2-5:4 Sodium dodccyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
The Bio-Rad Mini Protean II Gel apparatus was used for SDS-PAGE. The apparatus 
was cleaned and assembled according to the manufacturer's instructions The gels were 
made according to the method of Sambrook et al. (1989) at the required G acrylamide - 8% 
was used for most routine gels for PA and all gels had a 5G stacking gel. The higher 
concentration o f ammonium sulphate used eliminated the need for degassing of the gel mix. 
A 10 well comb was inserted into the stacking gel. The gel was allowed to set, the comb 
removed and the wells washed out with water. The gel holders were assembled into the 
apparatus and inserted into the tank which was filled with running buffer (15.15 g Tris,
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72.05 g Glycine. 5 g  SDS, make to 5 litres). 5-25 fi\ of samples and appropriate markers 
(Dalton V1I-L (Sigma) or pre-stained low range markers (Bio-Rad)) were loaded into the 
wells. The gel was electrophoresed at 200 V  until the dye front had reached the bottom of 
the gels.
2.5.5 Protein staining
2.5.5.1 Coomassie staining
The proteins separated by SDS-PAGE could be visualised in the gel by 
simultaneously fixing and staining them with Coomassie Brilliant Blue in methanol:glacial 
acetic acid (0.25 g Coomassie Brilliant Blue R250, 45 ml methanol, 10 ml glacial acetic 
acid, 45 ml water). The gels were stained for at least 2 hours and the stain was replaced 
with destain solution (as above, less the dye) and left until the required amount of destaining 
had occurred. The gels were stored in sealed plastic bags in 10% glycerol.
2.5.5.2 Protogold staining
Western blots were stained to show protein bands by staining with a stabilised 
colloidal gold solution. Protogold (BioCell Research Laboratories. Cardiff). The 
manufacturer's instructions were followed. Silver enhancing was not found to be necessary.
2.5.6 Western Blotting
2 5.6.1 Electrobloiting of proteins
During the PAGE, polyvinylidene diflouride (PVDF) membrane (Immobilon-P, 
Millipore, Watford) was wetted for 3 secs in methanol and then washed in water for 2 mins 
and placed into transfer buffer (25mM Tris, 192mM Glycine, 20% (v/v) Methanol pH 8.3). 
After electrophoresis the glass plates were split and the gels equilibrated in transfer buffer 
for 5 mins before being placed onto a filter paper pad. The gel was covered with the wetted 
PVDF membrane and another filter paper pad. This was placed between two fibre pads and 
sandwiched in a Bio-Rad Mini Trans-blot holder. The holder was replaced in the 
electrophoresis tank with an ice filled temperature stabilising compartment and eleclroblotted 
at 100 V for 1 hour. The gel was Coomassic stained to verify that the proteins had blotted 
across from the gel. The blotted proteins could also be visualised by running a duplicate gel 
onto PVDF membrane and then staining the protein bands with Protogold.
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2.5.6.2 Detection of blotted proteins
The PVDF membrane was blocked in either 1% Blotto (1% (w v) Semi-skinned Milk 
Powder in PBS) or 5% Bovine Scrum Albumin (BSA)-PBS for .10 mins at 37°C. All 
subsequent washes were performed with either 0.1% Blotto or 0.1% BSA-PBS respectively. 
The membrane was washed three times on a shaking table for 2 mins each. The membrane 
was incubated at room temperature for 1-3 hours on the shaking table in primary antibody 
diluted appropriately in 20 ml o f washing solution. The membrane was washed 3 times for 
5 mins each to remove the unbound primary antibody. The labelled secondary antibody was 
added for 1-3 hours, this was cither a 1:100 dilution of gold labelled antibody in 5% gelatin, 
0.1% BSA/PBS (Auroprobe BLplus) or a 1:1000 Horse Radish Peroxidase linked antibody 
(Sigma). If gold labelled antibody was used, the membrane was washed twice for S mins 
each and then washed twice for 1 min each in distilled water and equal volumes (7.5 ml) 
of enhancer and initiator solutions (IntenSE BL) added. For HRP-linked antibody the 
membrane was washed 5 times in PBS and then a fresh substrate solution o f DAB (55 mg 
3,3'-diaminobenzidine, a small crystal cobalt chloride, 100 id o f H20 : in 100 ml PBS) added. 
The colour was allowed to develop and the reaction stopped by washing in excess water.
2-5.7 Colony Blotting
Colonies were picked and streaked onto duplicate plates. The streaks were about 1 
cm long with approximately 20 streaks per plate. The plates were grown overnight. Circles 
of sterile nylon membrane (Hybond-N) were soaked in lOOmM 1PTG and allowed to dry. 
The membrane was placed over the plate and orientation marks drawn. The membrane was 
removed and placed colony side up on Filter paper soaked in L-broth and antibiotic. The 
membrane was incubated for 1-2 hours at 37°C. The bacteria were l\sed by suspending the 
membrane over chloroform in a bell jar for 30 mins. The membrane was then placed face 
down in a pctri dish containing 10 ml o f Tris-buffered saline (TBS - 8 g NaCl. 0.2 g KC1, 
3 g Tris, add 800 ml water and adjust pH to 7.4 with HQ. make to 1 litre), 4 mg lysozyme 
and 100 /ig  DNAse I (Bochringcr) and agitated on a shaking table. The membranes were 
washed twice in TBS and then blocked in 2% Blotto for 30 mins ai 37°C. The membrane 
was washed in PBS and then incubated in the primary antibody - 1:1000 mouse anti-PA 
MAb in PBS • for 1 hour. The membrane was washed three umes in PBS and then 
incubated with the secondary antibody - 1:1000 horse radish peroxidase labelled anti-mouse
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IgG (Sigma)- for 1 hour. After washing 3 times in PBS the substrate DAB was added (see 
Section 2.5.6.2) and the colour developed. The membranes were washed and allowed to dry. 
Positive colonies were identified and linked to the duplicate plate streak.
2.5,8 Enzvme-linked Immunosorbent assays (ELISAt 
2-5.8.1 LTJ3
The ELISA method for LT-B and the anti-LT-B monoclonal antibody was provided 
by Dr. T Hirst (University of Kent). Microtiter plates were coated with 100 ¿d per well of
1.5 ng/m\ of monosialogangliosidc GM1 (Sigma) dissolved in PBS. Plates were incubated 
overnight and then stored at 4°C until required. Plates were washed 2x with PBS and 
blocked with 200 fA o f 0.1% BSA dissolved in PBS at 37°C for 30 min. After 3xPBS 
washes the samples were added with serial dilutions in 0.1% BSA/PBS and a final well 
volume of 100 /A. The plates were incubated at room temperature for 60 min and then 
washed 3x in PBS/0.05% Tween-20. The anti-LT-B antibody was diluted 1:400 in 0.1% 
BSA/PBS and 100 fi\ added to each well and the plate incubated at room temperature for 60 
mins. After 3x washes in PBS/0.055% Tween-20, 100 /A o f a 1:1000 dilution of horse­
radish peroxidase labelled goat anti-mouse IgG antibody (Bio-Rad) in 0.1%BSA/PBS were 
added and incubated for 60 min at room temperature. The plate was washed 3x in 
PBS/0.05% Tween-20. 30 mg of 2,2'-Azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) 
(ABTS) (Sigma) were added to 50 ml o f buffer (0.2M phosphate/citrate buffer pH 4.3) with 
50 fA o f H20 2. 100 /d o f this substrate were added to each well and the plate read at 414nm 
in a Titcrtek Multiscan MCC/340 Mk II plate reader.
2.5.H.2 Anti-PA antibodies
Antibody titers against PA were measured using an ELISA by one o f two methods. 
Mouse sera was tested by Dr PCB Turnbull, CAMR using an inhibition ELISA described 
in Turnbull et al. (1986). Briefly, a flat-bottomed 96 well microtiter plate was coated with 
PA (15 /¿g/ml PA in coating buffer - 0.16 g Na2CO„ 0.29 g NaHCO, made to 100 ml, pH 
9.6) and allowed to dry. The wells were blocked with fetal calf serum, washed with PBS- 
0.0005% Tween 20 (PBST), and dried. For use, the plate was marked of in pairs o f rows. 
50 fA of PBST were added to the lefthand row of each pair o f rows, and 50 fA o f PA-PBST 
(15 ng/mY) to the righthand row of each pair of rows. In the first well o f each lefthand row
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add 25 fi\ o f  PBST. and add 25 fi\ PA-PBST lo the first well of each nghthand row. Add 
25 /d of sample to both first wells and double dilute 50 fjl down the row discarding the last 
50 fi\. Incubate for .TO mins at T7°C, wash and add a 1:800 dilution of HRP-labelled rabbit 
anti-mouse IgG (Sigma). After incubating at T7°C for 15 mins, wash and add 5 0 /d ABTS 
substrate (TO mg of ABTS added to 50 ml o f 0.2M phosphate curate buffer pH 4.T with 50 
fi\ of H ,0 2). Read Absw, on a microtitcr plate reader. The results are interpreted by looking 
for the last pair of wells which have a difference greater than 0.2 Abs^, units between the 
standard and inhibition rows.
The rabbit anti-sera was tested by Dr. ED Williamson. CBDE using a modification 
of the above technique. Inhibition rows were not run, the plates were blocked with 4% BSA 
in PBST and the secondary antibody was from Bio-Rad and was used at 1:1000. The 
endpoint was assumed to be 0.2 Abs^,, units once the values had been zeroed against normal 
rabbit serum controls.
The second method was used to test for anti-PA antibodies from the in-house mouse 
experiment using the appropriate anti-mouse reagents and controls.
2Ji Animal Experiment methods
2.6.1 Preparation of anti-PA polyclonal antibodies
Two female New Zealand White rabbits weighing T-5 kg were immunized with an 
initial injection of 0.25 ml of the human anthrax vaccine (DHSS. Russell Sq, London; Batch 
Number T.T0/E) given intramuscularly in two hindlimb sites. This was followed by two 
booster immunizations of 0.5 ml o f  vaccine at 2 and 4 weeks. As the anti-PA litres were 
only 1:640 at 6  weeks, two extra 0.5 ml immunizations were given at weeks 10 and 12 and 
the animals bled out at week 15. The blood was collected in 9.5 ml SST Gel and Clot 
activator Vacutainer tubes (Bccion Dickinson, Mavlan Cedex. France) and after the clot had 
formed, the tubes spun and the sera removed and stored at -21PC. The sera was tested for 
anti-PA antibodies by Dr. ED Williamson, CBDE.
2Jl2 Growth of cultures lor inoculations
2.6.2.1 Preparation of seed cultures
The strains to be used for animal inoculations were grown overnight on agar plates 
containing antibiotics if required. A single colony was picked into 10 ml L-broth (with
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antibiotic as required) and grown overnight. Sterile glycerol was added to 10% and the 
mixture aliquoted into sterile 1 ml screw-lopped tubes which were frozen at -70°C as a seed 
culture. One tube from each batch was checked for aro and his phenotypes with the 
appropriate minimal media plates and for antibiotic resistance by plating out on L-agar and 
L-agar/ampicillin plates. Plates were checked for a smooth colony morphology and the 
absence of contaminants. The smooth phenotype of the S. typhimurium was also verified by 
showing the ability of the smooth phenotype sensitive phage P22 to adsorb to and lyse the 
bacteria and by analysing the LPS pattern on silver stained gels for differences between the 
wild type LPS and the seed cultures.
For P22 lysis, the bacteria were grown overnight and then mixed with appropriate 
dilutions of a P22 HT105/1 ini transducing phage preparation. The infected bacteria were 
incubated for 45 mins at 37°C and then mixed with 3 ml o f 0.7% top agar at 47°C and 
spread onto L-agar plates. The plates were examined for the appearance of plaques.
LPS was prepared from a whole cell suspension boiled in sample buffer and treated 
with 25 pg o f proteinase K (Sigma) and then incubated at 60°C for 60 mins. The samples 
were analyzed by PAGE and stained with Bio-Rad silver stain kit according to the 
manufacturer's directions.
2.6.2.2 Preparation of inoculum for oral vaccination
For oral animal inoculations, one o f  the seed culture tubes was used to inoculate 
100-400 ml o f L-broth (with ampicillin if required). The seed culture tube was then 
discarded. The L-broth was grown at 37°C statically overnight. The Abswri was measured 
and the cells pelleted and washed in ice-cold PBS. The cells were pelleted and then 
resuspended in an appropriate amount of PBS (assuming an Abs**, of 1 was equivalent to 
2 x l0 9 cells) to give twice the required cell density. This allowed for losses in the 
experimental procedure. The Absu>, of a 1:10 dilution was checked and the final volume of 
PBS revised to give the required cell density. An appropriate amount of cell suspension was 
aliquoted into an Universal flask and kept on ice until required. Duplicate serially dilutions 
in PBS of the cell suspension were made and aliquots plated out on duplicate plates and 
grown overnight. Colonics were counted and the actual viable count calculated. Plates were 
checked for a smooth colony morphology and the absence o f contaminants.
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2.6.2.3 Preparation of inoculum for IV vaccination
For IV animal inoculations, one of the seed culture tubes was used to inoculate 100 
ml o f  L-broth (with ampicillin if required). The seed culture tube was then discarded. The 
L-broth was grown at 37°C statically overnight. The cells were pelleted and resuspended 
in 10 ml of sterile ice-cold PBS/10% glycerol. 0.7 ml aliquots were frozen at -70°C. To 
check the phenotype of the frozen inoculum, aliquots were defrosted at 37°C and plated out 
on L-agar and L-agar supplemented with ampicillin plates. Also the aro phenotype was 
checked by plating on minimal media plates with and without aromatic amino acid 
supplementation. The viable cell count of the frozen stock was determined by serial 
dilutions and spiral plating. Plates were checked for a smooth colony morphology and the 
absence of contaminants.
On the day of an experiment, a vial was defrosted at 37°C and diluted in ice-cold 
PBS to give 2.5x10s viable cells/ml. A dose o f 0.2 ml IV would therefore contain 5x10s 
viable cells/ml. The actual count for the inoculum was verified by spiral plating a 1:100 
dilution.
2.6.3 Method of inoculation
For oral (intra-gastnc) inoculation, mice were lightly anaesthetized by placing them 
in a bell jar containing halothane soaked gauze beneath a metal screen. Once the mice had 
lost their righting reflex they were removed from the bell jar and held by the skin at the back 
of the neck so that the axis o f the body was a straight line. A  blunt ended needle on the end 
of a 1 ml syringe containing the inoculation dose, was gently inserted down the oesophagus 
to mid-thoracic level and the inoculation administered. The needle was withdrawn and the 
mouse allowed to recover from the anaesthetic.
For IV inoculation, mice were restrained with their tail exposed. 0.2 ml of the 
inoculum was injected into the tail vein.
2.0,4 Antibiotic selection in v ivo
Ampicillin was used in some groups to attempt to maintain selection pressure so that 
plasmids would be maintained within the attenuated S. typhimurium. An ampicillin 
Trihydratc suspension (Penbrinn Injectable suspension POM, Smithklinc Bcccham Animal
53
Chapter 2. Materials and Methods
Health) containing 150mg/ml ampicillin was used. Mice were administered 50 /d (7.5 mg) 
SC once a day for seven days.
2.6.5 Vaccination with PA and rPA
Groups of mice were vaccinated with either PA (HPLC purified from B. anthracis 
culture supernatant) or rPA (purified from E. coli containing phagemid pORFl) mixed 50:50 
with FIA. The PA/rPA was diluted in PBS to give a concentration o f 50/d of this
were mixed with 50/d o f FIA and administered IP. Three doses were given 14 days apart.
2.6.6 Organ bacterial counts
At certain time points animals were euthanised by cervical dislocation and the 
animal's liver and spleen removed and placed in ice-cold PBS. The organs were placed 
separately into a Stomacher bag and 10 ml ice-cold PBS added. The organs were 
homogenised in a Stomacher Lab-Blender Model 80 (Seward Medical, London) for 2 min. 
Four 50Qul aliquots, a 25 f/1 and a 100 /A aliquot o f the homogenised organ were plated out 
on both L-agar plates and L-agar plates supplemented with ampicillin. The plates were 
incubated at 37°C overnight and colonies counted the next day. Depending on the colony 
density on the plates the total organ count was determined. The difference between the 
count on the L-agar and antibiotic supplemented plates was used to quantify the percentage 
of the bacteria which were still ampicillin resistant.
2.6.7 Serum anti-PA antibody levels
Mice were bled either from the tail vein or by cardiac puncture in anaesthetized 
mice. The blood was allowed to clot and the serum removed and stored at -20°C. The anti- 
PA antibody titre was determined by ELISA.
2,0.g Challenge with virulent B. anthracis
All procedures with B. anthracis took place in approved Advisory Committee on 
Dangerous Pathogens (ACDP) Category III containment facilities within CBDE. The 
animals were maintained within a negative-pressure flexible film isolator for the 14 day 
challenge experiment.
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B. anthracis Vollum 1B was grown from a frozen spore stock on nutrient agar plates.
The bacteria were washed from the plates in sterile water and heated at 60°C for 60 minutes 
to kill vegetative cells. The spore preparation was washed by centrifugation. Serial dilutions 
were plated out to establish the spore count of the preparation which was found to be 1(1' 
spores/ml. The stock was kept in a glass container at 4CC. On 3 occasions the spore stock 
was diluted to give 500 spores/ml and this was plated out to establish the accuracy and 
reproducibility of the dilution method.
For challenge experiments, the spore stock was diluted on the day of the challenge 
and an appropriate volume injected SC in the mice. 1 ml of the diluted stock was plated out 
on nutrient agar plates and incubated overnight at 37°C. The colonies on the plates were 
counted to determine the actual cfu/ml count and hence derive the dose given.
Mice were checked twice a day. Any moribund mice were humanely cuthaniscd. 
Deaths were confirmed as been due to anthrax by examination of blood smears from dead 
mice for evidence o f the M'Fadyean reaction. Staining and examination of slides was carried 
out by Mr A Stagg (CBDE).
2.6.8.1 Diagnosis o f  anthrax - the M'Fadvean reaction
Blood films were made by clipping the tail o f dead animals and smearing the blood 
onto a slide. The film s were air-dried in the ACDP Category III isolator and then transferred 
to a Class III microbiological safety cabinet The slides were heat fixed and stained for 
with polychrome methylene blue, which after 30 secs was washed off into hypochlorite 
solution. The slides were dried and examined microscopically for the reddish-purple 
capsular material and deep blue bacilli, an appearance referred to as the M'Fadycan reaction 
(Turnbull, 1990).
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Chapter 3. Detection of B. anthracis
3.1 Introduction
This chapter describes the development o f  the Polymerase Chain Reaction (PCR) and 
methods for the analysis o f PA by Western blotting which formed a background for the use 
of these techniques in this study.
PCR is a technique with many applications. Experience with this system was needed 
so that it could be used to detect the PA gene in recombinant organisms, assist in cloning 
precise fragments of the PA gene and also to identify the presence of recombinant organisms 
in animal tissue samples. Initial experimental work concentrated on using PCR to identify 
genes in the host organism B. anthracis and this experience was used to devise methods of 
identifying and amplifying the PA gene in other situations. The objective was to gain an 
insight into the requirements and limitations of the PCR.
There are a number of methods which could have been used for identifying the PA 
expressed from recombinant organisms. One possibility is an ELISA test which would 
measure the total amount of protein which was bound by the capture and detection 
antibodies used. This system is dependent on the specificity of the antibodies used and does 
not give any information on the size and fragmentation o f the immunoreactive protein. 
Western blotting allows visualisation o f immunoreactive protein bands which have been 
sepiarated by PAGE. This method provides information on the fragmentation of the protein 
and so is the method of choice. The objective o f  this work was to evaluate the different 
antibodies available for Western blotting and assess the quantitative nature of Western 
blotting.
1 2  Detection of B. anthracis and recombinant clones by the PCR
Spxires of B. anthracis are commonly found in the environment. They are also a 
potential Biological Warfare agent. One method o f detection of these spxircs is using the 
PCR. This relies on the amplification o f a gene unique to B. anthracis and preferably one 
which is required for virulence. The two important virulence factors arc the toxin and the 
capsule which are encoded on plasmids pXOl and pX 02. As the toxin is required for 
virulence, its encoding genes are possible targets for PCR. An initial study was made on the 
detection of spxircs by amplifying part o f the edema factor (EF) gene from spore 
preparations. Experience with this was useful in designing PCR primers for PA and their
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use to detect the PA gene in animal tissue samples and for the identification o f recombinant 
clones containing an insert of the PA gene.
3.2.1 Design of primers homologous to parts of the EF and PA genes
PCR primers were designed to bind to the EF gene of B. anthracis and amplify a 
1247 bp fragment o f the gene. After extensive homology searches through GcnBank, the 
primers used showed significant homology only with the EF gene (Carl et al., 1992).
The PA gene is a preferred target for detection of virulent B. anthracis strains as it 
is an essential component of the anthrax toxin complex. Strains lacking the EF gene, but 
still producing Lethal toxin (PA and LF), are still virulent (Pezard et al., 1991), but strains 
lacking a functional PA gene would have reduced virulence (Leppla, 1991; Pezard et a i,
1991). PCR primers ANTHPR3 and ANTHPR4 were originally designed for cloning 
purposes (see Chapter 5) and so were homologous to specific regions of the PA gene. These 
primers contained 5' tails which were not homologous to the PA gene but coded for 
restriction sites that would be incorporated into the PCR product. As these primers worked 
efficiently in PCR reactions with both plasmid and chromosomal DNA, their potential as 
PCR primers for detection was evaluated. For detection purposes primers ANPR3S and 
ANPR4S were made to contain only the homologous portion o f the original primers. The 
sequence o f the primers is shown:
5' to 3' sequence Length CG ratio
ANPR3S TCG AAC TCA AGA AAA AAG CGA 21 38%
ANPR4S TAT CCT ATC TCA TAG CCT TTT TTA 24 29%
The CG ratio of the primers was constrained by the AT richness o f B. anthracis DNA.
In order to assess the potential o f these primers to hybridise with genetic material 
from other pathogenic organisms or environmental contaminants, a search o f the 
GcnBank/EMBL database (release 74, 102947 entries) was conducted by Mr K Martin 
(CBDE). The search was conducted to identify matches with the primers at an homology 
of 78% or greater. This search revealed 47 panial sequence matches but, as can be seen in 
Figure 3.1, the partial matches were well separated from the 100% homology of the primers 
with the PA gene suggesting that it would be possible to avoid false positives by adjusting
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Figure 3.1. Homology between PCR primers and GenBank sequences
This Figure illustrates the % homology between the PCR primers designed from the 
B. anthracis PA gene (ANPR3S and ANPR4S) and other nucleotide sequences contained 
within the GenBank/EMBL database (release 74, 102947 entries). The homology of the 
primers with the PA gene (100%), is shown at the bottom right of graph. The nearest 
homology is at 84% homology (ANPR4S and an unspecified GenBank sequence) which 
suggests that it would be possible to modify the annealing conditions of the PCR reaction 
to exclude false positives.
The homology searches were performed using the GENEMAN program, part o f the 
DNASTAR software.
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Figure 3.1 Homology between PCR primers and GenBank sequences
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the stringency o f the PCR reaction conditions.
3.2.2 Detection of B. anthracis snores using PCR primers homologous to the EF gene
A PCR using the EF primers generated a visible band on an agarose gel when used
with a DNA template of 105 copies o f  a plasmid containing the gene or on the DNA released 
from 2 x 104 spores. If the product from a first round of the PCR was used as a template 
in a second PCR reaction, with primers that bind within the First PCR product (nested PCR), 
it was possible to produce a band from a dilution theoretically containing a single plasmid 
gene or 2 spores o f  B. anthracis. Various protocols were designed and tested to release the 
DNA from the spores so that it could act as a template in the PCR reactions.
3.2.3 Detection of PA gene in animal tissues
For the purposes of this study, the detection of the PA gene within animal tissues 
would allow screening o f animal samples for recombinant Salmonella containing the PA 
gene. As the bacteria would be expected to persist within the liver and spleen, these tissues 
were chosen for this study. These organs contain many enzym es which, when the cells are 
lysed, may degrade DNA. Thus an initial study was made to see if the PCR would identify 
the PA gene in a spleen tissue sample. Normal mouse spleens were removed and 
homogenised in 5 ml o f sterile water. Aliquots were inoculated with a colony of 
S. typhimurium either containing a plasmid with the PA gene or no plasmid. As the 
homogenate was found to coagulate on boiling, it was diluted. 5 p\ o f the spleen 
homogenates were mixed with 65 p\ o f water, boiled to lyse the bacteria, made to 100 p\ 
with a PCR master mix, and subjected to 35 cycles o f PCR with primers ANPR3S and 
ANPR4S. Negative controls included spleen homogenates without bacteria and water alone; 
the positive control was water inoculated with Salmonella. The controls gave negative and 
positive results as expected. Only two out of three positive inoculated spleen samples gave 
DNA bands o f the expected size. This showed that the PCR reaction can lake place in the 
presence of the diluted spleen material. As the spleens were initially homogenised in 5 ml 
of water, and tested at 1:1000 dilution, the concentration o f  positive bacteria within the 
spleen would need to be large enough to detect bacteria using this method. This would be 
expected to be the case in an animal clinically affected with anthrax, but with an oral dose 
of 1.6 x 1010 attenuated S. typhimurium SL 3261 the numbers o f  bacteria within the liver and
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spleen drop to 10M 03 bacteria per organ by 7 days post-infection (Maskell et a i,  1987). 
This would be close to the theoretical limit o f  detection of 1 bacteria in 5 /A of the spleen 
homogenate. It seems likely that to detect the PA gene in these circumstances a means o f  
concentrating the bacteria (or the DNA) would be required.
3.2.4 Use of PA PCR primers in identifying recombinant clones
A simple method for identifying recombinant clones by PCR has been described by 
several authors including Sandhu et al. (1989). Following transformation of bacteria with 
ligated DNA, the bacteria were plated on selective media and grown overnight. Part o f  a 
colony which grew was picked from the plate, suspended in water or PCR reaction mix, 
boiled to lyse the cells and subjected to PCR with primers which would only produce an 
amplified band from DNA template containing the insert. If the primers are chosen so that 
one binds within the vector and the other on the insert, a product will only be seen if  the 
insert is in the correct orientation.
This method was used to identify recombinant plasmids during several experiments 
as described in subsequent chapters. In one case false positive results were seen when 
colonies tested generated a PCR product but were subsequently proved not to contain the 
insert. These false positives were attributed to contamination o f the agar plate with unligated 
insert from the original ligation mix. This could be transferred from the plate to the PCR 
reaction mix when the colony was picked from the surface o f the plate. A protocol was 
established to treat bacteria suspensions with DNAse I prior to lysing the cells. This was 
shown to destroy insert DNA added to the sample, but not to prevent the PCR reaction 
producing a positive result with insert-containing recombinant clones. An alternative 
approach, which required a delay in analysing the samples, was to pick the colony and dilute 
it in 10 ml L-broth and grow overnight before removing 10 /ri for analysis. This diluted out 
any contaminated DNA. False positive results were not seen if PCR primers were used 
which bound across the vector insert junction.
3.3 Detection o f PA bv Western blotting 
1 M  Prc-stained Molecular Weight (MW) markers
In order to estimate the MW o f immunorcactive bands after Western blotting, 
prestained MW markers (Bio-Rad, Low Range) were used in SDS-PAGE. Prestained
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markers do not migrate within gels in the same position as the unstained proteins, and so are 
assigned apparent MWs by the manufacturer. During the course of this work it became 
evident that the apparent MW assigned to each marker did not agree with the expected size 
of the protein bands. To investigate this anomaly, and assign new apparent MWs to each 
band, dilutions of Sigma SDS 6H MW markers, a standard amount of prestained markers 
and trypsin cleaved and uncleaved PA w ere electrophoresed through an 8% SDS-PAGE gel. 
The amount of PA loaded approximated to that found in bands from whole cell lysates. The 
dilutions o f Sigma MW markers were adjusted to give bands o f similar intensity to the PA 
bands. To take into account any effects o f  blotting, the proteins were transferred using the 
standard protocol onto PVDF membrane. The Sigma MW markers and the PA were then 
visualised on the PVDF membrane by staining with Protogold protein stain. The developed 
blot is shown in Figure 3.2. The diluted MW markers (lane 3) gave bands of a similar 
colour density to the PA bands and so this lane was selected for a calculation o f the apparent 
MWs of the prestained markers compared to known MW markers. A  graph of log MW 
against relative mobility was plotted for the Sigma MW markers in lane 3 and used to 
estimate the apparent MW o f the prestained markers in lane 6. The results gave new 
apparent MWs which are shown below (in  kDa) and were used for this work. Other workers 
have reported similar apparent MWs for these markers and those quoted in Su et al. (1992) 
are shown.
Bio-Rad MW markers This study Su et aL, 1992
claimed size (kDa) (kDa) (kDa)
106 92 97.4
80 66 66.2
49.5 45 45 I
32.5 29 31 I I
2JL2 Polyclonal anti-PA Antibodies
Two types of anti-PA polyclonal sera were used in this study.
'Neptune' serum was raised in a horse given repeated injections o f  the Sterne live 
spore vaccine. This was produced at the Microbiological Research Establishment, Potion
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Figure 3.2. Protogold stained blot to compare MW markers.
MW markers and PA were separated by SDS-PAGE (8% gel), transferred onto 
PVDF membrane and the membrane stained with Protogold.
Lanes 1 and 6 contained 10 fi\ and 20 //I respectively of Bio-Rad prestained MW markers. 
Low range. The four bands present were assigned apparent MWs (Da) by the manufacturer 
of: 106.000, 80,000, 49,500, and 32,500.
Lanes 2 to 5 contained 20, 10, 5 and 2 fi\ o f Sigma 6H MW markers diluted 1:25 in water. 
The MWs (Da) are 205,000 (faint band 1.2 mm below blue line in lane 3), 116,000, 97,400, 
66.000, 45,000 and 29,000.
Lane 7 contained 2 0 /d o f  uncleaved PA (approx 1.1 fig)
Lane 8 contained 20 fi\ o f  trypsin cleaved PA (approx 1.1 fig)
/
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Figure 3.2 Protogold stained blot to compare MW markers
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Down during the 1950's. This scrum was not specific for PA but would be expected to 
contain antibodies to other B. anlhracis antigens and antibodies against other antigens that 
the horse had been exposed to.
A more specific anti-PA serum was raised in rabbits during this study. The animals 
were given 5 injections of human anthrax vaccine which consists mainly o f PA. After the 
second injection the anti-PA litres, measured by ELISA, were 1:640 and had risen to 1:3200 
after the fourth injection, but dropped to 1:1600 after the fifth injection.
When these polyclonal sera were used as the primary antibody in Western blots, 
multiple bands appeared on the gels including bands in the control lanes. Also the level of 
background staining was high. This is shown in Figure 3.3. Quenching of the antibodies 
with sonicated extracts o f 5. typhimurium cells was tried but was not found to reduce 
background staining levels (results not shown). As the quantity of PA produced by 
recombinant clones in this study was easily visible on Western blots, the use of monoclonal 
antibodies was investigated to reduce the immunoreactivc bands due to other antibodies 
present in the polyclonal sera.
3.3.3 Monoclonal anti-PA Antibodies
Three mouse monoclonal antibodies (3B6, 2D3 and 14C7) (Little et at., 1988), 
obtained from the US Army Medical Research Institute for Infectious Diseases, were 
evaluated for their suitability as primary antibodies for Western blots. The hybridomas 
secreting the antibodies were produced using different immunization schedules with purified 
PA. In vivo neutralization studies showed a significant delay of time to death (2D 3) or 
survival (3B6 and 14C7) in rats after IV injection o f the MAb and lethal toxin (Little et al., 
1988). 3B6 and 1 4 0  were assumed to recognise the same antigenic region on the basis of 
competitive-binding experiments and shown to inhibit binding o f PA to cells. These two 
MAhs arc thought to bind to the cell-receptor site which has been localized to the C-tcrminal 
end of PA (Singh el al., 1991). Deletions at the C-terminal end were shown to produce PA 
that was not recognised by these two MAbs (Little & Lowe, 1991). The binding site for 
2D3 differs from 3B6/14C7 and has not been identified. It has been reported that these 
MAbs do not bind to PA after immunoblotling from SDS-PAGE gels (Singh el al., 1991) 
but this effect was not seen in this study. It is possible that this was due to the PA re­
configuring during the Western blotting process in (he absence o f  SDS in the blotting buffer.
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Figure 3.3. Western blots with polyclonal anti-PA antibodies
Whole cell lysates were made of S. typhimuruun SL 3261 with pBluescript (lane 1) 
or pVET4M (lane 2). Trypsin-cleaved PA was diluted 1:10 with lxLB (lane 3). 10/4  of  
each were loaded and two repeats o f this were made. 10 /d  of Bio-Rad prestained MW 
markers, low range, were loaded on the lefthand side of the gel and the proteins separated 
by SDS-PAGE (8% gel). Apparent MWs are marked beside the gel. The proteins were 
transferred onto PVDF membrane, the repeats cut into two strips and treated with either a 
1:500 dilution o f Neptune (Horse) sera or 1:1000 dilution o f  rabbit anti-PA sera. The 
appropriate HRP conjugated anti-species IgG was used as the secondary antibody at 1:1000. 
The substrate DAB was used to detect the secondary antibody.
The Neptune sera was from a horse vaccinated with the live spore vaccine. The 
rabbit sera was from a rabbit vaccinated with the human anthrax vaccine which consists 
mainly o f adjuvanted PA.
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Figure 3.3 Western blots with polyclonal anti-PA antibodies
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As two o f the MAbs bind to a site at the C-terminal end it would be expected that they 
would only bind to PA-83 or fragments which contain the C-terminal end.
The MAbs were used in Western blots separately as shown in Figure 3.4. It was 
found that the MAbs bound to both cleaved B. anthracis PA and a recombinant PA-63 which 
has a modified C-terminal (addition of 5 amino acids, see Chapter 5). The MAbs which 
bind to the C-terminus o f PA show only the PA-63 band in the cleaved PA and the PA-20 
band is not visualised. The recombinant PA-63 is degraded and so shows multiple bands. 
As the 3 MAb produced similar patterns, in most routine blots the three MAbs were used 
together at a 1:1000 dilution.
3.3.4 Quantitisation of band intensity in Western blots
As it was necessary to make quantitative comparisons between immunoreactive 
bands of PA on Western blots the relationship between band intensity and the amount o f PA 
present was investigated. This experimental work also allowed an estimate of the limit of 
detection o f PA by Western blotting using the mouse MAbs.
Doubling dilutions o f cleaved PA were clectrophorcsed through an 8% SDS-PAGE 
gel, transferred onto PVDF membrane and reacted with a primary antibody (mouse anti-PA 
monoclonals) and a secondary antibody of rabbit anti-mouse IgG conjugated to HRP and 
developed with DAB. The result o f this experiment is shown in Figure 3.5. The dilutions 
of PA chosen for the experiment produced bands of similar intensity to that seen in whole 
cell lysates o f recombinant clones. On the original blot a faint band was also visible in lane 
7, and the limit o f detection was concluded to be between 26 and 52 ng of PA. To compare 
band intensity and quantity of PA more precisely, the PVDF membrane was scanned in a 
densitometer and the peak areas for the bands plotted against lane numbers (Figure 3.6). The 
relationship between the peak area and amount of PA was linear over the range 103 to 825 
ng of PA. However, due to possible differences in staining intensity between blots, only 
bands on the same blot were compared using this method.
1 4  Conclusions
The objectives o f this chapter were to develop the techniques o f the PCR and 
Western blotting for use in this study. PCR analysis was required to detect the presence of 
specific genetic material and Western blotting to detect the protein product.
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Figure 3.4. Western blots with monoclonal anti-PA antibodies
Whole cell lysates were made of S. lyphimurium SL 3261 with pBluescript (lane 1) 
or pVET4M (lane 2). Trypsin-cleaved PA (PA-63 and PA-20) was diluted 1:10 with lxLB  
(lane 3). 10 p\ samples were loaded on a gel and three identical repeats o f these three lanes 
were separated by SDS-PAGE (8% gel). 10 p\ of Bio-Rad prestained MW markers, low 
range, were loaded on the lefthand side of the gel. Apparent MWs are marked beside this 
lane. The separated proteins were transferred onto PVDF membrane which was cut into 
strips and reacted with a 1:1000 dilution of each monoclonal antibody - 14C7, 2D3 and 3B6 
(Little el al., 1988). Anti-mouse HRP conjugated was used as the secondary antibody at 
1:1000. The substrate DAB was used to detect the bound secondary antibody.
/
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Figure 3.4 Western blots with monoclonal anti-PA antibodies
67
Figure 3.5. Doubling dilutions o f PA
PA was cleaved with trypsin and diluted to give a concentration o f 110 ng//d. 15 
[A was loaded onto lane 1 and doubling dilutions made and loaded onto lanes 2 to 9. The 
amount of PA loaded in each lane was:
Lane 1 2 3 4 5 6 7 8 9  1
ng 1650 825 412 206 103 52 26 13
7
The PA was separated on an 8% SDS-PAGE gel, blotted onto PVDF membrane, 
incubated in mouse anti-PA monoclonal antibodies, secondary antibodies of rabbit 
anti-Mouse IgG conjugated to HRP and developed with DAB.
Bio-Rad prestained MW markers were separated on the left of the gel (lane MW). 
The position o f the markers is shown by four dashes on the left o f the photograph and the 
apparent MWs o f the markers, from the top, is 92 kDa, 66 kDa, 45 kDa and 29 kDa.
/
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Figure 3.6. Peak areas of doubling dilution bands o f PA
The PVDF membrane shown in Figure 3.5 was scanned on a LKB 2222-010 
Ultmscan XL Laser Densitometer (LKB, Bromma, Sweden) and analyzed using LKB 2400  
GelScan software. The bands were scanned at 1 and 5 times 800 ftm scan widths and the 
peak areas (AU/mm) for the bands in lanes 1 to 5 plotted. The peak area was determined 
using the signal (or dropline) integration method with each peak assigned its own baseline 
with the valley option. The peak area was plotted against the lane number on Figure 3.5.
/
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Figure 3.6 Peak areas o f doubling dilution bands of PA
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It has been shown that the PCR has the potential to detect the presence of 
B. anthracis genetic material in environmental samples. Although initial studies used 
primers for the EF gene, it may be more logical to use primers against the PA gene in order 
to detect B. anthracis spores as PA is required for both edema toxin and lethal toxin 
function. The B. anthracis PA gene is thought to be unique and a related toxin has not been 
identified in other bacteria. The PA gene is located on the plasmid pXOl and it's sequence 
is believed to be conserved between all virulent strains of B. anthracis. Attenuated strains 
may lose this plasmid, but all virulent strains contain this plasmid. As the PA gene is 
located on pXOl, detection o f this gene should be limited to bacteria which have retained 
the plasmid and so are potentially virulent. The capsule is also required for full virulence 
and the cap genes are located on the plasmid pX 02. Makino et at. (1993) have recently 
published details o f a PCR detection method using primers which bind to the capA gene. 
PCR with primers designed to bind to the PA gene and to one of the cap genes could be 
used to detect the presence o f both plasmids and so confirm the fully virulent plasmid 
genotype.
Candidate primers for detection of the PA gene have been identified and tested. 
They have been screened for cross-reactions against sequenced genes with a computer search. 
The search procedure identifies homology without differentiating which region o f the primer 
is homologous. Even with a low  percentage match between a primer and template, if the 
homology occurs at the 3' end o f  the primer, the primer could still produce a product in a 
PCR. If the match is higher, but the 3' end is not homologous, then the primer would not 
function well in the PCR. Thus the overall homology of the primers may not give an 
accurate assessment o f their ability to act as PCR primers. Also a primer can only function 
in a PCR if there is a second primer bound to the opposite strand within a suitable distance 
of the first. The requirement for two primers to bind appropriately within the same region 
reduces that possibility o f false positives. Before use in a test situation, the candidate 
primers could be screened against a DNA test panel from related bacteria and ubiquitous 
environmental bacteria. Uncontaminatcd B. anthracis samples can be identified relatively 
easily by culture and staining, but this method is less reliable when contaminated samples 
arc analyzed using selective media. PCR can detect the presence of B. anthracis genetic 
material in contaminated samples and also can detect it in non-viable samples, if the DNA  
is intact.
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The PCR can detect bacteria (B. anthracis and recombinant bacteria) which contain 
the PA gene in animal tissue samples. In samples from clinical cases of anthrax, large 
numbers of B. anthracis organisms will be present. These could be detected by culturing 
(if still viable), or by using the PCR. As the PCR can detect genetic material from non- 
viablc organisms, this techniques could have a role in diagnosing disease in sterile 
specimens. In an unopened carcase, viable B. anthracis may be destroyed by purification 
and PCR analysis may allow a diagnosis to be made. In the case of recombinant 
5. typhimurium, the number o f bacteria which may be present in a tissue sample could be 
below 100. As the sample must be diluted to lower the protein content in the PCR reaction, 
the threshold for detection by the PCR may be exceeded. In this case culturing methods 
may be more sensitive.
The bacteria in the spleen samples were lysed by boiling to release the template 
DNA. Makino et al. (1993) showed that a SDS, Sarkosyl and proteinase K lysis method 
gave a more sensitive result. Their method involved a 3 hour clearing incubation and three 
phenol-chloroform extractions and an ethanol precipitation. They were able to easily identify 
10* spores in a spleen sample, although their lysis and PCR method took eight hours in total. 
Their boiling method w as quicker (4 hours) but could only detect 106 spores. It is therefore 
possible to increase the sensitivity of the technique, but at the expense of time and 
simplicity.
PA PCR primers are o f use in identifying recombinant clones following ligations. 
This method allows the rapid screening of many clones and is particularly useful in 
blunl-end ligations where primers can be designed so that the product will extend across the 
vector-insert junction and so only identify inserts orientated in the desired direction. False 
positives can occur if the PCR primers only bind to the insert and the PCR reaction mixture 
becomes contaminated with unligatcd insert D N A  but various strategies can be used to 
overcome this.
Western blotting was chosen for the detection o f expressed PA because it could 
reveal information on both the quantity and quality of the protein. There is no simple test 
for the biological activity of PA that could have been used for quantisation. ELISAs can be 
performed quickly and can be 10 to 100 fold more sensitive than Western blotting (Harlow 
& Lane, 1988). but in this study speed and sensitivity were not an issue. An ELISA would 
only provide information on the total amount of bound antigen and, depending on the
71
Chapter 3. Detection o f B. anthracis
capture and detection antibodies used, the same reading could be obtained with full-length 
PA and degraded PA. Western blotting would show this difference, but the limitations 
imposed by the antibodies used must be understood. A polyclonal sera might contain 
antibodies which bind to many sites on the protein. Thus this sera would detect most 
fragments when transferred onto a membrane. Monoclonal antibodies only bind to one 
epitope and so will only identify the fragments which contain that site. Thus with 
monoclonal antibody in a Western blot the full range o f fragments will not be detected. If 
different monoclonals are used, which bind to different sites on the protein, a wider range 
of degraded protein bands will be detected. Polyclonal sera may contain antibodies which 
bind to other proteins in a cell lysate and so  give non-specific bands and also a higher 
background staining level. Monoclonal antibodies have the advantage of only detecting the 
protein o f  interest and of usually giving lower background staining. This allows a more 
accurate assessment o f  band densities.
When using Western blotting prestained MW markers can be used to estimate the 
MWs o f immunoreactive bands. The MW proteins are conjugated to a dye and this alters 
the electrophoretic properties o f  the molecule. The proteins migrate through the gel at a 
different rate to the unconjugated protein and, for use in Western blotting, must be assigned 
apparent MWs by calibrating the markers against known MW markers. The manufacturer's 
apparent MWs of the prestained markers used were found to be inaccurate in this laboratory. 
This may be related to the type of gel used or the conditions used during the PAGE. 
Therefore new apparent MWs have been determined and are used in this study. Horse 
polyclonal anti-£. anthracis antiserum was available at CBDE but a more specific anti-PA 
antiserum was raised in rabbits. Both polyclonal sera were shown to produce non-specific 
bands in Western blotting and high levels o f background staining. The use o f three mouse 
monoclonal anti-PA antibodies was investigated and found to give a clearer blot. Two of 
the MAbs (3B6 and 14C7) were known to bind to PA-83 and PA fragments which contain 
the antibody binding site near the C-tcrminus. Thus N-lcrminus fragments would not be 
detected. As the other MAb (2D 3) produces a similar banding pattern it probably also binds 
to a site close to the C-terminal end of PA, otherwise other fragment bands would be visible. 
When the three MAbs were used in combination, a similar banding pattern was seen. As 
only limited amounts o f the MAbs were available, they were used together to provide 
sufficient quantity o f a known mixture for this study.
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Doubling dilutions o f  PA were Western blotted. Densitometer scanning of 
transferred dilutions of PA produced a graph of peak areas against amount of PA and 
showed the relationship between these parameters. This show s the feasibility for a 
comparison of band intensity on a Western blot.
The information determined in these experiments was used as a basis for 
experimental procedures described in subsequent Chapters.
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4J. Introduction
To produce a potential vaccine strain PA must be stably expressed in the attenuated 
Salmonella strain. The coding sequence for PA was available on a pBR322 based plasmid 
designated pPA26 (see section 4.2.1) which expressed PA at low levels in £ . coli. The 
initial strategy to increase expression was to replace the B. anthracis PA promoter with an 
E. coli promoter which would be expected to function at a higher level in both £. coli and 
S. typhimurium. All the constructs made are shown on a fold-out page at Annex A. It was 
decided to clone the ribosome binding site (RBS) and open reading frame (ORF) of PA  
(from pPA26) after the lac promoter in the phagemid pBluescripl II. As the rcplicon of 
pBlucscript has a higher copy number compared to pBR322, this construct would probably 
also increase the copy number of the PA gene. Thus it was necessary to investigate the 
consequences o f increasing the gene copy number on expression o f PA. Therefore the first 
construct made contained the pPA26 insert in pBlucscript (designated pC Bl). Expression 
from this clone was compared to pPA26 and related to plasmid copy number. Secondly a 
construct with the RBS and ORF of PA after the lac promoter was constructed (pORFl) to 
compare the expression from this promoter and the B. anthracis PA promoter. The 
constructs were initially placed into £ . coli, but subsequently moved into the aroA 
S. typhimurium strain SL 3261 which can be used as a vector in mice.
4 2  Copy number effects
4,2.1 Plasmid pPA2(>
Plasmid pPA26 was derived from plasmid pSE36 (Vodkin & Leppla, 1983) which 
consists o f pBR322 with a 6 kbp BamHl fragment from the B. anthracis plasmid pX O l. 
Plasmid pPA26 was constructed from pSE36 by a partial //¿mil 11 digestion to leave a 4.235  
kbp insert which contained the PA gene. Plasmid pPA26 (Welkos et a i, 1988) had a DNA  
insert which contained the B. anthracis promoter, signal sequence and ORF for PA. The 
insert DNA also contained an ORF for an uncharactcriscd protein upstream from the PA  
ORF (Welkos et al., 1988). Plasmid pPA26 is illustrated in Figure 4.1 and a schematic 
representation of the DNA and the relevant restriction sites is shown in Figure 4.2.
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Figure 4.1 Plasmid pPA26
A. Plasmid pPA26 (Welkos el al., 1988) contains a HindlU-BamHl insert of 
B. anthracis DNA in the vector pBR322 to give a total size o f 8.25 kbp.
B. The B. anthracis DNA insert is shown. Within the insert is the open reading frame 
(ORF) for the PA gene located towards the 3' end of the insert. The ORF codes for 
the full-length (83 kDa) PA which can be cleaved by Trypsin into a N-terminal 20 
kDa fragment and a 63 kDa C-terminal fragment.
/
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Figure 4.1 Plasmid pPA26
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Figure 4.2 pPA26
A. This represents the regulatory and coding regions of the PA gene in plasmid pPA26. 
This pBR322 based plasmid contains the B. anthracis promoter followed by coding 
regions for the signal sequence and full-length PA which can be cleaved by trypsin 
into 20 and 63 kDa fragments.
B. This shows the relevant restriction enzyme sites in plasmid pPA26. The 
//tndlll-itomHI B. anthracis DNA insert in pBR322 is shown as a box. It contains 
an internal Hind\\\ site and the ORF for PA. There is a Clal site in pBR322 
upstream from the insert.
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4.2.2 Construction of phagemid pCBl
In order to evaluate the effects o f copy number differences between pPA26 and other 
constructs, the insert from pPA26 was moved into the vector pBluescript II KS+. The 
phagemid pBluescript allows the simple isolation o f ssDNA for sequencing. It also has 
many flanking restriction sites if the insert needs to be moved subsequently. pBluescript can 
be grown in E. coli which carry the la d “1 gene on the F  episome thus repressing the lac 
promoter. Expression can be induced with IPTG as required. The constructs can be moved 
to S. typhimurium SL 3261 where the lad"  gene is absent and expression will be 
constitutive. This is necessary for a candidate vaccine strain and would not be possible if  
la d q was present on the plasmid.
The pPA26 insert contains external //¿«dill and BamHl sites but also an internal 
Hindill site. In order to avoid the difficulties o f a partial //¿«dill - BamHl restriction digest, 
a Clal - BamHl fragment was cut from pPA26 and force cloned in Clal-BamHl cut 
pBlucscript II KS+. This construct was also made by Little & Lowe (1991) as a starting 
point for their investigation of C-tcrminal deletions. This is illustrated in Figure 4.3. 
Following the restriction endonuclease digestions o f pPA26 with Clal, Bam HI and Pvull (to 
cut the vector DNA into smaller fragments) and o f pBlucscript with Clal and BamHl, the 
appropriate bands were cut from agarose gels and purified using Qiaex. The vector and 
insert were ligated overnight, electroporated into E. coli and colonics which grew on L-agar 
plates supplemented with ampicillin were picked. These were grown up in 10 ml L-broth 
supplemented with ampicillin and mini-prepped. A clone with the appropriate sized insert 
was designated pCBl and a large scale Qiagcn plasmid preparation was made. The plasmid 
was restricted with several enzymes and cut as expected.
4.2.3 CQmpariWn »! pP.A26  and pCBl
Expression of PA from pPA26 was low and difficult to detect by Western blotting. 
In order to easily detect the expressed protein it is necessary to use a method designed to 
enhance expression. The method uses chloramphenicol to amplify the number o f  
recombinant plasmids per cell before washing out the antibiotic and allowing protein 
synthesis to recommence (Little & Lowe, 1991). The maximal plasmid gene copy number 
increases the ratio of plasmid proteins to cell proteins and makes detection easier. The 
plasmid copy number reached will depend on the plasmid rcplicon. This method was used
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Figure 4.3 pCBl
A. Phagemid pCBl was constructed to contain the B. anthracis DNA insert from the 
pBR322 based plasmid pPA26 in the phagemid pBluescript 11 KS+. This diagram 
shows that the PA ORF is still downstream from the B. anthracis PA promoter 
region and not the lac promoter of pBluescript.
B. This shows the relevant restriction enzyme sites in phagemid pCBl. The box 
represents the Clal-BamH 1 insert from pPA26 that was cloned into pBluescript. The 
PA ORF is shown with internal //(>tdlll and Pstl sites.
/
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so that the PA produced could be visualised on a Western blot and compared to plasmid 
copy number. As this method selects for maximal copy number, it does not necessarily 
represent the plasmid copy number ratio that might exist in normally growing cells.
4.2.3.1 Plasmid copy number
10 ml cultures of E. coli JM 109 containing either pBlucscript, pPA26 or pCBl were 
grown overnight and used to seed flasks of L-broth supplemented with ampicillin. Following 
initial growth, chloramphenicol was added. The next day the cells were washed and grown 
for 1 hour. From the A b s^  readings of the cultures, the densities were adjusted with 
L-broth to give equal Abs**, readings. Duplicate Qiagcn column plasmid preparations were 
made of the E. coli JM 109/pPA26 and pCBl cultures using columns with a 20/rg capacity. 
For pPA26, 3 ml of culture were used for each preparation and the plasmid pellets were 
resuspended in 20 fi\ o f water. For the pCBl cultures only 1.5 ml of culture was used (as 
the copy number was expected to be higher) and the pellets were resuspended in 50 fi\ o f 
water. 20 fi\ o f each plasmid solution were run on a agarose gel as shown in Figure 4.4. 
From the known amount of MW markers loaded, it was estimated that the bands present 
related to a total plasmid preparation content o f about 1.25 fig o f plasmid which is well 
within the capacity o f the 20 fig Qiagen column used, and so column overloading should not 
have been a problem. Owing to the different culture volumes and dilutions used, the amount 
loaded in the pPA26 lanes equates to 5 times more than in the pCBl lanes. The gel was 
photographed and the negative scanned on a densitometer to calculate areas for the bands 
of:
Plasmids pPA26 pCBl
Areas o f bands 0.134 0.132 0.239 0.282
Average areas 0.133 0.2605
Corrected for amount loaded 0.133 1.3025
This experiment showed that on a cell for cell basis there was 10 times more of the pCBl 
plasmid than of pPA26. This order o f magnitude difference is not unexpected as the copy 
number for pBR322's pMBl replicón is approximately 15-20 and for the pUC based
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Figure 4.4 Duplicate plasmid preparations o f pPA26 and pCBl
Duplicate plasmid preparations of E. coli JM 109 chloramphenicol amplified cultures 
were made using Qiagen columns. 20 fi\ aliquots were run on an 0.8% agarose gel with 4 
fxl o f  BCL DNA MW markers III. The gel was photographed. From the left o f the gel arc 
the duplicate pPA26 plasmids, then the duplicate pCBl plasmids with the MW markers on 
the right. Due to differences in the amount of medium used and the volume of water used 
to resuspend the DNA pellet (explained in the text) the plasmid present in the pPA26 lanes 
represents that recovered from five times more cells than that present in the pCBl lanes.
In order to verify that the Qiagen columns were not over loaded, a calculation of the 
amount of DNA recovered was made. The lop band present in the MW marker lane 
represents 428 ng o f D N A  (based on the manufacturers stated marker concentration). From 
this it is estimated that the pCBl band contains approximately 500 ng and so the total 
preparation would have contained 1.25 fig. This is well within the loading capacity o f  the 
20 fig Qiagen column used.
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pBluescripl II pMBl rcplicon it is 500-700 (Sambrook et al. , 1989). The difference in copy 
number is attributed by Minton et al. (1988) to a G to A mutation which alters the 
transcription start o f RNA I and so affects its binding to RNA II thus relaxing copy number 
control.
4.2.5.2 PA expression
The same cultures used for plasmid copy number preparations were used to provide 
whole cell lysates for Western blotting. 15 ml of the cultures were pelleted and resuspended 
in 1 ml o f loading buffer. The lysate was boiled and a fraction corresponding to 3 x 1CP 
cells subjected to SDS-PAGE and Western blotting with mouse MAbs. A  photograph of this 
gel is at Figure 4.5. The double band in lanes 2 and 3 was suggested by Little &. Lowe 
(1991) to represent PA with and without the signal sequence. However the signal sequence 
is only 29 amino acids in length (Welkos et aL, 1988) and would only correspond to a 
3 kDa difference. Conformational changes between the two species may account for a 
further spread between the bands. This is discussed in Chapter 6. Faint breakdown product 
bands are also seen on the gels. The bands present were scanned on a densitometer but the 
double band and staining between the bands did not give a clear graph and the peaks could 
not be quantified this way. However it is clear that the pCBl lane contained more PA than 
the pPA26 and this increase could be o f the same order o f magnitude as the 10 limes 
increase in plasmid copy number.
4Ji Prompter effects
To investigate the effect o f changing the promoter from the B. anthraas PA  
promoter to the E. coli lac promoter, the ribosome binding site, signal sequence and ORF 
for PA was cloned into pBlucscript after the lac promoter and a short region of the 
/3-galaclosidasc sequence. The phagemid was designated pORFl.
4.3.1 Construction of phagemid pORFI
The construction of pORFl is illustrated in Figure 4.6. Two PCR primers were 
designed which bound to either end o f the required region in pPA26. Each primer also had 
a non-complimentary 5' tail which contained appropriate restriction sites for cloning the PCR 
product into pBlucscript. This is illustrated in Figure 4.7. The upstream pnmer (PAALL5)
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Figure 4.5 Western blot comparing PA expression from pPA26 and pCBl
Whole cell lysates from chloramphenicol amplified cultures of E. coli JM 109 
carrying either pBlucscript (as a negative control), pPA26 or pCBl were loaded on a 8% 
SDS-polyacrylamide gel. The amount loaded was between 6 and 10 fi\ related to the cell 
density of the original cultures thus each lane represents approximately 3 x 10* cells. 10 /j! 
o f Bio-Rad prcstaincd MW markers were loaded on the lefthand side of the gel and apparent 
MWs (kDa) are noted beside them. The gel was blotted onto PVDF membrane, incubated 
in a primary antibody solution o f  mouse monoclonal anti-PA antibodies and a secondary 
antibody solution o f HRP-linked anti-mouse antibodies. The bands were visualised with 
DAB.
Lane 1 E. coli JM 109 /  pBluescript 
Lane 2 E. coli JM 109 / pPA26 
Lane 3 E. coli JM 109 /  pCBl
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Figure 4.6 Phagemid pORFl
A. This shows the regulatory and coding regions for pORFl. It is the same as pCBl 
except that the promoter for the PA ORF is now the E. coli lac promoter from 
pBlucscript.
B. This shows the DNA insert cloned into pBlucscript II. PCR primers were designed 
to allow amplification of the PA ORF from the ribosome binding site (RBS) to 
beyond the C-terminal end o f the PA ORF. See Figure 4.7. The PCR product was 
restricted to leave Kpnl and Xbal ends, litis  was cloned into Kpnl-Xbal cut 
pBluescript.
/
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Figure 4.7 PCR primers for pORFl
A. This shows the HuvXWl-BamHl insert from pPA26 which contains the PA gene. 
PCR primers PAALL5 and PAALL3 were designed to allow amplification and 
cloning of the Ribosome binding site (RBS) and PA ORF into pBluescript after the 
lac promoter. Primer PAALL5 has an homologous region from the start point o f  the 
PA mRNA transcript and includes the RBS o f the PA gene and a 'tail' which 
contains the sequence restricted by Kpn\. the primer PAALL3 has an homologous 
region to the 3' end of the insert, beyond the stop codons o f the PA gene. It also 
contains a 'tail' with a unique sequence for the restriction enzyme Xbal. During PCR 
amplification the 'tails' will become incorporated into the product.
B. The PCR product was restricted with Kpnl and Xbal and cloned into similarly cut 
pBlucscript II KS+. Phagemid pORFl contains the PA  ORF transcribed from the 
lac promoter.
/
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was designed to bind at the start point o f the PA mRNA transcript and also had in its tail 
a stop codon in frame with the /3-galactosidasc ORF of pBlucscript. Although the BamHl 
site downstream o f the gene could have been used, a Xbal site was included in PAALL3 (the 
downstream primer) to allow insertion in the same manner into pUC plasmids, if  required.
The primers were used in a standard PCR reaction with CsCl purified pPA26 as the 
template and cycles of 94°C for 3 mins, 25 cycles of 94°C for 30  secs - 37°C for 30 secs - 
72°C for 90 secs, 72°C for 10 mins and refrigeration until required. Four 100 p\ reaction 
tubes were cycled and the combined products analyzed by agarose gel electrophoresis, the 
appropriate band was excised and Qiaex purified. The PCR product was then digested with 
Kpnl and Xbal restriction endonucleases. pBlucscript II KS+ was also digested with Kpnl 
and Xbal enzymes and gel purified. The vector and insert were ligated and electroporated 
into E. coli JM 101. Clones containing the insert were identified using 2 PCR primer sets. 
One contained primers T3 and T7 which bound outside o f the polylinker. These show the 
size o f the inserted DNA. The other PCR primer set contained primer T7 and, what was 
originally designed as a sequencing primer, PAS7R which binds within the insert and will 
only produce a product with T7 if the insert DNA is in the correct orientation. The results 
obtained with these primer sets are shown in Figure 4.8. Whole cell lysates from induced 
cultures of the four clones were Western blotted with mouse MAb and the clones which 
were positive with PCR showed expression of full-length PA. One clone was designated 
pORFl. A  large scale Qiagen plasmid preparation was made and it restricted with a panel 
of enzymes as expected. Large amounts of ssDNA could not be recovered following 
co-infection with a helper phage. Therefore ssDNA was prepared using the Dynabead 
method with primers Biotinylated-T3 and T7. The product was sequenced from PA SH  and 
the sequence at the junction o f the polylinkcr and PAALL5 verified.
4.3.2 PA expression from pORFl
Initially the expression of PA from pORFl was investigated in E. coli and then 
subsequently in S. typhimurium.
E. coli clones containing pBlucscript (as a negative control), pPA26, pCBl and 
pORFl were grown overnight in L-broth supplemented with ampicillin. IPTG was added 
to the E. coli /  pORFl culture, to induce expression from the lac promoter, and incubauon 
continued for 1 hour. 10 ml o f the cultures were centrifuged and lxLB added to the pellet
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Figure 4.8 PCR to identify pORFl clones
Four colonics were picked from a E. coli JM 101 ligation plate and mixed into 100 
fi\ o f water in a PCR tube and also streaked onto a fresh plate to preserve the clone. The 
PCR tube was heated for 3 mins in a boiling water bath to lyse the cells and then the 100 
fi\ was split into two 50 fA samples. One aliquot was amplified with 50 fA o f a master mix 
containing primers T3 and T7 which bind outside the polylinker. These show the size of 
the inserted DNA. If the insert is present these primers would be expected to give a band 
of 2.55 kbp. The other 50 fA aliquot was amplified with T7 and what was originally 
designed as a sequencing primer, PAS7R, which binds within the insert and will only 
produce a product (1.52 kbp) with T7 if the insert DNA is in the correct orientation. 10 fA 
of the reaction mixes were run on a 0.7% agarose gel. The photograph shows that colonies 
1, 3 and 4 give the expected pattern.
Three MW bands are labelled to allow size comparisons.
Lancs, from the left
Lane 1 BCL DNA MW markers III
Lane 2 Colony 1, T3 and T7
Lane 3 Colony 1, T7 and PAS7R
Lane 4 Colony 2, T3 and T7
Lane 5 Colony 2, T7 and PAS7R
Lane 6 Colony 3, T3 and T7
Lane 7 Colony 3, T7 and PAS7R
Lane 8 Colony 4, T3 and T7
Lane 9 Colony 4, T7 and PAS7R
Lane 10 Negative control, T3 and T7
Lane 11 Negative control, T7 and PAS7R
/
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lo give equal cell numbers /  ml (based on A b s^  readings). A fraction of the whole cell 
lysates equivalent to 1.5 x 10* cells was analyzed by SDS-PAGE and Western blotted. This 
is shown in the top half o f Figure 4.9. Under these experimental conditions. PA expression 
from pPA26 and pCBl was too low to be visualised without chloramphenicol amplification 
even though 50 times more cells were loaded in each lane than in Figure 4.5. Expression 
of PA from pORFl was visible on this Western blot showing that altering the promoter 
sequence increased the level o f protein expression. The double banded appearance seen in 
chloramphenicol amplified lysates from pPA26 and pCBl (Figure 4.5) is easily seen in 
E. coli /  pORFl. In addition, several breakdown products were visible.
Altering the promoter sequence has therefore increased the expression of PA in 
£ . coli but it was necessary to see if this also applied, as expected, in 5. typhimurium. To 
investigate this, plasmids were recovered from E. coli and electroporated into S. typhimurium 
LB 5010. The modified plasmid was recovered and electroporated into S. typhimurium 
SL 3261. Clones containing the plasmids were identified and cultured as above with cell 
numbers in the lysates adjusted to match the E. coli lysates (1.5 x 10*). As S. typhimurium 
SL 3261 does not contain the lac!“ gene the lac promoter in pBluescnpt would not be 
repressed and so IPTG induction was not required. Expression o f  PA from these clones is 
shown in Figure 4.9. A  similar banding pattern lo E. coli was seen although the bands 
produced by the S. typhimurium /  pORFl clone appear less dense. To investigate if all the 
bacteria were still ampicillin resistant (Amp') at the end of the incubation period. 10-5 
dilutions of the S. typhimurium cultures were plated out on both L-agar and L-agar 
supplemented with ampicillin. The same number of colonies grew on both plates for all 
cultures except the S. typhimurium /pORFl clones where only 80% of the colonies were 
Amp'.
A4 mRNA secondary structure predictions
In changing the promoter from the B. anthracis PA promoter in pPA26 lo the £. coli 
lac promoter in pORFl, the mRNA primary sequence has been changed. The PA mRNA 
is preceded by a short region o f the 0-galaciosidasc mRNA in pORFl. This would be 
expected to lead to a different mRNA secondary structure. mRNA secondary structure can 
influence expression. The secondary structure of the mRNA can be predicted using the 
algorithm of Zukcr & Sticglcr (1981) which is implemented within the computer programme
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Whole cell lysates, adjusted for cell number, were prepared from cultures of E. coli 
/ pBlucscript, pPA26, pCBl and pORFl. The E. coli /  pORFl culture was induced with 
IPTG for 1 hour prior to harvesting the cells. S. lyphimurium SL 3261 containing the same 
plasmids were grown similarly but without IPTG induction of S. typhimurium /  pORFl (as 
expression is constitutive). The pellet from 10 ml of each culture was suspended in 660 to 
1240/¿I of lxLB (depending on Abs«,, o f the culture) and boiled for 3 mins. This lysate was 
diluted 1:5 in lxL B  and 20 p\ loaded in each well. This is equivalent to the protein from 
approximately 1.5 x 10* cells loaded in each lane. Bio-Rad prestained MW markers were 
run in the left lane and apparent MWs are shown. The gels were blotted onto PVDF 
membrane, blocked in Blotto, and incubated in a primary antibody o f mouse anti-PA 
monoclonal antibodies, and a secondary HRP-conjugated anti-mouse IgG. The substrate used 
to visualised the bands was DAB.
E. coli lysates arc shown in the top blot, 5. typhimurium in the bottom.
Lane 1 pBlucscript 
Lane 2 pPA26 
Lane 3 pCBl 
Lane 4 pORFl
Figure 4.9 Western blot comparing PA expression from pPA26, pCBl and pORFl
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Figure 4 .9  Western blot comparing PA expression from pPA26, pCBl and pORFl
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Genmon.
The predicted secondary structures for the first 100 nt o f the mRNA produced by 
pPA26 (and pCBl) and the first 150 nt o f the mRNA produced by pORFl are shown in 
Figure 4.10. For pPA26 the free energy of this region is -3.4 kcal with 3/3 bases o f the 
AUG start codon and 0/4 o f  the RBS AGGA involved in base-pairing. For the 150 nt folded 
in pORFl the free energy is -13.6 kcal with 0/3 and 3/4 bases o f  the PA gene's AUG and 
AGGA involved in base-pairing.
4.5 Conclusions
PA expression from the PA gene, driven by the B. anihracis PA promoter, can only 
be detected by Western blotting under special conditions. A candidate vaccine strain should 
express the heterologous protein at levels approaching 5% of the cell protein producing a 
band which should be easily visualised on a Coomassie stained gel. The experimental data 
presented here suggests that plasmid copy num&cr can affect expression but only in 
proportion to the plasmid number. However, the amount expressed in E. coli using the 
native B. anihracis sequence is still small. This may be due to a sub-optimal regulatory 
region and so the effects o f  altering the promoter sequence to one active in £. coli were 
evaluated. Replacing the B. anthracis PA promoter with the E. coli lac promoter did 
increase expression from undetectable levels on a standard whole cell lysate Western blot 
to an easily detectable band. When expressed in Salmonella, the intensity of the PA band 
on a Western blot was less than in E. coli. An explanation for the weaker bands is that the 
plasmid is less stable in 5. typhimurium than E. coli and that a proportion of the bacteria 
have lost the plasmid and arc not expressing PA. This situation would arise if the fi- 
lactamasc produced by the bacteria depletes the ampicillin present in the media allowing 
survival o f plasmid-free ampicillin sensitive (Amp‘) bacteria. It was shown that pORFl was 
lost from a proportion o f the bacteria. The stability of the phagemids and the ame-course 
o f expression is further investigated in Chapter 7.
The level o f  expression o f a protein is determined by the rate o f transcription, 
stability of the mRNA and efficiency of translation. In this chapter the effect of altering the 
promoter has been investigated. This may also have indirectly affected interactions at the 
RBS and also the stability o f the mRNA. In order to try and explain the experimental 
results, a comparison of the promoters, RBSs and mRNA secondary structures was made.
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Figure 4.10 Predicted secondary mRNA structures
mRNA secondary structures were predicted using the algorithm o f Zuker & Stiegler
(1981) implemented within the Genmon suite o f programmes on a VAX computer.
A. Predicted structure for the first 100 nt of the mRNA of pPA26. The AGGA region 
of the PA S/D region is underlined. The AUG start codon and direction of 
translation for PA are shown by an arrow.
B. Predicted structure for the first 150 nt o f pORFl. This region is shown in
Figure 4.11. 150 nt are folded as the PA RBS is located downstream o f the
/3-galactosidase (/3-gal) fragment ORF on the mRNA. The AGGA of the S/D  
regions of PA and /3-gal are underlined and marked. The AUG start codon and 
direction of translation for PA are shown by a wide arrow; the AUG for /3-gal with 
a narrow arrow.
/
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Figure 4 .10 Predicted secondary mRNA structures
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The consensus sequences o f Bacillus and Salmonella promoters are known to differ 
and so it would be expected that altering the promoter sequence to one known to be active 
in Salmonella would increase expression o f  PA, although other factors could be limiting the 
level o f expression. It is generally accepted that E. coli RNA polymerase can utilize many 
Gram positive promoters efficiently, although the reverse is not true. Many Gram positive 
genes have been expressed in E. coli (Graves & Rabinowitz, 1986). The consensus 
sequences for the E. coli Eon promoters, B. subtilis Ecr43 promoter and the sequences of the 
promoters in pPA26 and pORFl are shown in Table 4.1, A  and B. The regions shown are 
the main areas of homology but other areas, such as an AT rich area around -43, are also 
important. The E. coli consensus sequence was derived from 168 promoter sequences. It 
was not optimised for high level expression promoters. The lac promoter is a common 
promoter in cloning vectors as it produces good levels o f expression and it can be regulated 
(Winnacker, 1987). Expression from this promoter can be increased by specific mutations 
(such as UV5 which alters the lac -10 box to the consensus TATAAT) and the construction 
of hybrid promoters such as lac. Apart from the actual sequence of the -10 and -35 regions, 
the spacing between these regions is important. The spacing in the lac hybrid promoter toe 
is optimal at 16 bp. Increasing the spacing in lac to 17 or 18 bp reduces expression to 90% 
and 65% respectively (Brosius et al., 1985). The comparison shows that the PA promoter 
has an identical -10 box to both the E. coli and B. subtilis consensus sequences and only 
one base different in the -35 region. The PA promoter -10 and -35 regions therefore have 
better homology with the consensus sequences than the lac promoter, yet when the PA 
promoter was replaced with the lac promoter, expression was increased. The spacing 
between the -10 and -35 regions is greater in the PA promoter than the consensus sequences 
(20 verses 16-18 bp). As this spacing has been shown to have a large effect on expression 
from the tac promoter, the 20 bp spacing may be the reason for the lower expression from 
the PA promoter compared to the lac promoter. This would have to be shown 
experimentally by deleting up to 4 bases from the region between the -10 and -35 boxes of 
the PA promoter.
The RBS has been defined as the area containing the Shinc.Dalgamo (S/D) region 
and the AUG start codon, but the term is also used for the longer region protected by the 
ribosome during binding. The term 'translation initiation region' (TIR) defines a similar 
region although some authors use it to also encompass more distant regions of the mRNA
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Table 4.1 Comparison of promoter and RBS sequences
A  This shows the sequences for the -35 and -10 boxes of four promoter regions with 
the spacing between them. The promoter consensus sequences for E. coli is from 
Winnackcr (1987) and for B. subtilis is from Moran el al. (1982). The PA promoter 
sequence is from Welkos et al., (1988) and the sequence of the lac promoter from 
pBlucscript (Stratagene Ltd).
B This shows the sequences o f the promoters aligned on the -10 box. The E. coli 
consensus sequence is from Winnacker (1987), with representing bases with little 
consensus and small letters where homologies are less than 70%. The B. subtilis 
consensus sequence is from Graves and Rabinowitz, (1986), with small letters for 
bases with more than 41% homology, capital letters for homologies above 50% and 
bold letters for homologies above 75%. For comparison, the sequences for the PA 
and lac promoters arc shown as well. All sequences end at the -1 position.
C  This shows the sequence at the 3' end o f the E. coli 16SrRNA (Shine & Dalgamo, 
1974) and its compliment aligned with the consensus region o f the E. coli RBS 
(from Scherer et al., 1980) and the RBS o f PA and lacZ in pORFl. The last three 
sequences are aligned on the AUG start codon. For purposes of orientation, the 
AGGA motif in the RBS is underlined.
/
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A
| Promoter -35 box spacing (bp) -10 box
1 E. coli Eo'3 TTGACA 16-18 TATAAT
B. subtilis 
Eo"
TTGACA 17-18 TATAAT
PA in pPA26 TTGAAA 20 TATAAT j
1 lac in p0RF1 TTTACA 18 TATGTT !
B
Promoter sequence aligned on -10 box
E. coli --- TTGaca-ttt (6-9) attttgtLVTAATg(4-7)c
B. subtilis -Ta-AAAAA--- TTGAcA---a— A— a-T-TG-TATAATAAtAt—
PA TTATATTATATTGAAACTAAAGTTTATTAATTTCAATATAATATAAAT
lac GGCACCCCAGGCTTTACACTTT ATGCTTCCGGCTCGT ATGTTGTGTGG
C
RBS sequences aligned on start codon
3 ' end 
16SrRNA
AUUCCUCCACUAG
UAAGGAGGLGAUC - compliment
E. coli UU. UUAAAAALTJAAGGAGGLAUAUUAUGAAAAAAAIUAAAAAACUCAA
PA AUUUUAUACAAAAAGGAGAACGUAUAUGAAAAAACGAAAAGUGLUAAU
lacZ UAACAAUUUCACACAGGAAACAGCTAUGACCAUGALUACGCCAAGCGC
T+ 1
Table 4.1 Comparison of promoter and RBS sequences
r
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that can affect translation. In this discussion, RBS is used to mean the region from the S/D  
sequence to the start codon, and the TIR to include regions up- and down-stream of the RBS 
that affect initiation of translation. The efficiency of translation is affected by the primary 
and secondary structure o f the mRNA in this region. This region has been characterised 
extensively by both an analysis of the nucleotide sequences in many different TIRs (Stormo 
el al., 1982) and by the effect o f alterations in this site on expression (Curry & Tomich, 
1988). The S/D region sequence is complimentary to the 3' end o f  the 16S ribosomal RNA  
and is usually 5-10 nt from the start codon. In addition, the codons either side of the start 
codon can affect translational efficiency (Curry & Tomich. 1988; Looman el al., 1987) as 
can the primary sequence at the 5' end of the ORF.
pORFl was constructed to translate the PA gene using the PA RBS, but with the lac 
promoter controlling transcription, so that a comparison could be made between this 
construct and pPA26. The nucleotide sequences of the PA gene RBSs in pPA26 and pORFl 
arc therefore identical. pORFl also contains the lacZ RBS upstream of the PA RBS. These 
RBSs can be compared to the E. coli consensus RBS sequence and 3' end of the 16S rRNA 
sequence. This is shown in Table 4.1, C. The E. coli consensus sequence was obtained 
from a comparison of 68 sequences and does not relate to highly expressed genes. It can 
be seen that the PA RBS is similar to the E. coli consensus sequence and it does meet all 
o f the rules proposed by Scherer el al. (1980) and Stormo et al. (1982) except that the PA 
RBS does not have an A or T at position +10 or +11. This small change may reflect the 
different codon usage of Bacillus genes. Although the PA RBS should function adequately 
in E. coli, the sequence may not be optimal. The lacZ RBS also shows a significant 
variation from the consensus sequence.
Subsequent to the construction of pORFl, it was realised that the lacZ RBS upstream 
of the PA coding region might affect expression o f PA. Although the ORF for 
/3-galactosidasc is terminated in the region of the AUG initiation codon of PA, and is out of 
frame with the coding region of PA, it is possible that the ribosome may terminate 
translation of /3-galactosidasc but remain bound to the mRNA. It may then recognise the PA 
RBS, shift frame, and translate the PA open reading frame. This region is shown in 
Figure 4.11. This effect has been described for the two cistron expression of Bovine Growth 
Hormone (Schoncr et al., 1984). The effect o f this would be to raise the apparent translation 
initiation efficiency of the PA gene.
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Figure 4.11 Nucleotide sequence o f TIR of pORFl
The nucleotide sequence from the lac promoter to the ORF o f PA is shown. The 
-10 and -35 regions o f the promoter are underlined and marked beginning at 2096 and 2072  
respectively. The proposed transcription start is marked in bold at 2108. The 
/9-galactosidasc and PA RBSs are marked. The amino acid sequence coded for by the ORFs 
is shown below the nucleotide sequence using the single letter amino acid code. The amino 
acid sequence for /9-galactosidase is shown in lowercase letters. It is terminated at a TGA  
stop codon which overlaps the ATG start codon for the PA ORF. The amino acid sequence 
for PA is shown in uppercase letters.
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lac promoter
-3 5  -1 0
cactcattaggcaccccaggciiia£Actttatgcttccggctcgiatci
------- . ------- +------- . ------- +------- . --------+------- . ------- +-------. ------- +
GTGAGTAATCCGTGGGGTCCGAAATGTGAAATACGAAGGCCGAGCATACA 2100
P-galactosidase RBS 
S/D Start codonstart of mRNATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGAC
-------- +----.----+--- .----+--- .----+--- .----+ 2150
ACACACCTTAACACTCGCCTATTGTTAAAGTGTGTCCTTTGTCGATACTG
P-GALACTOSIDASE » m  t
CATGATTACGCCAAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCT
------- . ------- +----- . ----------+------- . ------♦ --------- . ------- +-------. ------- + 2200
GTACTAATGCGGTTCGCGCGTTAATTGGGAGTGATTTCCCTTGTTTTCGA
m i t p  s a q  I t  l t k g n k s v
?A RBSS/D Start codon
GGGTACCTTTTATACAAAAAGGAGAACGTATATGAAAAAACGAAAAGTGT
------- . ------- +------- . ------- +------- . --------+------- . --------+-------. ------- - 2500
CCCATGGAAAATATGTTTTTCCTCTTGCATATACTTTTTTGCTTTTCACA
v p f i q k g e r i .
EA » M  K K R K V L
Figure 4.11 Nucleotide sequence of TIR of pORFl
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Thus, the PA RBS should initiate translation quite effectively. There is no ideal 
RBS, due to the interactions which occur with other regions of the gene (Curry & Tomich, 
1988), and changes would have to be made and tested experimentally to arrive at a better
sequence.
Although the primary sequence is identical for the RBS o f pPA26, pCBl and 
pORFl, the secondary structure may vary. mRNA secondary structure around the RBS is 
considered important in regulating the initiation of translation (Schoner et al., 1984; 
Schauder & McCarthy, 1989). Secondary structure may also affect the stability of the 
mRNA. The structure o f the mRNA was predicted using the algorithm of Zuker & Stiegler 
(1981) which was implemented within the computer programme Genmon. This found a 
conformation o f minimum free energy for the RNA molecule based on published values of 
stacking and destabilising energies. The structures produced represent one possible 
configuration with the lowest free energy; but totally different structures, with free energies 
close to the minimum, may be more biologically significant. The programme produced a 
structure without weighting the increased likelihood of base-pairing occurring locally rather 
than between distant regions o f the RNA molecule. The predicted structure for any region 
will therefore vary depending on the total length of the mRNA presented for folding. As 
the mRNA is synthesised, the 5' end is more likely to become involved in local interactions. 
One method of using the prediction programme is to fold progressively more of the S' end 
of the mRNA and look for stable secondary structure features involving the RBS (Schoner 
et al., 1984).
The information from secondary structure predictions has been correlated with 
expression in two ways. Firstly, the free energy of the predicted structure has been shown 
to correlate with translational initiation efficiency (Schauder & McCarthy. 1989). Secondly, 
the masking or exposing of the S/D region and start codon within regions of secondary 
structure may also affect expression (Schoner et al., 1984; Winnacker, 1987). Although one 
of these approaches may explain many results o f expression studies, some authors have 
found exceptions that cannot be explained (Looman et al., 1987). This failure is probably 
due to the complexity o f the interactions between primary sequence changes and secondary 
structure predictions.
The free energies o f the predicted TIR structures (-3.4 kcal for pPA26 and -13.6 kcal 
for pORFl) do not support the observed expression results as pORFl expresses more PA
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than pPA26 and yet has the more stable structure. The involvement of the initiation codon 
in base-pairing in pPA26 could limit expression, as could the involvement of the AGGA of 
the PA RBS in pORFl. The AUG and AGGA for the /3-galactosidasc RBS are not involved 
in base-pairing and it is possible that a ribosome translating the /3-galactosidase ORF could 
breakdown the secondary structure involving the PA RBS and so aid translation of this 
second cistron (Schoner et al., 1984). This could be partly responsible for the increased 
expression of PA from pORFl.
Although predictions of secondary structure can produce direct correlations with 
expression in tightly controlled studies, the complex interactions of changes in the primary 
sequence of the TIR make it difficult to predict the overall effect o f changes designed to 
produce favourable secondary structural changes.
From the above it can be seen that the PA promoter and RBS should function in 
E. coli, but the level o f  expression is disappointing. Altering the promoter to the E. coli lac 
promoter increased expression (pORFl). The level o f expression is known to be a complex 
interaction of many factors. Although experimental evidence has shown particular features 
which can affect expression, a small change can have many potential effects. A  point 
mutation in the first few codons might alter the affinity of the ribosome for the RBS, the 
mRNA secondary structure and the codon usage. It is therefore not possible to make 
specific and authoritative predictions concerning alterations to the PA genes promoter and 
TIR which would increase the level of expression. Any changes would have to be 
investigated experimentally and would not be certain to lead to increased expression.
In conclusion, PA expression can be increased by altering the gene copy number but 
this only produces a proportional increase to the change in copy number. Changing the 
promoter from the B. anthracis PA promoter to the E. coli lac promoter had a significant 
effect on expression. When this change was analyzed at the DNA sequence level several 
possible reasons for this effect were identified but their contribution to expression would 
need to be experimentally assessed. Further improvements to expression should be possible, 
but no obvious limiting sequences were identified in this analysis. Other factors may be 
limiting expression.
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5.1 Introduction
As discussed in Chapter 4, increased production o f PA in 5. typhimurium would 
probably improve the potential of a putative vaccine strain. It has been shown that 
increasing the copy number o f the PA gene (pPA26 to pC Bl) had a small effect on 
expression, but altering the promoter from the PA promoter to the lac promoter (pCBl to 
pORFl) had a larger effect on expression. The level o f  expression of a gene is determined 
primarily by three factors: the rate of transcription, the stability of the mRNA, and the 
efficiency o f translation. The amount of protein present in a cell is also related to the 
stability of the protein once it is produced. There are various strategies to affect each of 
these factors so as to maximise the protein present in the cell. These include modifications 
of the promoter sequence and ribosome binding region, changes affecting mRNA secondary 
structure, alterations o f  the codon usage and modifications to the protein conformation and 
cellular location. M ost of the experimental work related to the level o f protein expression 
has been carried out in E. coli. It is considered that in general the same effects will usually 
occur in the closely related S. typhimurium. As discussed in Chapter 4, the lac promoter, 
PA RBS and mRNA secondary structure should be adequate for initiating expression of PA. 
It is therefore possible that the efficiency o f translation could be limiting expression, possibly 
due to codon usage differences. This factor was considered to see if any obvious changes 
could be made to increase expression o f  PA further. From all the available information a 
strategy to increase expression was selected and constructs made to evaluate this.
1 L I  Codon usage
Codon usage within the ORF of a gene has been reported to affect expression (Sharp 
& Li. 1986). Although the nucleotide sequence of the N-terminal amino acids can have a 
large effect on expression by affecting the RBS and mRNA structure (Looman et a i, 1987; 
Barnes et al., 1991), this is considered in section 4.5. In this section, the codon usage o f the 
PA ORF as a whole w ill be considered.
The usage o f  codons is non-random and varies from organism to organism (Makoff 
et al., 1989; Andcrsson & Kurland. 1990). It is also known that there is a positive 
correlation between the degree of codon bias and level of expression within E. coli. It 
appears that this forms a means o f regulation of expression within E. coli (Sharp & Li, 1986).
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It has been shown that B. suhtilis has an unbiased codon usage compared to £. coli 
(Ogasawara, 1985) and S. typhimurium (Wada el al.. 1992). The codon usage for £. coli, 
S. typhimurium. Bacillus species and PA is shown in Table 5.1. From this data the 
frequency of amino acid use was calculated. This showed that £. coli and S. typhimurium 
have similar amino acid use which differs to Bacillus species. PA amino acid use is more 
similar to Bacillus species but docs have some major differences. For instance, asparagine 
(A SN ) occurs at a frequency of 90 per 1000 amino acids in PA but only 54 per 1000 in 
Bacillus codons. This is displayed graphically in Figure 5.1.
For expression studies a comparison of the use of synonymous codons is more 
valuable. From the data shown in Table 5.1 it was concluded that £ . coli and 
S. typhimurium have similar codon usage but this differs, markedly in some cases (eg LEU), 
from Bacillus and PA codon usage. A  comparison of codon usage for three amino acids 
is shown in Figure 5.2. Although Bacillus codon use was different to £ . coli and 
S. typhimurium, codon usage within the PA gene was even more diverse. An analysis o f 
codon usage in £ . coli (Grosjcan & Fiers, 1982) and S. typhimurium (Sharp, 1991) showed 
that different codons are used in strongly and weakly expressed genes (possibly related to 
the strength of codon-anticodon interaction) and codons which are predominately found in 
weakly expressed genes can be identified. Other codons within a synonymous set may occur 
rarely in highly expressed genes of £. coli and this may be correlated to tRNA pools (Sharp 
& Li, 1986). Several theories concerning the mechanism of codon usage affecting level o f  
expression have been suggested. One theory favours the selection o f rare codons to limit 
expression. Codon usage might affect expression w hen tRNA pools become limiting or the 
interaction between the codon and anticodon is cither too strong or too weak. Thus even if 
the level of mRNA is increased, unfavourable codon usage may limit expression. Rare 
codons may cause ribosome stalling which could expose regions of the mRNA to 
endonucleases and so alter the mRNA turnover (Makoff el al., 1989). An alternative view  
suggests that the occurrence o f  rare codons in regulatory and weakly expressed genes results 
from the absence o f strong negative selection rather than from positive selection as a means 
of regulation of expression (Andcrsson & Kurland. 1990). The same authors conclude that 
the codons preferred by strongly expressed genes are positively selected to optimise growth 
rates in good culture conditions by allowing a smaller subset of tRNAs to predominate. The 
ratios o f  isoacccptor tRNA levels do change as growth rates increase to favour the codons
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Table 5.1 Codon Usage
The percentage codon usage for each amino acid is shown on the left side o f  the
table.
The codon use per 1000 codons is shown on the right side o f the table.
Data for E. coli (E.c), S. typhimurium (S.t) and Bacillus (Bac) are derived form 
Wada el at., (1992). The data for PA (PA) was obtained using the PA sequence from 
Welkos el al., (1988) and the TRANS programme from DNAStar.
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p e r c e n t  c o d o n  u a a g e c o d o n s p e r  'OOO
Acid Codon E . c 1 5 1 p e r  | V e, V 1. r B* r
"  PÀ
Arvo 10.5" 5 .1 3 . 9
CGC 3 8 . S 3 9 . 3 1 8 . 5 0 2 2 . 1 2 2 . 5 8 .1 0
CGC 8 1 0 . 8 10 1 3 . 8 4 . 6 6 . 2 4 . 4 5 . 2
CCU 42 3 4 . 8 23 1 0 . 3 2 4 . 1 1 9 . 9 13 . 1 3 . 9
AGA 3 . 7 5 . 4 2 8 . 7 5 5 . 2 2 . 1 3 .1 1 2 . 6 2 0 . 9
AGG 2 . 4 3 . 5 6 . 2 1 0 . 3 1 . 4 2 3 . 6 3 . 9
L K CUA 3 . 2 4 . 6 8 . 2 4 . 8 3 . 2 4 . 6 7 .1 3 . 9
CUC 9 . 9 9 . 9 8 . 8 3 . 2 9 . 9 9 . 9 7 . 6 2 . 6
CUG 5 4 . 4 4 9 . 6 1 6 . 3 1 . 6 5 4 . 6 4 9 . 4 14 . 1 1 . 3
CUU 1 0 . 2 1 0 . 6 2 2 .  1 9 . 7 1 0 . 2 1 0 . 5 1 9 . 2 7 . 9
UUA 1 0 . 9 1 3 . 5 2 9 . 8 6 7 . 7 1 0 . 9 1 3 . 4 2 5 . 8 5 4 . 9
UUG 1 1 . 5 1 1 . 8 1 4 . 9 1 2 . 9 1 1 . 5 1 1 . 7 1 2 . 9 1 0 . 5
SES UCA 1 1 . 9 1 2 . 5 2 1 . 1 2 0 . 8 6 . 6 7 . 4 1 3 . 7 1 9 . 6
ucc 1 6 . 5 1 8 . 4 1 2 . 8 4 . 2 9 . 4 1 0 . 9 8 . 3 4
UCG 14 14 10 9 . 7 8 6 . 3 6 . 5 9 .  1
UCU 1 8 . 2 1 4 . 7 2 2 . 9 30 6 1 0 . 4 8 . 7 1 4 . 9 2 8 . 8
AGC 2 6 .  7 2 7 . 7 1 7 . 7 2 . 8 1 5 . 2 1 6 . 4 1 1 . 5 2 . 6
AGU 1 2 . 6 1 2 . 8 1 5 . 5 3 1 . 9 7 . 2 7 . 6 10 . 1 30
TH3 ACA 1 2 . 1 1 2 . 4 3 9 . 8 3 7 . 9 6 . 5 6 . 8 2 4 . 1 2 6 . 7
ACC 4 5 . 3 4 4 . 1 1 3 . 9 1 0 . 3 2 4 . 3 2 4 . 1 8 . 4 7 . 8
ACC 2 3 . 6 2 8 . 3 2 4 . 8 19 1 2 . 7 1 5 . 5 15 1 4 . 4
ACU 19 1 5 . 2 2 1 . 6 3 2 . 6 1 0 . 2 6 . 3 • 3 . 1 2 4 . 9
PRO CCA 1 9 . 1 1 4 . 8 3 1 . 3 3 7 . 9 8 . 2 6 . 5 1 2 . 1 1 4 . 4
CCC 10 1 3 . 7 6 . 7 1 0 . 3 4 . 3 6 2 . 6 3 . 9
CCG 5 5 . 5 54 3 2 . 6 2 0 .  7 2 3 . 8 2 3 . 7 1 2 . 6 7 . 8
CCU 1 5 . 4 1 7 . 5 2 9 . 5 31 6 . 6 7 . 7 1 1 . 4 1 1 . 8
ALA GCA 2 1 . 8 1 4 . 7 3 1 . 2 4 6 . 3 2 0 . 6 1 3 . 5 2 2 . 1 2 4 . 6
GCC 2 4 . 8 29 1 7 . 3 4 . 9 2 3 . 5 2 6 . 7 1 2 . 3 2 . 6
GCG 35 4 0 . 4 23 1 7. 1 3 3 . 1 3 7 . 2 1 6 . 3 9 . 2
GCU 1 8 . 4 16 2 8 . 5 3 1 . 7 1 7 . 4 1 4 . 7 2 0 . 2 17
CL Y GGA 9 . 4 1 0 . 2 3 2 . 2 5 2 . 6 7 7 . 4 2 2 . 6 2 4 . 6
CGC 4 0 . 5 4 7 . 2 2 7 . 1 5 . 6 3 0 . 2 3 4 . 3 19 2 . 6
CGC 13 1 5 . 6 1 6 . 3 3 0 . 6 9 . 7 1 1 . 3 1 1 . 4 1 4 . 4
GGU 37 27 2 4 . 4 1 1 . 1 2 7 . 6 1 9 . 6 17 . 1 5 . 2
val GUA 1 6 . 3 1 7 . 3 2 8 . 5 3 9 . 5 1 1 . 6 1 2 . 2 • 9 . 5 2 2 . 2
GUC 1 9 . 9 2 5 . 1 2 0 .  1 4 . 7 1 4 . 2 1 7 . 7 13.6 2 . 6
GUG 3 5 . 5 3 5 . 2 2 1 . 8 2 7 . 9 2 5 . 3 2 4 . 8 1 4 . 9 1 5 . 7
GUU 2 8 . 2 2 2 . 4 2 9 . 6 2 7 . 9 2 0 . 1 1 5 . 8 2 0 . 3 1 5 . 7
LYS AAA 7 5 . 3 7 5 . 4 73 7 8 . 3 3 6 . 5 3 6 . 7 4 6 . 4 6 1 . 4
AAG 2 4 . 7 2 4 . 6 27 2 1 . 7 12 12 1 7 . 2 17
ASS AAC 5 9 . 5 5 1 . 3 4 0 . 3 2 3 . 2 2 3 . 9 2 1 . 3 2 1 . 7 2 0 . 9
AAU 4 0 . 5 4 8 . 7 59 .  7 7 6 . 8 1 6 . 3 2 0 . 2 32 . 1 6 9 . 3
GLA CAA 3 0 . 5 2 9 . 2 6 5 . 6 6 3 . 9 1 3 . 2 1 2 . 8 2 5 . 9 34
CAG 6 9 . 5 7 0 . 8 3 4 . 4 16 . 1 3 0 . 1 31 1 3 . 6 6 . 5
e:s CAC 48 4 4 . 1 2 9 . 8 10 1 0 . 7 9 . 4 6 . 2 1 . 3
CAU 52 5 5 . 9 7 0 . 2 90 1 1 . 6 1 1 . 9 1 4 . 6 1 1 . 8
GLL GAA 6 9 . 3 6 3 . 9 7 0 . 3 7 4 . 5 4 3 . 4 3 8 . 4 4 9 . 5 4 9 . 7
GAG 3 0 . 7 3 6 . 1 2 9 . 7 2 5 . 5 1 9 . 2 2 1 . 7 2 0 . 9 17
ASP GAC 4 0 . 3 3 8 . 7 3 2 . 1 1 2 . 8 2 1 . 6 2 1 . 5 1 7 . 9 7 . 9
GAU 5 9 . 7 6 1 . 3 6 7 . 9 6 7 . 2 3 2 . 3 3 4 . 1 3 7 . 8 5 3 . 6
77* UAC 4 6 . 5 4 1 . 7 3 1 . 9 2 1 . 4 1 3 . 4 1 2 . 6 1 2 . 4 7 . 8
UAU 5 3 . 5 5 8 . 3 6 8 . 1 78  6 1 5 . 4 1 7 . 6 2 6 . 5 2 8 . 8
CTS UGC 5 6 . 5 5 5 . 8 4 5 . 2 0 6 . 1 6 . 3 3 . 3 0
UCU 4 3 . 5 4 4 . 2 54 S 0 4 . 7 5 4 0
PSI uuc 4 8 . 7 4 0 . 5 3 2 . 9 2 0 . â 1 6 . 2 1 5 . 3 • 3 . 4 6 . 5
uuu 5 1 . 3 5 9 . 5 6 7 . 1 7 9 . 2 1 9 . 2 2 2 . 5 2 7 . 3 2 4 . 8
: lx AUA 7 .1 1 1 . 2 16 3 1 . 6 4 . 1 6 . 7 ’ 0 . 6 2 3 . 5
AUC 4 5 . 8 4 1 . 5 12.  1 1 7 . 5 2 6 . 5 24  B 2 1 . 7 13
AUU 4 7 . 1 4 7 . 2 5 1 . 9 50  9 2 7 . 2 2 8 . 2 35 .1 3 7 . 9
s i r AUG 100 100 100 1 »  | 2 6 . 5 2 5 . 5 2 2 . 2 1 3 . 1
ru? UGC 100 100 100 100 I 1 2 . 6 1 1 . 6 • 2 . 2 9 . 2
TT* UAA 6 6 . 7 6 6 .  7 63 100 1 2 2 1 . 7 1 . 3
UAG 6 . 7 6 .  7 1 4 . 8 ° 0 . 2 0 . 2 0 . 4 0
UGA 2 6 . 7 2 6 .  7 2 2 . 2 ° 0 . 8 0 . 6 0 . 6 0 .
Table 5.1 Codon Usage
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Figure 5.1 Frequency o f amino acid use
Data from Table 5.1 was used to provide totals for the frequency (per 1000) that 
each amino acid occurs in the sequences analyzed. The totals for each amino acid are 
displayed for E. coli, S. typhimurium. Bacillus species and PA.
Note the particular differences for Ser and Asn.
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Figure 5.2 Codon use for three amino acids
Data from Table 5.1 was used to compile three graphs showing the % use o f  each 
synonymous codon for three amino acids, Arg, Leu and Scr.
Note that E. coli and S. typhimurium have similar codon usage in all cases. Bacillus 
use is different to E. coli and 5. typhimurium and generally shows less biased codon usage. 
PA codon use is particularly biased though and very different to E. co li , see for instance the 
AGA codon for Arg and the UUA codon for Leu.
/
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Figure 5.2 Codon use for three amino acids
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found in strongly expressed genes. Organisms that show a pronounced codon usage bias, 
such as the enterobacteria and yeasts, are thus better adapted to periods of rapid growth 
(Andersson & Kurland, 1990). Possibly the less pronounced codon usage bias in Bacillus 
reflects the lack o f selection pressure for rapid growth in this species.
It is possible to list codons whose use within an ORF translated in E. coli may 
adversely affect expression. Gram positive genes, with a higher A/T ratio compared to 
E. coli genes, often contain a high proportion o f codons found in weakly expressed genes 
(termed 'weak') or codons with small tRNA pools (termed 'rare') and this is the case for the 
PA ORF. The use of 'rare' or 'weak' E. coli codons within PA is shown in Table 5.2. Of 
a total o f  764 codons in PA, 244 (52%) can be classified as 'weak' (157 codons, 18%) or 
'rare' (107 codons, 14%). The 'weak' and 'rare' codons in PA occur throughout the gene, 
there are no specific areas containing clusters o f these codons. Although some genes with 
up to 10% of 'rare' codons are expressed at up to 10% of cell protein, the AT rich fragment 
C of tetanus toxin contains 11.7% 'rare' codons and expression was increased from 5-4% of 
cell protein to 11-14% by replacing the sequence with optimised codons (M akoff el al.,
1989). The large number of 'weak' and 'rare' codons present in PA might be expected to 
limit expression once mRNA levels arc elevated.
Therefore the codon usage in PA is far from ideal for expression of this gene in 
E. coli (and similarly S. typhimurium). The scattering of 'weak' or 'rare' codons throughout 
the gene means that the whole ORF may have to be chemically synthesised so as to correct 
the codon usage. This would require the design of a cloning strategy, synthesis of 
complimentary oligonucleotides with optimised codon usage, annealing and cloning of the 
oligonucleotides, confirmation o f the clone sequence, and ligation of the cloned fragments 
in order to recreate the ORF. The oligonucleotides could be synthesised at up to 150 bp and 
so at least 15 pairs would be required. This approach is impractical in this study.
5.1.2 Fusion proteins and expression of fragments
Another approach to increase the expression of heterologous proteins is to create a 
fusion protein o f the novel protein (85 kDa PA) to the promoter, TIR and all or part o f the 
ORF of a known highly expressed protein. The level o f transcription and initiation of 
translation is therefore known and expression is only limited by factors such as mRNA 
stability and codon usage o f the heterologous protein coding region. Fusion proteins may
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Tabic 5.2 Codon replacement strategy
The table shows an analysis o f  the PA gene to identify the extent of the use of 
'weak' or 'rare' codons. Theses codons are listed with a possible replacement codon which 
might improve the expression in E. coli. The frequency o f the occurrence o f these 
undesirable codons within the PA gene is shown.
(a) Amino acid three letter code
(b) 'Weak' or 'rare' codon in PA ORF
(c) Preferred codon to use in E. coli instead of codon in (b). Identified by Grosjean and 
Fiers (1982), on the basis o f their occurrence in strongly expressed genes.
(d) Refers to the use of the 'wcak'/’rarc' codon (column (b)) in PA ORF. '%' is the % 
use of the codon amongst synonymous codons for the amino acid, 'no.' is the 
number o f occasions that the 'weak'/'rare' codon is used in the PA ORF (total 764 
amino acids). From analysis o f  sequence in W clkos et al. (1988).
(c) Reason for inclusion o f codon in column (b). 'Weak' (W) codons are derived form 
Grosjean & Fiers (1982) and relate to the codon's occurrence in weakly expressed 
genes. 'Rare' codons are from Sharp & Li (1986) and arc related to tRNA pool 
sizes.
/
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(a) (b) (c) (d) (e)
Amino
Acid
Change
from
Change
to
PA
% no.
Weak or 
Rare
Asn AAU AAC 77 53 W j!
Arg AGA CGU 55 16 R
Arg AGG CGU 10 3 R
Ile AUA AUC 32 18 R
Ile AUU A U C 51 29 W
Pro c c c CCG 10 3 WR
Arg CGA CGU 10 3 R [
Arg CGC CGU 0 0 W
Arg CGG CGU 14 34 R
Leu CUA CUG 5 3 R
Ala GCC GCU/
GCG
5 2 W
Gly GGA GGU 53 19 R
Gly GGC GGU 6 2 W
Gly GGG GGU 31 11 R
Tyr UAU UAC 79 22 W
Ser UCG UCU 10 7 R
Phc u u u UUC 79 19 W
Total 244
Table 5.2 Codon replacement strategy
105
Chapter 5. Rational approach to increasing expression
also be protected against proteolytic degradation (Enfors, 1992).
This strategy can be refined by only expressing fragments of the heterologous protein 
as fusion proteins. This may have benefits in that toxic proteins can be expressed as 
non-toxic but immunogenic fragments. Also, if codon usage is limiting, the bacteria may 
express proportionally more of the smaller immunogenic fragment, than the full-length 
construct, before tRNA pools become limiting. For this approach to work, an appropriate 
fragment must be identified. Epitope predictions or mapping may help identify a suitable 
region, or experimental approaches can be used to evaluate the immune response to 
expressed or chemically produce defined fragments.
5.2 Expression of 63 kDa PA
Production of PA might be increased by expressing a fragment of PA as a fusion 
protein. As it might be expected that conformational epitopes would be important in the 
generation o f neutralising antibodies, the PA expressed should have the possibility of 
configuring in as natural a conformation as possible. One strategy that might achieve this 
with PA makes use of the trypsin cleavage site present between the 20 kDa and 6? kDa 
fragments. Protease cleavage at this site occurs in vivo to release the active 63 kDa 
C-terminal fragment which contains both the cell-surface receptor and the binding site for 
LF or EF (Leppla. 1991). It is known that neutralising monoclonal antibodies bind to this 
fragment (Little et at., 1988). The 20 kDa fragment appears to play little role in 
immunogenicity as it is very difficult to generate monoclonal antibodies against this fragment 
(Little et aL, 1988): it may of course have other important functions. Thus the 63 kDa 
fragment appears to contain the important epitopes and could be expressed as a fusion 
protein whilst still maintaining the trypsin cleavage site between the carrier protein and the 
63 kDa PA. The protein that PA is fused to may stabilise the fusion protein within the 
bacteria so slowing degradation and thus allowing accumulation in higher amounts. Once 
released from the bacteria the trypsin cleavage site may allow proteases to cleave the 63 kDa 
PA from the carrier protein and it may then be able to configure in a natural manner with 
the presentation of conformational epitopes to the immune system.
A possible advantage for this construct is that the PA signal sequence would not be 
present. There is a possibility that PA may be toxic due to it becoming partially integrated 
into the bacterial membrane during export. The strategy of removing signal sequences
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and/or hydrophobic trans-membrane regions from heterologous antigens has proved useful 
in reducing their toxicity and stabilising expression (Curtiss et al., 1990).
The vector chosen for expression o f the 63 kDa form of PA was pBluescript II. This 
was the vector used for pORFl and so would allow a direct comparison. The 63 kDa 
fragment could be expressed as a fusion with /9-galaclosidase from the lac promoter. As 
there are no appropriate restriction sites in the PA ORF the new construct was made using 
PCR and the insert was nucleotide sequenced to check for fidelity errors introduced during 
PCR.
A final consideration in the strategy for expression o f the 63 kDa fragment of PA 
was based on a comparison with the experimental work on E. coli Heat-Labile toxin B 
subunit (LT-B). LT-B, like PA, is a non-toxic cell-binding protein and LT-B has been used 
for the targeting o f fused antigens/epitopes to the immune system. Although LT-B and the 
related Cholera Toxin B subunit are particularly strong immunogens, if PA could be 
expressed stably in S. typhimurium it might have possibilities itself as a carrier molecule. 
To allow for the possibility o f  this, unique restriction sites were introduced at both ends of 
the PA insert so that subsequently sequences expressing other proteins or epitopes could be 
cloned onto the PA gene. The result o f this modification was to alter the C-terminal end of 
the 63 kDa fragment by the addition o f 5 aa.
In this chapter the construction o f this first 63 kDa fragment phagemid and the 
expression o f PA from it is described. Subsequently the same fragment was expressed from 
a different promoter (ire) and, as questions were raised about the possible effects o f the 5 
aa modifications to the C-terminal ends, constructs were made from both the lac and tre 
promoters with unmodified C-terminal ends. The four constructs made arc shown 
diagrammatically in Figure 5.3.
5.3 Construction of phagemid pVET4m
pVET4m was constructed to express the 63 kDa C-terminal fragment o f PA as a 
fusion protein with part o f /3-galactosidasc. The phagemid pBlucscript was used to express 
this construct from the lac promoter. The trypsin site was included to offer the potential for 
cleavage of the 63 kDa fragment from /3-galactosidasc. The modified C-terminal end of the 
fragment containing unique restriction is identified by the'm' in the phagemid designation. 
The phagemid structure is illustrated in Figure 5.4.
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Figure 5.3 Diagrammatical representation o f  the four constructs made in Chapter 5
The construct designation is shown to the left o f each drawing.
pVET4m pBluescript II KS+ based construct expressing the 63 kDa fragment of PA 
as a /3-galactosidasc fusion from the lac promoter. Has a modified (5 amino 
acid addition) C-terminus.
pVET4n As pVET4m except has native PA C-terminus.
pNIKln pTrc99A based construct expressing the 63 kDa fragment of PA fused to a
short linker sequence from the tre promoter. Native PA C-terminus.
pNIKlm As pNIKln except with modified (5 amino acid addition) C-terminus.
/
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Figure 5.4 Phagcmid pVET4m
A. Phagemid pVET4m was constructed to express the C-terminal 63 kDa fragment of 
PA fused to a short /3-galactosidasc fragment.
B. A blunlcd-cndcd PCR product was ligated into £c«R V  cut pBlucscript II KS+. This 
prtxluct created an £coRV site at the N-tcrminal end but not at the C-terminal end. 
The PCR primers used contained non-homologous tails which coded for unique 
restriction sites at both ends. There is one internal Pstl site and another Pstl site in 
the pBluescript polylinker downstream of the insert. These sites were used for 
manipulations described in the text. The construction strategy is shown in 
Figure 5.5.
/
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The ORF in pVET4m codes for:
-34 aa from 'he N-terminal end of the /3-galactosidase fragment in pBluescript 
-a 5 aa linker coded for by the PCR primer ANTHPR3 sequence containing unique 
restriction enzyme sites
-3 aa from PA and then the 4 aa RKKR trypsin cleavage site and the 568 aa 
C-terminal 63 kDa fragment of PA (575 aa)
-5 aa addition to the C-terminal end o f PA coded in the sequence o f PCR primer 
ANTHPR4 and containing unique restriction enzyme sites 
Thus the total length of the expected product is 619 aa and the calculated MW is 68.9 kDa. 
The C-terminal fragment cleaved at the trypsin cleavage site has a calculated MW of 64 kDa 
(corresponding to the 63 kDa C-terminal fragment o f native PA with a 5 aa C-terminal 
addition).
As there were no appropriate restriction enzyme sites in pPA26 which could be used 
to construct this clone, PCR primers were designed to accomplish this. The strategy is 
illustrated in Figure 5.5. The primers ANTHPR3 and ANTHPR4 were designed to generate 
a PCR product for blunt-ended cloning into EcoRV cut pBluescript II KS+. The primers 
contained the appropriate nucleotides to reconstitute the EcoRV sites at each end of the 
insert. The primers were used in a standard PCR reaction using CsCl purified pPA26as the 
template. Four 100 fA reaction tubes were run and the reaction mixes combined and run on 
a 0.7% agarose gel and the band o f interest was purified using DEAE cellulose paper. The 
PCR product was blunted with KJenow and ligated into EcoRV cut pBluescript II K.S+. The 
ligated DNA was electroporated into E. coli JM 109 and ampicillin resistant clones identified 
on L-agar plates supplemented with ampicillin. Colonies were picked, grown overnight in 
L-broth supplemented with ampicillin and the plasmid isolated. Two clones with the 
expected restriction pattern were identified except that they only contained one EcoRV site 
at the 5' end of the insert. These two clones were designated pVET4m and pVET6m and 
were shown to express a protein after IPTG induction which reacted with rabbit anti-PA 
antibodies by Western blotting.
ssDNA preps were made from both clones and the ssDN A  was sequenced with the 
Universal primer (M13 -20) to establish the sequence at the 3' end o f the insert. Both clones 
had lost the 3'T from primer ANTHPR4 to give GAATC rather than reconstituting the 
EcoRV site GATATC. As this did not alter the coding sequence, being 3' to the stop codon,
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Figure 5.5 Strategy for the construction of pVET4m
A. PCR primers ANTHPR3 and ANTHPR4 were designed to amplify the 63 kDa C- 
tcrminal fragment o f the PA gene from the Trypsin cleavage site to the stop codon. 
They contained non-homologous tails which would become inserted into the PCR 
product and introduce unique restriction sites at either end.
B. The PCR product was blunted with KJenow and cloned into £coR V  cut 
pBlucscript II KS+. Although the primers were designed to recreate the tw o£coR V  
sites at either end o f  the insert, the downstream site was not recreated due to a base 
deletion at this end.
/
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it was not considered significant. As both clones contained this difference it is possible that 
the PCR primer was synthesised without this nucleotide. To check for fidelity errors during 
PCR, the entire insert sequence for one of the clones, pVET4m, was verified by sequencing 
along the ssDNA template using sequencing primers PAS 1-8 and dlTPs and Taq chases 
where necessary to resolve CG compressions and premature termination due to template 
secondary structure.
The sequence obtained was compared to the reported sequence (Welkos el at., 1988). 
Using the numbering used for the entire 4235 insert DNA in pPA26, a single base change 
was found at position 2743 (G to C) which would change a GAA codon to a CAA codon 
(glutamic acid to glutamine). This change was also found in pVET6m when this same 
region was sequenced. In order to establish if this was a PCR fidelity enor, this same region 
was sequenced in pPA26, and DNA from the B. anthracis strains. New Hampshire, Steme, 
Ames and Vollum (+1). The method used was to PCR amplify the 1.7 kbp region from all 
the templates and then dsDNA sequence this region in both directions using primers PAS7 
and PAS7R. Primers ANPR3S and ANPR4S (see Section 3.2.2) were used in 3 x l0 0 /d  PCR 
reactions which were cycled 30 times and then another aliquot of Taq enzyme added and the 
reactions cycled an additional 20 times. The products were gel purified and recovered using 
DEAE cellulose paper, alkali denatured and sequenced using standard methods with a Taq 
chase. This showed that the base change from the published sequence occurred with all 
templates. It was concluded that the reported sequence was incorrect.
5.3.1 Expression o f PA from pVET4m
Whole cell lysates from E. coli JM 101 containing pVET4m (made using the 
methodology described in Section 4.3.2. for pORFl clones) were subjected to SDS-PAGE 
and Western blotted. This is shown in Lane 3 of Figure 5.6.
As can be seen in Figure 5.6 an immunoreactivc protein o f the expected MW was 
expressed but also present were bands o f lower molecular weights which presumably 
correspond to breakdown products o f  the protein. The difference between this recombinant 
protein and cleaved native PA is only 4.9 kDa and even on gels run with trypsin-cleaved 
native PA and recombinant PA a difference could not be distinguished. Thus it is not clear 
if the band seen represents the full-length recombinant protein or the cleaved C-tcrminal 
portion. The Western blot in Figure 5.6 was developed with mouse monoclonal antibodies
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Figure 5 .6  Western blot o f  expression o f pVET4m and pVET4n in E. coli and 
S. lyphimurium
Whole cell lysates, adjusted for cell number, were prepared from cultures of E. coli 
/  pBluescript, pORFl, pVET4m and pVET4n. The cultures were induced with IPTG for 
1 hour prior to harvesting the cells. 5. lyphimurium SL 3261 containing the same plasmids 
were grown similarly but without IPTG induction. The pellet from 10 ml of each culture was 
suspended in approximately 1 ml o f  lxLB (proportional to the A b s^  o f the culture) and 
boiled for 3 mins. This lysate was diluted 1:5 in lxL B  and 2 0 p\ loaded in each well. This 
is equivalent to the protein from approx 1.5 x 10s cells loaded in each lane. Bio-Rad 
prestained MW markers were run in the middle lane and apparent MWs are shown. The 
gels were blotted onto PVDF membrane, blocked in Blotto, and incubated in a primary 
antibody o f  mouse anti-PA monoclonal antibodies, and a secondary HRP-conjugated 
anti-mouse IgG. The substrate used to visualised the bands was DAB.
Lane 1 E. coli JM 109 /  pBluescript 
Lane 2 E. coli JM 101 / pORFl 
Lane 3 E. coli JM 101 /  pVET4m 
Lane 4 E. coli JM 109 /  pVET4n 
MW markers
Lane 5 S. lyphimurium SL 3261 / pBluescript 
Lane 6 S. typhimurium SL 3261 /  pORFl 
Lane 7 S. typhimurium SL 3261 /  pVET4m 
Lane 8 5. typhimurium SL .3261 / pVET4n
/
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Figure 5.6 Western blot o f expression o f pVET4m and pVET4n in E. coli and 
S. typhimurium
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which bind to the C-terminal end o f  the fragment. Therefore other breakdown product bands 
consisting of the N-ierminal portion o f  the protein may not be visualised. Also this suggests 
that the 5 aa addition to the C-terminal end o f PA expressed in pVET4m docs not 
significantly alter the epitope that the mouse MAbs bind to.
The presence o f  so much o f  the immunoreactive protein within smaller MW bands 
suggests that it is being degraded. Fusions to /3-galactosidase have been used to stabilise 
heterologous proteins against proteolytic degradation (Enfors, 1992). In this case only 34 
amino acids o f /3-galactosidasc remain and this may not be sufficient to stabilise the fusion. 
Thus it appears that fusion of this fragment of PA to /3-galactosidase has not stabilised the 
construct although overall total expression levels may be higher than for pORFl. For 
comparison, expression from pORFl is shown in Lane 2 of Figure 5.6. As the product from 
pORFl appears to be all full-length, the bands are proportional to the level o f expression. 
For pVET4m, the total expressed is the sum of the bands plus any protein bands which are 
undetected by the MAb.
When the phagemid pVET4m was electroporated into S. typhimurium SL 3261 a 
similar pattern o f bands was seen. Lane 7, Figure 5.6. The overall level o f expression 
appears to be lower in S. typhimurium than E. coli.
5A  Construction o f phagemid pVET4n
A s pVET4m has an additional 5 aa coded in the 5' non-complimentary tail o f 
ANTHPR4, this may have affected protein stability. A phagemid with a naturally configured 
C-tcrminal end to PA was constructed to compare expression, stability and immunogenicity 
with pVET4m. Plasmid pNIKln (sec Section 5.5) contains the coding region for the natural 
C-terminal end o f PA and this can be removed from pNIKln on a Pstl-Pstl fragment. This 
fragment can be cloned into Psil cut pVET4m to replace the original Pstl fragment and so 
express PA with a natural C-tcrminal end. This is illustrated in Figure 5.7.
pVET4m was cut with Pstl, CIP treated and the vector and insert bands separated 
on an agarose gel. The vector band was recovered using Qiaex. pNIKln was cut with Pstl 
and the insert gel-purified and recovered using Qiaex. Suitable ligation mixes were made 
and incubated overnight. The ligated DNA was electroporated into E. coli HB 101 (JM 101 
or 109 should have been used as they have the lacP gene and so would have been able to 
regulate the promoter) and recombinant clones identified by plating on L-agar plates
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Figure 5.7 Phagemid pVET4n
A. Phagemid pVET4n is similar to pVET4m except for the C-terminal end of the 
expressed PA fragment. In pVET4n the modified 5 amino acid addition is not 
present and the sequence is the same as for native PA. The fragment is expressed 
from the lac promoter in pBlucscript as for pVET4m.
B. This show s the important restriction enzyme sites in pVET4n. It was constructed 
by replacing the Pstl-Psil fragment with the same fragment from pNIKln, a plasmid 
containing the native PA sequence at the C-terminal end.
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supplemented with ampicillin. Clones with the insert present and in the correct orientation 
were identified using PCR. Primers PAS7R (originally a sequencing primer) and PA 1219 
bind either side of the internal Ps/I site and amplify a product of 400 bp if the clone has the 
insert in the correct orientation. 5 out of 18 clones were identified as positive by PCR and 
shown to produce an immunoreactivc product o f  the expected MW on Western blotting with 
mouse anti-PA monoclonal antibodies. One o f these clones was designated pVET4n ('n' for 
native PA C-terminal end) and shown to have the expected restriction enzyme profile.
5.4.1 Expression of PA from pVET4n
Expression of PA from pVET4n is shown in Figure 5.6. Lane 4 shows expression 
in £ . coli and Lane 8 from S. typhimurium SL 3261. Although the bands may be slightly 
denser than for pVET4m, the overall pattern is the same. It seems that the modified 
C-tcrminal end was not responsible for the degradation of this fusion protein.
I S  Construction of plasmid pNIKIp
In order to see if an alternative fusion system gives similar results, it was decided 
to express the same 63 kDa fragment of PA as a fusion protein from another vector. As 
discussed in Section 4.5, the lac promoter is not optimised for transcription. Therefore an 
alternative more active promoter was looked for and, after studying several commercially 
available plasmids, pTrc99A was chosen for further work. This contains the strong IPTG 
inducible promoter tre in a vector with the pBR322 ori. The tre promoter is similar to the 
lac promoter but with 17 bp spacing separating the -35 and -10 regions of the promoter, this 
leads to only 90% of the activity o f  the la c  promoter (Brosius el al., 1985). The vector does 
not express a particular protein, but the PA-63 would be preceded by 24 aa coded for by the 
linker sequences between the start codon and the beginning o f the PA-63 ORF. One 
drawback with this plasmid in this project is that the lac/-' gene is present on the plasmid. 
This ensures good repression of the tre promoter, in case the protein is toxic, yet suit allows 
in vitro expression by induction with IPTG. But the plasmid borne lac!* would prevent 
constitutive expression from this promoter in vivo. Following an examination of restriction 
sites in the plasmid, it was found that the lari'1 gene contained the only two FVulI sites in 
the constructs that were to be made. Thus removal o f this /VuIL/Vull fragment offered a
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supplemented with ampicillin. Clones with the insert present and in the correct orientation 
were identified using PCR. Primers PAS7R (originally a sequencing primer) and PA 1219 
bind either side o f  the internal Psrl site and amplify a product o f 400 bp if the clone has the 
insert in the correct orientation. 5 out of 18 clones were identified as positive by PCR and 
shown to produce an immunoreactive product of the expected MW on Western blotting with 
mouse anti-PA monoclonal antibodies. One o f these clones was designated pVET4n ('n' for 
native PA C-terminal end) and shown to have the expected restriction enzyme profile.
5.4.1 Expression of PA from pVET4n
Expression of PA from pVET4n is shown in Figure 5.6. Lane 4 shows expression 
in E. coli and Lane 8 from S. typhimurium SL 3261. Although the bands may be slightly 
denser than for pVET4m, the overall pattern is the same. It seems that the modified 
C-terminal end was not responsible for the degradation of this fusion protein.
1 5  Construction of plasmid pM K lfl
In order to see if an alternative fusion system gives similar results, it was decided 
to express the same 63 kDa fragment of PA as a fusion protein from another vector. As 
discussed in Section 4.5, the lac promoter is not optimised for transcription. Therefore an 
alternative more active promoter was looked for and, after studying several commercially 
available plasmids, pTrc99A was chosen for further work. This contains the strong IPTG 
inducible promoter ire in a vector with the pBR322 ori. The tre promoter is similar to the 
tac promoter but with 17 bp spacing separating the -35 and -10 regions of the promoter, this 
leads to only 90% of the activity of the tac promoter (Brosius et a i,  1985). The vector does 
not express a particular protein, but the PA-63 would be preceded by 24 aa coded for by the 
linker sequences between the start codon and the beginning of the PA-63 ORF. One 
drawback with this plasmid in this project is that the lac/-' gene is present on the plasmid. 
This ensures good repression of the tre promoter, in case the protein is toxic, yet sail allows 
in vitro expression by induction with IPTG. But the plasmid borne lac/" would prevent 
constitutive expression from this promoter in vivo. Following an examination of restriction 
sites in the plasmid, it was found that the lad" gene contained the only two Pvull sites in 
the constructs that were to be made. Thus removal o f  this /VuII-PvuIl fragment offered a
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method to inactivate the repressor. If the constructs were found to be useful, this deletion 
would allow constitutive expression in vivo.
It was decided to clone the 63 kDa fragment o f native PA (without the 5 aa 
C-tcrminal modification) downstream of this promoter so as to be able to compare expression 
of this fragment from both the lac promoter in pVET4n and the tre promoter. Construction 
of the plasmid is illustrated in Figure 5.8.
A phagemid, designated pBPA9, had been constructed to contain the 63 kDa 
fragment o f PA, with the natural C-tcrminal end, in pBluescript II KS+. It was constructed 
using primers BPA3 and BPA4 to amplify the region required from pPA26 and, following 
Klenow blunting, it was cloned into EcoRV cut pBluescript. The ligated DNA was 
electroporated into E. coli JM 109 and recombinant clones selected for on L-agar plates 
supplemented with ampicillin. Clones with the insert were identified by PCR using the 
original primers BP A3 and BPA4, positive clones were then mini-prepped and restriction 
mapped using EcoRV and S a d  to identify clones with the insert in the correct orientation. 
A helper phage induced ssDN A  preparation was made and the insert sequenced to confirm 
that no PCR induced mutations had occurred using sequencing primers PAS1-9, the universal 
primer (M13 -20) and the SK primer.
The Kpn\ - Xba\ fragment o f pBPA9 contains an 18 amino acid linker coupled to 
the 63 kDa fragment o f PA beginning with 3 aa then the trypsin cleavage site and the 568 
PA ORF. This fragment was cloned into Kpn\-Xba\ cut pTrc99A which adds another 6 
amino acids expressed by the coding region o f the polylinker before the 63 kDa fragment 
o f PA. The final product would therefore be expected to have the 63 kDa fragment of PA. 
as found in pVET4n, expressed as a fusion protein to a 24 aa linker protein.
pBPA9 and pTrc99A were cut with Kpnl and Xbal, separated on agarose gels and 
the appropriate bands recovered using Oiacx. The vector and insert were mixed in 
appropriate ratios, ligated, and electroporated into £. coli HB 101 (pTrc99A contains lacl' 
on the plasmid). Colonics expressing PA were identified using colony blotting with IPTG 
induction as shown in Figure 5.9. A  clone was designated pNIKln and was shown to 
express a PA-immunorcaclivc protein and have the expected restriction enzyme profile.
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Figure 5.8 Plasmid pNIKln
A. The 63 kDa fragment o f  PA was expressed in vector pTrc99A. This contains the 
trc promoter in a pBR322 based vector. The construct pNIKln expresses the 63 
kDa fragment o f PA after a 24 amino acid linker protein. The trypsin cleavage site 
is present and the construct has the native sequence at the C-terminal end.
B. The construct was made by cloning the Kpnl-Xbal fragment o f plasmid pBPA9 into 
similarly cut pTrc99A. There is one internal Pstl site and two Pst\ sites beyond the 
ORF for PA. One o f these was from the polylinker of pBluescript and derives from 
pBPA9, and the other is in the pTrc99A polylinker.
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Figure 5.9 Colony blots to identify pNIKln clones
During the construction of plasmid pNIKln, an insert from pBPA9 was ligated into 
pTrc99A. Part o f the ligation mix was electroporated into E. coli HB 101 and the bacteria 
plated onto ampicillin selection plates. Colonies that grew on these plates were streaked 
onto fresh plates and grown overnight to give 1 cm long ridges of bacteria. The bacteria 
were picked up on IPTG treated Hybond N membrane and incubated for 2 hours at 37°C. 
The bacteria were lysed with chloroform and treated with lysozyme and DNAse. The 
membranes were blocked with Blotto and incubated with a mouse anti-PA monoclonal. The 
MAb was detected with HRP linked anti-mouse IgG and the substrate DAB.
Four filters are shown. Positive colonies either appear as brown spots within the 
streak o f bacteria, or as a larger brown area.
/
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Figure 5.9 Colony blots to identify pNIKln clones
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5.5.1 Expression of PA from pNIKln
Expression of PA from pNIKn was similar in E. coli and S. typhunurium. so only 
expression in S. typhimurium is shown. Expression was tightly regulated as the la d “ gene 
is on the plasmid and so the repressor w ill be present at a high level. Without 1PTG 
induction no immunogenic protein can be seen; Lane 6, Figure 5.10. With 1PTG induction 
bands can be seen on the Western blot (Lane 8) which can be compared to expression from 
pORFl and the pVET4 phagemids (Lanes 2, 3 and 4). The full-length product band is much 
less dense than for pVET4n suggesting that the protein is less stable and is degraded to give 
the lower MW protein visible on the blot. It was found that this plasmid was very unstable 
without antibiotic selection pressure; this is discussed further in Chapter 7.
5.6 Construction o f plasmid pNIKlm
In order to complete the comparison of the effects o f C-terminal changes identified 
between pVET4m and pVET4n, the same modified C-terminal end from pVET4m was 
cloned into pNIKln. This construct is illustrated in Figure 5.11.
The Pstl fragment from pVET4m (containing the modified C-terminal) was gel 
purified and recovered using Qiaex. pNIKln was cut with Pstl and CIP treated and then the 
vector band gel purified and recovered with Qiaex. The vector and insert were mixed in 
appropriate ratios and ligated overnight. The ligated DNA was electroporated into E. coli 
HB 101 (lad* on plasmid) and recombinant clones identified by plating on L-agar plates 
supplemented with ampicillin. Clones with the insert present and in the correct orientation 
were identified using PCR. Primers PAS7R (originally a sequencing primer) and PA 1219 
bind cither side of the internal Pstl site and amplify a product o f 400 bp if the clone is 
correct. 4 out o f  18 clones were identified as positive by PCR and shown to produce an 
immunorcactive product o f the expected MW on Western blotting with mouse anti-PA 
monoclonal antibodies. One o f these clones was designated pNIKIm and further 
characterised by restriction mapping.
5.6.1 Expression o f PA from pNIKIm
Lancs 5 and 7 of Figure 5.10 show uninduccd and induced cultures of 
S. typhimurium SL 3261 / pNIKm. This shows a similar pattern o f bands to the pNIKn 
Western blot lanes with little full-length product but degradation product bands.
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Figure 5.10 Western blot o f expression o f pVET and pNIK plasmids in 
S. typhimurium SL 3261
Whole cell lysates, adjusted for cell number, were prepared from uninduced cultures 
of S. typhimurium /  pBluescript, pORFl, pVET4m, pVET4n, pNIKlm and pNIKln. 
Separate cultures containing pNIK plasmids were also induced with IPTG for 1 hour prior 
to harvesting the cells. The pellet from 10 ml of each culture was suspended in 
approximately 1 ml o f lxLB (proportional to the A b s^  o f  the culture) and boiled for 
3 mins. This lysate was diluted 1:5 in lxL B  and 20 p i loaded in each well. This is 
equivalent to the protein from approx 1.5 x 10s cells loaded in each lane. Bio-Rad 
prestained MW markers were run in the left lane and apparent MWs are shown. The gels 
were blotted onto PVDF membrane, blocked in Blotto, and incubated in a primary antibody 
of mouse anti-PA monoclonal antibodies, and a secondary HRP-conjugated anti-mouse IgG. 
The substrate used to visualised the bands was DAB.
MW markers
Lane 1 S. typhimurium SL 3261 / pBlucscripl
Lane 2 5. typhimurium SL 3261 /  pORFl
Lane 3 S. typhimurium SL 3261 / pVET4m
Lane 4 S. typhimurium SL 3261 /  pVET4n
Lane 5 S. typhimurium SL 3261 /  pNIKIm uninduced
Lane 6 S. typhimurium SL 3261 /  pNIKln uninduccd
Lane 7 S. typhimurium SL 3261 /  pNIKlm induced
Lane 8 5. typhimurium SL 3261 /  pNIKln induced
/
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Figure 5.10 Western blot o f expression of pVET and pNIK plasmids in 
S. typhimurium SL 3261
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Figure 5.11 Plasmid pNIKlm
A. Plasmid pNIKlm is the same as plasmid pNIKIn except that it contains the /»srl-Psrl 
fragment of plasmid pVET4m which codes for the modified C-terminal end o f PA.
B. This shows the restriction enzyme sites involved in the construction o f plasmid 
pNiklm . The Pstl-Psil fragment is from pVET4m.
/
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5.7 Conclusions
In Chapter 4 it was shown that altering the B. anthracis promoter to the E. coli lac 
promoter could significantly increase the level of expression o f PA. As a further increase 
in expression was desirable the possibility of modifying the promoter and RBS was 
investigated but no obvious solution was apparent In this Chapter the possibility that codon 
usage could be limiting translation was discussed. The PA gene's codon usage was found 
to be far from ideal for expression in E. coli or S. typhimurium. A  strategy to chemically 
re-synthesise the gene w as considered but found to be impractical in this study. It was 
therefore decided that the most practical strategy to try and increase expression was to fuse 
PA-63 to part o f  /3-galactosidase. This strategy has produced mixed results. With phagemid 
pVET4m, the overall level o f expression compared to pORFl appeals increased. This has 
been at the expense of producing a fusion protein that appears susceptible to degradation. 
As pVET4m had a modified C-terminal end it was possible that this could affect stability 
and activity. Recent evidence has shown the importance of the C-terminal end of PA in 
receptor interactions (Little & Lowe, 1991; Singh et al., 1991) with deletions o f  as little as 
12 aa completely abolishing PA binding to cells. These deleted proteins also do not bind 
monoclonals 3B 6 and 14C7 which are known to bind to the cell-receptor site on PA. As 
pVET4m has an additional 5 amino acids coded in the 5' non-complimentary tail o f  
ANTHPR4, this may affect the stability around this region. The 5 aa added to the 
C-terminal end (Tyr, Leu, Gly, Ala and Leu) are all hydrophobic. They were not selected 
for this attribute but are a consequence o f  the nucleotide sequence designated by the unique 
restriction sites added for further manipulations. The hydrophobicity of the C-terminal end 
of native PA is relatively neutral (as predicted by both Kyte-Doolittle and Hopp-Woods 
methods) but with this 5 aa modification both methods of prediction show increased 
hydrophobicity, see Figure 5.12. This might destabilise the conformation of the C-terminal 
end and affect the protein's degradation. Singh ei al. (1991) showed that when they deleted 
5-12 aa from the C-terminal end of PA-83 the proteins became wry unstable. It is 
surprising that the monoclonal antibodies that are known to bind to the C-terminal region 
arc still able to recognise this modified PA if the C-tcrminal end is so destabilised. In order 
to evaluate the effect o f this modification a construct was made with a C-terminal end 
identical to the native PA. Phagemid pVET4n with a C-lcrminal end identical to PA had 
a similar pattern o f  degraded protein bands on Western blotting. It was concluded that the
123
Figure 5.12 Hydrophobicity plots for PA and modified PA
The hydrophobicity plots (Kyte-Doolittle and Hopp-Woods) for both native PA and 
modified PA with the 5 amino acid extension expressed by pVET4m were produced using 
the PROTEAN programme from DNASTAR for the Mac computer with the standard default 
settings. The same regions arc shown for both proteins.
A. This shows both hydrophobicity plots for the 30 amino acids at the C-terminal o f 
native PA.
B. This shows the hydrophobicity plots for the 35 amino acids at the C-terminal end 
of the modified PA expressed by pVET4m. The last five amino acids are all 
hydrophobic and so alter the hydrophobic moment of this region.
/
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Figure 5.12 Hydrophobicity plots for PA and modified PA
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modified C-terminal was not responsible for the protein's degradation.
Changing the nature o f the peptide that PA-63 was fused to made the situation 
worse, with less full-length product from the pNIK plasmids compared to the pVET4 
phagemids. The more active promoter tre did not obviously increase the expression level 
but direct comparisons to the pVET4 phagemids are not possible as the fusion protein was 
different.
Thus the strategy of expressing a fragment o f PA has not produced the expected 
benefits. Although more protein was produced, it was less stable. It might be expected that 
the pORFl product, with the PA gene signal sequence, would be secreted into the periplasm. 
Conversely, a /3-galactosidasc fusion protein would be expected to be cytoplasmically 
located. The different cellular location might effect the stability of the protein. There is a 
different proteolytic environment in the periplasm compared to the cytoplasm. Another 
alternative for the stability o f full-length PA could be that the N-terminal 20 kDa fragment 
may have a role in stabilising the protein and protecting it from proteolytic degradation. As 
it would be useful to identify why full-length PA expressed by pORFl is more stable, the 
cellular location of the PA will be addressed in the next chapter.
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6J . Introduction
The cellular location o f expressed antigens can have a number of important 
consequences. These include the stability of the antigen, conformation o f the antigen and 
immune responses to the antigen. Heterologous antigens are prone to proteolysis as they 
may be considered by the cell as aberrant proteins and so be degraded by bacterial proteases 
(such as Protease La, the product o f  the Ion gene) designed for this purpose (Enfors, 1992). 
The protease environment in different cellular compartments varies and so the stability of 
a protein may differ with location (Oliver, 1987; Enfors, 1992). The conformation, and in 
som e cases toxicity, o f a protein can vary in different cellular compartments. The B-subunit 
o f the heat-labile toxin (LT-B) of E. coli cannot form stable penlamcrs until it is exported 
and processed in the periplasm (Hirst et al., 1992). Also the immune response to proteins 
in different cellular compartments may vary (Gao et al., 1992), probably as a consequence 
o f the manner of antigen presentation. It is therefore important to identify the location of 
the PA produced by the constructs and assess the possible effects o f altering the cellular 
compartment of the heterologous protein.
Before the experiments to establish the location of PA could be carried out, the 
method of cell fractionation and verification o f the fractions with enzyme assays was tested 
using a periplasmically located protein: the B-subunit of the heat-labile toxin (LT-B) of 
E. coli.
Gram positive protein signal sequences arc known to function in Gram negative 
bacteria (Holt era/., 1982; Sarvas, 1986; Curtiss, 1990). As phagemid pORFl contains the 
B. anthracis PA gene signal sequence the PA protein might be exported into the periplasmic 
space. On the other hand, /3-galactosidase is a cytoplasmic protein and the /3-galactosidasc 
fusion protein produced by pVET4m would be expected to be located cytoplasmically.
If the location of the above proteins were shown to be as expected, their location 
could be correlated with the stability o f the proteins. One hypothesis that might explain the 
apparent stability of the PA produced from pORFl was that a periplasmic location protected 
it from cytoplasmic proteolytic enzymes. This is in contrast to the 63 kDa product from 
pVET4m which appears to be degraded. Strategics that might control this proteolysis 
include expression in protease negative mutants, sequence modifications, fusions to proteins 
that encourage inclusion body formation or prevent proteolysis, or secretion (Enfors, 1992). 
If the stability of full-length PA is due to its secretion, the 63 kDa fragment might also be
127
Chapter 6. Influence o f cellular location on expression
protected if it is exported and it might then accumulate in higher amounts. This would 
improve the potential for this construct as a vaccine strain. The 63 kDa fragment might be 
exported if fused to a signal sequence such as the sequence for LT-B.
<±2 Cellular location of LT-B in E. coli HB 101
Naturally expressed E. coli LT-B is known to be located pcriplasmically (Witholt 
el al., 1988). A plasmid containing the gene for LT-B (Schodel & Will, 1989) designated 
pFS2.2, contained the entire coding sequence for LT-B from a human isolate of E. coli 
(Clements et al., 1986) placed downstream of the lac promoter, in pUC19. In order to show  
that the method for fractionating the cells was working as expected, it was first shown that 
this known periplasmic protein could be detected as expected.
From earlier work to identify PA production from pPA26, it was known that 
sonication could breakdown PA into fragments. A method of fractionation of cells which 
used three freeze/thaw cycles to disrupt spheroplasts was therefore chosen. It is usual to 
confirm the fractionation of the cells by assaying for both a cytoplasmic and a periplasmic 
enzyme. /3-galactosidasc can be used as the cytoplasmic marker enzyme and alkaline 
phosphatase as the periplasmic marker enzyme. As the gene for /3-galactosidase has been 
deleted in some strains o f  E. coli to allow complementation, E. coli HB 101 was used for 
these studies. The appropriate plasmids were electroporated into E. coli HB 101. In order 
to induce large amounts o f the enzyme alkaline phosphatase, the bacteria can be grown in 
modified M9 media which contains low phosphate and so induces expression of alkaline 
phosphatase. Unfortunately PA production could not be identified by Western blotting when 
this media was used. It was therefore found necessary to grow the bacteria in L-broth. This 
still led to expression o f enough alkaline phosphatase to detect, although lower dilutions of 
the fractions were used in these assays than when E. coli was grown in modified M9 
medium.
E. coli HB 101 containing pFS2.2 were grown overnight in L-broth supplemented 
with ampicillin. The culture was incubated for 2 hours with IPTG (1 mM) and then 40 ml 
of the culture was fractionated according to the described method, but with a 30 minute 
incubation with the TES/lysozyme solution. When alkaline phosphatase was assayed in the 
periplasmic and cytoplasmic fractions it was found that 90% was located in the pcriplasmic 
fraction. /3-galactosidase assays showed that 97-99% of this enzyme was located in the
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cytoplasmic fractions. The membrane fractions were optically dense and so difficult to use 
in enzyme assays. The location of LT-B within these fractions was assessed using a GM, 
gangliosidc capture ELISA with an anti-LT-B MAb. This showed that approximately 10 
times more LT-B was present in the cytoplasmic fraction than the periplasmic fraction. This 
unexpected result was probably due to an anomaly of this cell fractionation method 
combined with the ability o f LT-B to aggregate at low ionic concentrations. It is known that 
LT-B is exported into the periplasm, proteolytically processed, folded, and only then 
assembled to form the pcntamcric structure that can bind with the GM, gangliosidc (Witholt 
et at., 1988; Hirst et at., 1992). Thus the LT-B detected by the ELISA must have been 
exported correctly before it could produce a positive reaction in the ELISA, even if it was 
apparently found in the cytoplasmic fraction. It is known that in low ionic conditions 
periplasmically located LT-B can form large aggregates. These might be co-sedimcnted with 
the spheroplasts and so appear to be within the cytoplasmic fraction (pers. comm. Dr T 
Hirst). The use o f only 30 mM Tris in the TES/lysozyme may mean that the LT-B was not 
solubilized. Therefore the experiment was repeated using 100 mM Tris in the 
TES/lysozyme. In this experiment 97% o f  the alkaline phosphatase activity was found to 
be located in the periplasmic fraction and 99% of the /3-galactosidase activity was found in 
the cytoplasmic fraction. Using the high ionic concentration buffer the LT-B was now 
identified as being mostly (103 times more) in the periplasmic fractions.
It was concluded that the cell fractionation method was working satisfactorily, but 
the solubility o f  the heterologous protein could cause anomalous results if aggregates were 
formed. This potential problem would be considered when analysing the location of PA.
6.3 Cellular location of PA expressed by pQRFl in E. coli and S. nnhimurium
The phagemid pORFl expressed lull-length PA with the B. anihracis PA gene signal 
sequence. It was shown to produce two closely spaced bands on Western blots (Figure 4.9) 
which possibly corresponded to the expected position of the gene product with and without 
a signal sequence. To evaluate the cellular location o f PA from this construct, the phagemid 
was electroporated into E. coli HB 101. Cultures were grown overnight and the bacteria 
were fractionated using high ionic (100 mM) Tns TES/lysozyme. Enzyme assays showed 
93% of alkaline phosphatase within the pcriplasmic fraction and 98% of /3-galactosidasc
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within the cytoplasmic fraction. When the fractions were subjected to SDS-PAGE and 
Western blotted the PA-83 was present mainly in the periplasmic fraction (Figure 6.1, Lanes 
pORF-P versus pORF-Q. On a Coomassic stained gel a band of the expected size was seen 
in the periplasmic fraction lane of pORFl extracts Figure 6.2).
Although it was not possible to confirm correct cell fractionation in 5. typhimurium 
with these enzyme assays, a cell fractionation preparation of 5. typhimurium SL 3261 
containing pORFl was made. Western blots and Coomassie stained gels are shown in 
Figure 6.3. Although the level of expression is apparently lower than in E. coli (a PA-83 
band cannot be clearly identified on the Coomassie stained gel), the Western blot confirms 
that PA is exported in 5. typhimurium and also shows a two banded appearance which 
supports this. In the periplasm the smaller o f  the two bands predominates whereas in the 
cytoplasm the larger o f the two bands was stronger (lower photograph. Figure 6.3).
6.4 Cellular location of PA from pVET4m
In a similar experiment it was shown that the 63 kDa fragment expressed from 
pVET4m was cytoplasmically located (data no; shown). This was expected for a 
/8-galactosidase fusion protein. It had been shown (Figure 5.6) that pVET4m expressed a 
63 kDa protein but also many smaller bands which represent degradanon products. To 
investigate the effect o f exporting the product o f p\'ET4m, it was decided to try and export 
the 63 kDa PA fragment by fusing it to a signal sequence. If the protein being produced by 
pVET4m could be protected from degradation, then 'he amount accumulaung might increase. 
This could improve the possibility o f this construe; inducing an immune response.
6.5 Construction of PS1G13
In order to evaluate the effect o f exporting the PA-63, the gene coding for this 
region was fused to a signal sequence. Although it was shown that the B. anthracis PA gene 
signal sequence was active in E. coli, it was felt that an E. coli signal sequence might be 
more effective at exporting a heterologous protein. The signal sequence for LT-B was 
present in plasmid pFS2.2 which has been shown u? export LT-B and to export LT-B fusion 
proteins into the periplasm o f both E. coli and 5 typhimurium (Schodel & Will, 1989). 
Plasmid pFS2.2 also had two Sacl sites with one located after the signal sequence and the 
other at the end o f the ORF o f LT-B (Figure 6.4). These allow the ORF to be removed and
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Plasmids pBlucscript II KS+, pSlG13 and pORFl were electroporated into E. coli 
HB 101. Clones containing the plasmids were identified. Cultures were grown overnight 
in 50 ml L-broth supplemented with ampicillin to AbsM„ of approximately 4. 30 ml o f each 
culture were fractionated as described in Chapter 2 using 1.5 ml of 100 m.VI Tris in the 
TES/lysozyme solution for 30 mins incubation. Each fraction was adjusted to 1.5 ml. The 
fractions were assayed for alkaline phosphatase and /3-galactosidase activity to verify the 
effectiveness o f the cell fractionation procedure. 50 fi\ of each fraction was mixed with 50 
H1 2xLB and boiled. The pORFl fractions were diluted 1:20. Bio-Rad prestained MW 
markers were loaded on the left o f the gel and apparent MWs are shown (kDa). The 
samples were subjected to SDS-PAGE through an 8% gel. transferred onto PVDF membrane, 
blocked with Blotto, incubated with mouse anti-PA MAbs followed by HRP-conjugatcd 
anti-mouse IgG which was detected with DAB.
pBS pBlucscript II KS+
pSIG13 signal sequence and 63 kDa PA fragment
pORF pORFl, lac promoter with PA signal sequence and full-length PA (l/20th
loaded compared to pBS and pSIG13)
P pcriplasmic fraction
C cytoplasmic fraction
M membrane fraction
Figure 6.1 Western blot to identify the cellular location of PA in E. c o li
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Figure 6.1 Western blot to identify the cellular location of PA in E. co li
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Figure 6.2 Coomassie stained gel showing cellular location of PA in E. c o li
E. coli HB 101 containing plasmids pBluescript II KS+, pSIG13 and pORFl were 
grown overnight. Cell fractions were assayed for alkaline phosphatase and /3-galactosidase 
activity to verify the effectiveness o f the cell fractionation procedure. 50 fi\ o f each fraction 
was mixed with 50 /A 2xLB and boiled. Bio-Rad prestained MW markers were loaded on 
the left o f the gel and apparent MWs are shown (kDa). The samples were loaded in 
different amounts to prevent overloading, in the ratio o f P:C:M o f 10:1:2.5 with the pORFl 
pcriplasmic fraction amount equivalent to 20 times the amount loaded on the respective 
Western blot lane (Figure 6.1). The samples were subjected to SDS-PAGE through an 8% 
gel and the gel was stained with Coomassic Blue.
pBS pBluescript II KS+
pSIG13 signal sequence and 63 kDa PA fragment
pORF pORFl, lac promoter with PA signal sequence and full-length PA
P periplasmic fraction
C cytoplasmic fraction
M membrane fraction
/
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Figure 6.2 Coomassic stained gel showing cellular location o f PA in E . c o li
132
Figure 6.3 Western blot and Coomassie stained gel showing cellular location o f pORFl 
expressed PA in S. typhimurium SL 3261
The top photograph show a Western blot and matching stained gel o f different 
cellular fractions of S. typhimurium SL 3261 / pORFl. The lower photograph shows an 
enlargement o f the bands present in the Western blot around the level o f  the 92 kDa MW 
marker.
S. typhimurium SL 3261 /  pORFl was grown overnight, without shaking, in 50 ml 
L-broth supplemented with ampicillin to an Abs«*, o f  1.4. 30 ml of culture was pelleted and 
the cells fractionated as described in Chapter 2 using 1.5 ml of 100 mM Tris in the 
TES/lysozyme solution for 30 mins incubation. Each fraction was made to 1-5 ml.
For the Western blot 10 pi o f each fraction was mixed with 90 pi lxLB and boiled. 
Bio-Rad prestained MW markers were loaded on the left o f the gel and apparent MWs are 
shown (kDa). 20 p\ o f all the 1:10 diluted samples were subjected to SDS-PAGE on an 8% 
gel, blotted onto PVDF membrane, blocked with Blotto, incubated with mouse anti-PA 
MAbs followed by HRP-conjugated anti-mouse IgG which was detected with DAB. The PA 
is mainly present in the periplasmic fraction, and in the enlargement it can be seen to have 
a lower MW than the PA band in the cytoplasm. This may represent the cleavage of the 
signal sequence.
For the Coomassie stained gel, Sigma 6H MW were run as standards. The samples 
were loaded in different amounts to prevent overloading, in the ratio of P:C:M of 10:1:5 with 
the cytoplasmic fraction amount equivalent to the amount loaded on the Western blot. The 
samples were separated by SDS-PAGE and the gel was stained with Coomassie. It is 
difficult to identify a band corresponding to the PA present.
P periplasmic fraction
C cytoplasmic fraction
M membrane fraction
/
Facing page 133
Chapter 6.
Influence o f cellular location on expression
bl°L and Coomassic stoincJ 8cl showing cellular location of pORFl expressed PA in S. typhimurutm SL 3261 ^
133
Figure 6.4 Construction of pSIG13
A. Physical map of plasmid pFS2.2 (Schodel & Will, 1989). a pUC19 based plasmid 
containing the open reading frame for the £. coli heat-labile enteroloxin B subunit 
(LT-B) expressed from the lac promoter.
B. A  blunt-ended fragment containing the 63 kDa coding region o f  PA was cut from 
the plasmid pVET4. This £coRV-5maI fragment contained a short region o f /3-gal 
and the trypsin cleavage site at the 5' end and the stop codon for the open reading 
frame at the 3' end. Plasmid pFS2.2 was cut with S ad  and gel purified. The S ad  
overhangs were blunted with Klenow and dephosphorylated with C1P. The pVET4 
fragment was ligated to the vector and electroporated into £. coli JM109. Colonies 
with the insert in the correct orientation were identified by PCR and restriction 
mapping. One clone with the correct restriction pattern »as designated pSIG13.
/
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Figure 6.4 Construction of pSIG13
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replaced by another ORF. In order to keep the insert of pVET4m in frame with the signal 
sequence, a blunt ended EcoRV - Sma\ fragment o f pVET4m was isolated from an agarose 
gel and Qiacx purified. S ad  digested pFS2.2 was blunted with Klenow and CIP treated to 
prevent recircularization o f the vector. The vector and insert were ligated and electroporated 
into E. coli JM 109. Clones with the insert in the correct orientation were identified by PCR 
and restriction mapping. A clone expressing PA of about 63 kDa size was identified and 
the plasmid designated pSIG13. The sequence at the vector-insert junction was verified by 
sequencing. The plasmid was electroporated into S. typhimurium LB 5010, recovered and 
electroporated into S. typhimurium SL 3261. Whole cell lysates were made and PA 
expression compared to pVET4m. This is shown in Figure 6.5, lanes 3 and 4. The 
calculated MW of the pSIG13 product was 67.6 kDa if the signal sequence was attached and
65.2 kDa if the signal sequence was cleaved. From the Western blot it appears that the 
pSIG13 product is slightly smaller than the predicted MW of the product from pVET4m 
(68.9 kDa) as expected; but whether the signal sequence is present cannot be resolved.
<L6 Cellular location of PA from pS|G13 in E. c o l i
The cellular location o f  PA expressed by pSIG13 is shown in Figure 6.1 and 
Figure 6.2. Most o f the PA was located with the membrane fraction. This may be because 
the protein is complexed with the membrane or because it was insoluble and so 
co-sedimented with the membrane fraction. The signal sequence did not appear to cause the 
protein to be exported into the pcriplasmic space.
6 J  Conclusions
The full-length PA expressed by pORFl was exported into the periplasm and it was 
concluded that the B. anthracis PA gene signal sequence is functional in E. coli. This was 
supported by the size difference seen between the PA in the cytoplasm and the periplasm. 
The signal sequence was uncleavcd in the small amount o f cytoplasmically located PA but 
the pcriplasmic PA was a smaller protein band and presumably lacked a signal sequence. 
The observation that most o f the PA has accumulated in the periplasm, in the signal peptide 
cleaved form, suggests that the protein is being rapidly and successfully secreted.
The 63 kDa fragment of PA expressed cytoplasmically as a /3-galactosidasc fusion 
from pVET4 is less stable as smaller MW products are visible on a Western blot. This
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S. typhimurium SL3261 alone or containing either pPA26, pVET4m or pSIG13 were 
cultured overnight in 5 ml L-broth supplemented with ampicillin if appropriate. The A b s^  
readings o f the cultures were used to adjust the amount pelleted so that equal cell numbers 
could be lysed. The pellets were resuspended in 100/il of lxL B  and boiled. 10/il o f the 
lysates were loaded onto a 8% gel with Bio-Rad prestained MW markers and subjected to 
SDS-PAGE, blotted onto PVDF membrane, blocked with Blotto, incubated »nth mouse 
anti-PA MAbs followed by HRP-conjugatcd anti-mouse IgG which was detected with DAB.
Bio-Rad MW markers (apparent MWs shown in kDa)
Lane 1 S. typhimurium SL 3261 
Lane 2 5. typhimurium SL 3261 /  pPA26 
Lane 3 S. typhimurium SL 3261 /  pVET4m 
Lane 4 S. typhimurium SL 3261 /  pSIG13
Figure 6.5 Western blot showing expression o f PA from pSIG13 in S. typhim urium
/
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Figure 6.5 Western blot showing expression of PA from pSIGl.3 in S. typhim urium
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degradation o f the expressed product could prevent the accumulation o f large amounts of 
heterologous protein and would also affect the immunogenicity o f the protein in as far as it 
reduces the possibility o f conformational epitopes being presented to the immune system. 
This degradation is not apparent in the PA expressed from pORFl (sec Figure 5.6). This 
could be due to it being exported into the periplasm where it would be subjected to a 
different protease environment than in the cytoplasm, or due to a stabilising effect o f the 20 
kDa fragment. The amount of immunorcactive protein present in the degradation product 
bands may account for more protein than is found in the 63 kDa band. It was hypothesised 
that exporting the 63 kDa fragment into the periplasm might reduce degradation. The 
strategy of fusing it to an E. coli signal sequence failed to lead to export of this heterologous 
antigen. In order to discuss this failure of export it is necessary to consider the mechanism 
of protein export in more detail.
Proteins are targeted for export by an N-terminal signal sequence. A comparison of 
signal sequences reveals a surprising lack of strict homology, except within the cleavage site, 
but signal sequences do show common areas of residue type (Gierasch, 1989). The 
N-terminal region carries a net positive charge and is followed by a hydrophobic core region. 
The cleavage site is usually 5-7 residues. The lack of specific patterns suggests that binding 
between the signal sequence and other proteins or membranes occurs in an unspecific way. 
Indeed, even random hydrophobic regions can act as a signal sequence (Schalz & Beckwith,
1990). On the other hand, it is known that point mutations can lead to loss o f function, 
usually when a charged residue is introduced within the hydrophobic core (Gicrasch, 1989).
Many genes associated with protein export have been characterised. This has led to 
a proposed model for export. The signal sequence targets the protein for export, but the 
protein must not be configured or folded in such a way that its translocation through the 
membrane is inhibited. Once through the membrane the cleavage site must be recognised 
by a signal peptidase so that the mature protein can be released (Gicrasch, 1989). The secB 
protein is thought to bind to the signal sequence of some protein chains as they form and 
have a 'chaperone' role in preventing early folding of the protein. Other proteins may also 
have an anti-folding role, such as Trigger Factor and the GroEL heat shock protein (Saier 
et al., 1989). The prccursor-SccB complex then binds to SccA  which recognises both 
regions of SccB and the signal sequence (Bassford et al., 1991). The SecA binds to the 
membrane complex of SccE/SecY and translocation occurs driven by ATP hydrolysis and
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the proton motive force (Bassford et al., 1991). SecD, SecF and the signal peptidases play 
a role in later steps o f the process (Schatz & Beckwith. 1990).
As many cytoplasmic proteins can be exported by attaching them to a signal 
sequence, it seems that the mature protein docs not contain any essential regions for export. 
However, features o f the mature protein can inhibit export. The amino acid sequence at the 
N-terminal end of the mature protein can influence export. A net positive charge in the first 
5 amino acids o f the mature protein can severely reduce export (Schatz & Beckwith, 1990) 
and it has been suggested that positively charged segments adjacent to signal sequences are 
preferentially retained on the cytoplasmic side o f the membrane (Saier et al. , 1989). 
Similarly, alterations to the amino acids at the C-terminal end o f  LT-B were found to delay 
or prevent its release from the membrane export mechanism and this may be due to changes 
in the hydrophobicity o f the molecule (Hirst et al., 1992). Jagusztyn-Krynicka et al. (1993) 
showed that addition o f a five amino acid C-terminal linker to E. coli L T-B, containing four 
hydrophobic amino acids, specified a protein that was not exported into the periplasm and 
was cytotoxic when induced.
With some proteins the inhibition of export is attributed to the protein adopting a 
secondary structure which is not compatible with translocation. The best-studied example 
of this is /3-galactosidase which enters the translocation mechanism but becomes embedded 
in the cell membrane and, at high levels, blocks the cell export mechanism (Schatz & 
Beckwith, 1990). The success of the translocation step depends on the export-competent 
conformation o f the protein. This is supported by the chaperone role o f SecB and other 
similar proteins which are thought to prevent the formation o f secondary structure in the 
protein which could prevent translocation. Also the close coupling of translation and export 
may be designed to decrease the potential for undesirable protein folding to occur.
Therefore protein export may be inhibited by ar inappropriate charge gradient, or 
by the protein adopting a secondary structure which is incompatible with translocation (Saier 
et al., 1989).
The signal sequences for PA and LT-B arc shown in Figure 6.6. The signal 
sequence for PA is 29 amino acids long. The average length of the signal sequence m 
Bacillus species is longer, usually between 30-40 amino acids. This is in comparison to an 
average length of 22 amino acids in other species (Sanaa. 1986; Watson, 1984). The PA 
signal peptide also has an N-tcrminal region which is rich in basic residues as has been
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Figure 6.6 Signal sequences of PA and LT-B
Amino acid sequence o f the signal sequences of E. coli LT-B and PA. Above each 
sequence the N-tcrminal positively charged amino acids are marked with V  and the 
predicted cleavage site with 'V. Below the sequence, hydrophobic amino acids in the signal 
sequence are marked with 'H'.
The E. coli signal sequence is from Yamamoto & Yokota (1983).
The PA signal sequence is from Welkos el al. (1988).
/
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reported for other Bacillus signal peptides (Sarvas, 1986). The cleavage site also conforms 
to the general pattern for prokaryotes. Cleavage occurs after an alanine residue as found in 
other Bacillus cleavage sites (Sarvas, 1986). Many Gram positive signal sequences are 
known to function satisfactorily in E. coli and from an analysis o f the signal sequence of PA 
it would appear to meet the criteria of a Gram negative signal sequence. Therefore it would 
be expected to target PA for export in E. coli. The fact that the full-length PA from pORFl 
is exported suggests that the PA is not only targeted for export but also is conformed in an 
export-competent structure.
The E. coli LT-B signal sequence is 21 amino acids long and conforms to the 
characteristic pattern for signal sequences of E. coli (Von Heijne, 1983; Watson, 1984; 
Oliver, 1987). The failure o f the sequence to effect the export o f the 63 kDa fragment of 
PA is therefore unlikely to be due to the sequence not targeting the protein for export. 
When the signal sequcnce-PA-63 fusion was made the amino acids downstream from the 
cleavage site were modified. An analysis o f the site in pSIG13 shows that it still conforms 
to the pattern of amino acids at cleavage sites (Von Heijne, 1983). Thus a failure of 
cleavage, which could produce a failure of export and the appearance o f the heterologous 
protein with the membrane fraction, seems unlikely. It appears that it is more likely to be 
the features of the mature protein, causing an inhibition of translocation, which is responsible 
for the failure of export.
It has been shown that export can be inhibited by a net positive charge close to 
(within about 3 amino acids) the N-terminal end o f the mature protein (Schatz & Beckwith, 
1990). In the fusion protein produced by pSIG13, the positively charged trypsin cleavage 
site RKKR is located 9 amino acids from the cleavage site. This may be too far from the 
cleavage site to affect export adversely but the presence o f  four positively charged amino 
acids may be enough to alter the charge profile in the region. This may cause this region 
to be retained on the cytoplasmic side o f the membrane (Saier et al.. 1989).
As reported, changes to the C-tcrminus of LT-B also adversely affected export (Hirst 
ei al., 1992; Jagusztyn-Krynicka, 1993). Another explanation for the failure of export o f PA 
expressed by pSIG13 is that the alterations to the PA molecule made it more hydrophobic 
and increased its potential for remaining bound to the membrane. As discussed in 
Section 5.7 the modifications to the C-tcrminal end o f PA to introduce restriction enzyme 
sites created a more hydrophobic C-tcrminal end to PA expressed by pVET4m. This same
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sequence occurs in pSlG13. It is possible that this alteration may interfere with export of 
the PA from pSIG 13. Although these features may affect export, precise modifications to 
both regions would have to be made to determine this. It is also possible that the failure of 
export is due to the structure adopted by the fragment of PA being incompatible with export.
In conclusion, although many proteins have been successfully exported by the 
addition o f a signal sequence (Smith et a i,  1987; Gierasch, 1989; Gao et a i,  1992), other 
workers have also found difficulties with export o f proteins by this method (Strahan, 1992; 
Su et al., 1992). The finding that PA from pSIG13 is detected mostly in the membrane 
fraction may suggest that it is fused with the membrane and so may have been targeted for 
export but failed to pass through the membrane and become stuck in the secretory 
mechanism. The signal sequence targets the protein chain for export but the configuration 
and charge distribution of the protein are important if it is to pass through the membrane.
Due to the failure to export 63 kDa PA into the periplasm, it is not possible to 
evaluate the effect o f the periplasmic environment on this protein fragment. Approaches to 
effect the export o f the fragment would include trying other signal sequences, fusions to the 
C-tcrminal end of an exported protein, or modifications to the C-terminal end of PA to affect 
its hydrophobicity. Alternatively, as it is known that the B. anthracis PA gene signal 
sequence can export the full-length PA protein, this might be the best starting place for a 
rational investigation o f export of PA fragments.
As it is known that cytoplasmic heterologous antigens can generate immune 
responses, export is not essential for a candidate vaccine strain. The reason for attempting 
to export the 63 kDa fragment of PA was to try and prevent proteolytic cleavage. As time 
docs not permit a thorough and rational evaluation of export, this approach will not be 
pursued.
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7.1 Introduction
Various plasmids and phagemids have been constructed to express all. or part of PA 
in S. typhimurium SL 3261. For various reasons, none of these recombinant organisms are 
ideal for use as a vaccine. They all rely on antibiotic selection to maintain the plasmids, the 
level o f expression is not very high and S. typhimurium SL 3261 only has a single 
attenuating lesion. However, before additional effort is put into solving these problems, it 
would be useful to show that PA expressed by S. typhimurium can induce protective immune 
responses. Even if only limited protection occurs with these preliminary recombinant 
organisms, further work to develop a vaccine strain would be justified.
Therefore the recombinant organisms must now be assessed to select the most 
suitable for animal studies of protection. The factors to be considered in the selection are 
the stability and level o f PA expression of the plasmids in vitro (as an indicator of their 
in vivo stability and expression). Additionally, some preliminary animal data was available 
from an experiment using three o f the plasmids. The potential stability of the plasmid in 
vivo can be assessed by culturing bacteria without antibiotic selection and then plating out 
the culture on plates, with and without antibiotic, so that the percentage of cells that are still 
antibiotic resistant can be evaluated. The level o f heterologous antigen expression may be 
evaluated at different phases of the growth cycle. As expression may be detrimental to the 
bacteria and so slow or prevent growth, expression can be related to growth curves for 
cultures. From all the available data the most suitable construct for animal testing can be 
identified.
7.2 Stability in vitro
The stability of the plasmids in \itro was determined by picking a colony from an 
ampicillin selection plate and resuspending the colony in 5 ml o f L-broth to form the stock 
culture. Part o f this was stored as a -70°C glycerol stock and used in subsequent 
experiments. In order to assess the percentage of bacteria in the stock culture that were 
antibiotic resistant. 100 p\ aliquots were plated onto L-agar or L-agar supplemented with 
ampicillin and the ratio o f colonics on each plate determined.
100 p\ of the stock culture was inoculated into media, with or without 
ampicillin/lPTG, and the cultures incubated overnight at 37°C. Different incubation 
conditions were used to give three different rates o f growth. The cultures were cither grown
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in a static sealed Universal (in 10 ml of media), a shaken sealed Universal (10 ml) or a 
shaken flask (50 ml). These different conditions led to increasing cell densities by the end 
of the growth phases reflected by the final A bs^  readings in the approximate ranges of 
0.3-0.5, 0.9-1.0and .1-4, respectively. After incubation the cultures were diluted in ice-cold 
PBS to give an approximate concentration of 104 cells/ml This dilution was plated out 
using a spiral plater onto L-agar plates or L-agar supplemented with ampicillin. The colony 
distribution was determined by a laser colony counter and the count computed by using BEN 
software. The ratio o f the colony counts on the plates was used to calculate the percentage 
o f colonies that were ampicillin resistant.
7.2.1 Stability in vitro Results
The results are shown in Table 7.1, A. (and discussed by vector group below).
pPA26 is pBR322 based and only expressed PA at low levels. It was relatively 
unstable in S. typhimurium SL 3261 when grown without antibiotic selection pressure with 
only 30% of bacteria retaining the plasmid after growth with aeration.
The pBluescript phagemids fall into two groups. The phagemid without an insert 
and the construct pCBl which only expresses PA at low levels, were quite stable with 95 
to 100% retaining the plasmid even after aerated growth in a flask. Constructs expressing 
higher levels o f PA were less stable. pORFl was the most unstable: only 1% of bacteria 
retained the phagemid even after a static incubation to low cell densities. In fact the starter 
culture made by picking a colony from an ampicillin selection plate was found to only 
contain 50% ampicillin resistant cells. It was possible to maintain the phagemid in L-broth 
supplemented with ampicillin, but as soon as selective pressure was relaxed the phagemid 
was rapidly lost. pVET4m was stable at low growth rates but lost at higher rates and 
pVET4n was almost as unstable as pORFl. Both o f these phagemids could be stabilised 
when grown with ampicillin in the media (see Table 7.1, B.)
The pTrc99A based plasmids, pNIKlm and pNIKln were shown to be stable even 
when grown in a shaken flask, but because of the presence of loci"1 on the plasmid, they 
would not be expressing PA. Thus they were also grown with IPTG induction, with and 
without ampicillin selection, to see if the plasmids became unstable when producing PA. 
As can be seen in Table 7.1, B. the plasmids remained stable under all growth conditions. 
This was surprising as it had previously been noted that pNIKln was very unstable without
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A. %  = the percentage still ampicillin resistant.
Abs = the final Absw„ after overnight culture.
ND = not done
5. typhimurium SL 3261 containing various plasmids was grown overnight 
in L-broth in one of three ways: statically in 10 ml in a sealed Universal, shaking 
in 10 ml in a sealed Universal, or shaking in 50 ml in a loosely scaled flask. The 
AbSt«, was measured and aliquots diluted in PBS to give approximately 104 cells /  
ml. 50 p \ o f these dilutions was plated out using a spiral plater on both l^agar and 
L-agar supplemented with ampicillin and the plates incubated overnight. The 
colonies present were scanned with a laser counter and the count computed using 
BEN software. The ratio o f colonics on the plates was used to find the percentage 
that were still ampicillin resistant.
B . In a similar experiment four o f the constructs were cultured in either 
l^broth, L-broth+Amp, l^broth+IPTG or L-broth+Amp+IPTG. The cultures were 
either grown statically in 10 ml in a sealed Universal or in 50 ml in a shaken flask. 
Only % still ampicillin resistant are shown.
'ND' = not done as these plasmids arc constitutivcly expressed in S. typhimurium.
C. S. typhimurium SL 3261 containing pNIKln plasmids designated C l or E5 
were grown as described above in shaken flasks containing cither 50 ml of L-broth 
or L-broth+IPTG. The % still ampicillin resistant is shown
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A.
1
S  typhim urium  S L S t a t i c  U n i v e r s a l S h a k e n  U n iv e r s a l S h a k e n  F la s k  L
3 2 6 1  c o n ta i n in g
5* A b s % A b s % A b s
¡1 p B l u e s c r i p t  II 9 5 0 . 3 4 9 0 0 . 9 3 9 5 2 .4
p P A 2 6 6 0 0 . 4 2 3 0 0 9 8 3 0 4 .3 5
p C B l 1 0 0 0 . 3 6 9 5 0 . 8 3 1 0 0 3 .2
p O R F l 1 0 . 3 9 N D N D N D N D
p V E T 4 m t o o 0 .4 1 1 0 0 . 9 7 1 3 .6
p V E T 4 n 1 0 0 . 4 7 5 0 . 9 7 1 3 .8 5  1
p N I K l m 1 0 0 0 . 4 7 9 0 0 . 9 8 5 4 .1
p N I K l n 9 0 0 . 4 3 8 5 0 . 9 8 0 3 .8
p S l G 1 3 2 5 0 . 3 2 10 0 .9 5 5 3 .4
B.
S. typ h i­
m urium  S L
L - b r o t h L - b r o t h  +  A m p r 1 + I P T G L - b r o th  ♦ 
IP T
A m p  ♦
G  ||
3 2 6 1
c o n ta i n in g S t a t i c S h a k e n S t a t i c S h a k e n S t a t i c S h a k e n S ta t i c S h a k e
p V E T 4 m 1 0 0 i 9 0 7 0 N D N D N D N D
p V E T 4 n 1 0 i 9 0 8 0 N D N D N D N D
p N I K l m 1 0 0 8 5 1 0 0 9 0 9 0 1 0 0 1 0 0 1 0 0
| p N I K l n 9 0 8 0 9 0 8 0 9 0 9 0 9 5 1 0 0
C.
S. typhim urium  S L  3 2 6 1  
c o n ta i n in g
L - b r o th L - b r o th  +  I P T G
p N I K l n  C l 6 5 5
p N I K l n  E 5 1 0 0 9 0
Table 7.1 Stability o f constructs
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antibiotic selection (Section 5.5.1). The possibility arose that by plating the original 
construct on ampicillin selection plates, to make the original starter culture, this had selected 
a mutation which stabilised the plasmid. To investigate this, the original -70°C stock of 
S. typhimurium SL 3261 / pNIKln (designated C l) was compared to the -70°C stock made 
from the ampicillin selection plate as described above (designated E5). The results are 
shown in Table 7.1, C. This shows that the two cultures behaved differently, with the 
original culture (C l) being more unstable, especially when induced. A Western blot showed 
that pNIKln E5 still expressed PA with the typical banding seen with pNIKln C l.
The pL'C19 based plasmid pSlG13 behaves in a similarly unstable manner to the 
pBluescript phagemids with the 6.3 kDa insert. pBluescript II has the same origin of 
replication as the pUC plasmids.
As plasmid stability, without antibiotic selection, was a problem with many o f  the 
clones, a method to stabilise the plasmids was investigated.
7.2.2 Mechanisms o f plasmid instability
Plasmids are lost (and hence unstable) when bacteria divide and produce a high 
incidence o f daughter cells without the plasmid. Low and intermediate copy number 
plasmids have specific active mechanisms to ensure stable inheritance of the plasmids such 
as the par region in the 5. typhimurium virulence plasmid (Tinge & Curtiss, 1990). This 
region can stabilise the segregation of low to moderate copy number plasmids but was 
deleterious to cells containing the locus on a high copy number pUC18 clone (Tinge & 
Curtiss, 1990).
The naturally high copy number plasmid ColEl is very stably maintained but without 
an analogous par region. Various models for the stability of high copy number plasmids 
have been suggested including purely random models where the likelihood o f a daughter cell 
not containing at least one o f the many plasmid copies is remote (Summers & Shcrratt, 
1984). However, it has been found that the commonly used cloning vectors derived from 
C olEl are lost from cultures at frequencies between 10': and 10‘5 per cell per generation 
(Summers & Sherratt, 1984). This is now known to be due to the formation of multimcrs 
of these plasmids which can randomly partition into only one daughter cell. During the 
construction of the commonly used cloning vectors a region of ColEl. called the cer locus, 
has been lost. This region is necessary for a recombination event that converts multimcis
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to monomers and so increases the chances that the plasmid copies will segregate evenly 
between the daughter cells. The cer region can be inserted back into cloning vectors and 
sometimes increase their stability (Summers & Shcrratt, 1984; Charles & Dougan, 1990).
The cer locus therefore offered the possibility o f stabilising the plasmids. pORFl 
was selected as a model because it produces the full-length PA which seems from Western 
blots to be fairly stable.
7.2.2.1 Construction of phagemid pORFlc
pORFlc was constructed by cloning the cer region into pORFl. The cer locus was 
available on the plasmid pKS492 (Prof. DJ Sherratt. University of Glasgow). "This plasmid 
was constructed by cloning the 279 bp Hpa\\-Taq\ cer fragment from ColEl into the AccI 
site o f pUC9 to form plasmid pKS490. The Bam\\\-Pst\ fragment from pKS490 was cloned 
in to the Bam\\\-Pst\ sites o f pUC18 to form plasmid pKS492.
The cer locus can be expected to function when it is cloned into any non-essential 
region of the plasmid. This can be accomplished by cloning the locus in the unique 
restriction sites downstream o f the coding region of the expressed gene. The cer locus does 
not need to be in a specific orientation. Phagemid pORFl was constructed by cloning a 
PCR product into the Kpn\-Bam\\\ sites of pBluescript II KS+. This removes many sites 
from the polylinker and leaves few unique sites downstream from the PA gene insert. After 
checking the sites available it was found that the cer locus could not be directly cloned into 
pORFl. A strategy was devised to sub-clone a BamH\-Hin&\\\ cer fragment from pKS492 
into BamHI-//indIII cut pACYC184. Then a BamHbXbal fragment can be cloned from the 
pACYC184/cer construct into BamHl-Xbal cut pORFl. This positions the cer locus 
approximately 135 bp downstream of the PA ORF stop codon.
The phagemid pORFlc was constructed and sequenced over the region of the cer 
insertion to verify that the construct was correct.
7 3-2,2 Stability Qf pORFlc
When pORFlc was grown in 10 ml L-broth in a shaken Universal tube, no amp' 
colonies could be found after an overnight culture. When grown in 10 ml L-broth 
supplemented with ampicillin in a shaken Universal tube the cultures grew slowly only
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reaching an Abs^, o f 0.3 overnight rather than the expected 1.0 (see Table 7.1 A) and only 
20-40% o f the cells grew on L-agar plates supplemented with ampicillin.
7,3 Growth curves and expression
Growth curves were determined by growing an overnight culture o f the appropriate 
organisms in L-broth supplemented with ampicillin. The A b s^  was used to estimate the cell 
density and then equal numbers o f cells were used to seed 100 ml of L-broth supplemented 
with ampicillin. This culture was grown at 37°C with shaking and the Abs^,, determined 
every hour until 10 hours and then at 24 hours. The log o f the Abs«,,, was plotted against 
time. Aliquots o f the culture were also removed each hour and used to make whole cell 
lysates. From the A b s^  readings the cell density was calculated and a known number of 
cells were run on SDS-PAGE and were subsequently Western blotted.
With the unstable clones it was found that as the cell density increased the ampicillin 
in the medium was depleted by /3-lactamase activity and this allowed plasmid free segregants 
to arise. This invalidated an analysis o f the growth curves as they did not represent the 
growth o f  plasmid-containing cells at all time points. Growth curves for the more stable 
clones are described below.
7-3.1 Growth curves and expression results
Growth curves for S. typhimurium SL 3261 alone or with phagemids pBluescript, 
pVET4m or pVET4n, are shown in Figure 7.1. S. typhimurium SL 3261 alone was able to 
grow faster than bacteria containing a phagemid. It was interesting to note that pBluescript 
caused a similar slowing o f growth to phagemids which also were expressing PA. This 
suggests that PA expression is not responsible for the slower growth and has no additional 
effect on growth. This was unexpected as it was presumed that the increased instability of 
these PA producing phagemids over pBluescript (Table 7.1, A .) was related to a toxic or 
metabolic load effect o f PA expression on the bacteria and would be reflected by a slower 
growth rate.
The amount o f  PA present in 5. typhimurium /  pVET4m and pVET4n was shown 
to be at approximately a constant level from 4 to 7 hours but was lower at 24 hours (results 
not shown). This might reflect degradation o f  the PA during the static growth phase.
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Figure 7.1 Growth curves for S. typhimurium SL 3261 alone, and with phagemids 
pBlucscript, pVET4m and pVET4n
Starter cultures were grown overnight from -70°C stocks in L-broth supplemented 
with ampicillin except for the S. typhimurium SL 3261 cultures. The A b s^  was used to 
estimate cell densities and the same number of cells added to flasks containing 100 ml of 
L-broth with ampicillin if required. The flasks were grown at 37°C in a shaking incubator 
and aliquots removed every hour for Abs*,, readings (0-10 hours and at 24 hours). If the 
A b s^  reading was greater than 1, a ten-fold dilution in L-broth was measured and the Abs«*, 
reading multiplied by 10. The log values of the Abs«*, readings were plotted against time.
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Figure 7.1 Growth curves for 5. typhimurium SL 3261 alone, and with phagemids 
pBlucscript, pVET4m and pVET4n
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1A Animal experiments
A preliminary animal experiment was carried out at CAMR in collaboration with Dr. 
P.C.B. Turnbull. Five groups o f  8-10 week old female BALB/c mice were used.
To test the effectiveness o f  aro S. typhimurium SL 3261 in protecting against 
homologous wild-type S. typhimurium SL 1344 challenge, a control group was given 0.2 ml 
PBS by intragastiic inoculation and another group given 0.2 ml of a suspension of 
S. typhimurium SL 3261 (approximately 109 cells). Both groups were challenged 21 days 
later with 0.2 ml of a suspension o f  S. typhimurium SL 1344 (approximately 4x10* cells) 
which ts equivalent to 250 LDW (O'Callaghan et a i, 1988).
The other three groups were intragastrically inoculated with 0.2 ml (approximately 
109 cells) o f preparations of S. typhimurium SL 3261 containing either pPA26, pVET4m or 
pSIG13 on days 1 and 14. Sera from these groups were obtained at day 28 and tested by 
both ELISA and Western blotting for the presence of antibodies to PA, and by Western 
blotting for antibodies against 5. typhimurium antigens. It was not possible to challenge the 
animats with B. anthracis in this experiment.
Positive anti-PA control serum was produced by inoculating one mouse with a 
mixture of the human PA vaccine supplemented with additional purified PA (50 ng PA in 
0.65 ml vaccine). Six 100 p\ doses of the mixture were given S/C on days 1, 2 , 3 ,  4, 7, 9 
and sera collected on day 14.
7:4,1 Results of animal experiment
The experiment to test the effectiveness of vaccination against challenge with 
S. typcimurium SL 1344 had to be prematurely terminated eight days after challenge. At this 
point only 2/11 of the control group had survived but 10/12 of the vaccinated group were 
alive. This was disappointing in that the vaccinated group should have been solidly 
protected. This may reflect inexperience in the intragastric inoculation procedure leading to 
a variation in the amount each mouse was inoculated with.
The anti-PA inhibition ELISA was carried out by Dr. P.C.B. Turnbull at CAMR and 
failed to show any anti-PA antibodies except in the positive control sera.
Western blotting showed that all groups vaccinated with 5. typhimurium SL 3261 had 
produced antibodies against Salmonella antigens, but only the positive control sera contained
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antibodies against PA. Blots for the control groups and S. typhimurium SL 3261 / pVET4m 
are shown in Figure 7.2. Sera from animals vaccinated with S. typhimurium SL 3261 
containing pPA26 and pSIG13 produced similar results to pVET4m (results not shown).
Therefore it was concluded that the S. typhimurium recombinants had induced an 
immune response against the Salmonella antigens, but using only the anti-PA antibody 
ELISA and Western blotting a response against the PA could not be detected.
7.5 Conclusions
Assuming that in vitro experiments can predict in vivo results, there is not an 
obvious recombinant that is ideal for in vivo evaluation. The use o f the pUC plasmid based 
phagemid pBluescript as the vector in many constructs may have created some problems. 
Although the phagemid is relatively stable (90-95%) it appears to have an inhibitory affect 
on growth rate compared to S. typhimurium SL 3261 alone (Figure 7.1). When PA is 
expressed at low levels in pBluescript (pC B l) the stability is unaffected (95-100%) but as 
expression o f PA is increased (pORFl) the stability is greatly reduced (1%). The level of 
expression o f PA from pCBl is low and for this reason it is not considered suitable as a 
vaccine candidate. pPA26 expresses less PA than pCBl and is also less stable. Expression 
of PA-63 (pVET4m and n) gives intermediate stability (ranging from 100% to 1% at 
different growth rates) but does not further inhibit growth in addition to pBluescript's effect. 
Stability was difficult to determine when the phagemids were able, in the later stages of 
growth, to evade the ampicillin selection pressure by presumably depleting the antibiotic 
concentration by 0-lactamase production. It therefore appears that pBluescript alone can 
affect the growth rate and that high expression of PA can diminish stability.
An attempt was made to stabilise the phagemid pORFl by inserting the cer locus 
after the PA ORF. This could not be shown to enhance the phagemid's stability and 
appeared to further inhibit growth when antibiotic selection pressure was applied although, 
by 12 hours, this selection pressure was evaded and plasmid free segregants were found. 
This approach to stabilising the plasmids was not pursued.
The pNIK plasmids were stable but did not produce a large amount o f  full-length 
product and they had an undefined character. It appears that some change has occurred that 
affects plasmid stability, but without preventing PA production. The isolation of this 
mutation probably reflects the unstable nature of pNIKln C l. As it was produced by
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Figure 7.2 Western blot with animal sera showing antibodies against Salmonella antigens 
and PA
Control (negative) sera was from mice orally administered PBS (labelled 'Control'). 
Two other groups of mice were orally inoculated with S. ryphimurium SL 3261 alone 
(labelled 'SL 3261’) or containing phagemid pVET4m (labelled 'SL 3261/pVET4'). Sera 
from mice in each group were pooled and 60 p\ diluted in 4 ml PBS. One mouse was 
vaccinated with PA, as described in the text, and 10 p\ o f this sera was mixed with 4 ml 
PBS (labelled 'PA vaccinated').
S. typhimurium SL 3261, with and without phagemid pVET4m, were used to make 
whole cell lysates for use as negative and positive controls for PA production and as positive 
controls for Salmonella antigens. Purified PA (83 kDa) was used as another positive control 
for PA. Bio-Rad prestained MW markers were run on each gel, the apparent MWs of the 
lop four markers are 92 kDa, 66 kDa, 45 kDa and 29 kDa. Samples were separated by SDS 
PAGE on 8% gels and blotted onto PVDF membrane. Four strips containing the same 
antigen lanes were incubated in the four different diluted animal sera. Antibodies bound to 
the strips were detected with HRP linked anti-mouse IgG antibodies and developed using 
DAB.
The control mice did not have antibodies against either Salmonella antigens or PA. 
The PA vaccinated mouse serum contained antibodies against both 63 kDa PA expressed by 
S. typhimurium (lane 2, PA vaccinated) and purified PA (lane 3, PA vaccinated) but did not 
have antibodies against Salmonella antigens (lane 1, PA vaccinated). The group vaccinated 
with 5. typhimurium SL 3261 only had anti-Salmonclla antigens (lanes 1 and 2, SL 3261), 
as did the group vaccinated with the S. typhimurium containing pVET4m (lanes 1 and 2, SL  
3261/pVET4). This suggested that the PA expressed by the S. typhimurium SL  
3261/pVET4m had not induced an anti-PA antibody response (no bands in lane 3, SL  
3261/pVET4).
Lane 1 Whole cell lysate of 5. typhimurium SL 3261
Lane 2 Whole cell lysate o f S. typhimurium SL  3261 /  pVET4m
Lane 3 Purified PA (83 kDa)
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Figure 7.2 Western blot with animal sera showing antibodies against Salmonella antigens and 
PA
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selecting on an ampicillin plate, without IPTG, it appears that the instability is not related 
to expression of PA but to some consequence o f the plasmid sequence. As pNIKlm does 
not show  the same instability two possibilities are apparent. Firstly, pNIKlm may have 
mutated in the same manner as pNIKIn E5, but at an earlier stage before the unstable 
construct was identified. Secondly, the sequence differences between pNIKlm and pNIKln 
may be responsible for the different stabilities. The two plasmids only have known sequence 
differences at the C-terminal o f the PA ORF with pNIKlm  having a 25 bp region which 
differs to a 48 bp region in pNIKln. If this region was responsible for the instability, a 
mutation could have occurred in this region in pNIKIn E5. Sequencing over this region 
would be possible, but even if a sequence change between pNIKIn C l and E5 could be 
found, it would not prove that such a change is responsible for the stability differences as 
other unidentified changes may be present elsewhere on the plasmid. Plasmid stability is 
more likely to be affected by mutations in the regulatory regions of the plasmid. Before 
these plasmids could be used for in vivo evaluation, it would be necessary to inactivate the 
lacl" gene and the constitutive expression o f PA might adversely affect stability.
As pSIG13 does not export the 63 kDa fragment as expected it would not seem to 
have any particular advantage over the pVET4 phagemids.
The animal experiment at CAMR showed that oral challenge with the constructs 
tested did not induce a detectable antibody response. This suggests that either other 
constructs or a different method o f  administration is needed to generate an immune response. 
The m ice responded to the S. typhimurium antigens suggesting that the vaccine strains were 
able to colonise and persist as expected.
The aim of the animal challenge experiments is to show if 5. typhimurium expressing 
PA can induce protective responses against challenge with B. anthracis. As it is known that 
full-length purified PA can induce protective responses when administered with adjuvants 
it seem s logical to choose a construct expressing full-length PA. pORFl is unstable, but for 
the purposes of this experiment, it might be stabilised by the administration of antibiotics. 
Antibiotic treatment has been shown to stabilise plasmids which otherwise are rapidly lost 
in vivo (Tarkka el al. , 1989; Molina & Parker, 1990). Therefore pORFl was selected as a 
recombinant for use in the animal study. Also, it was decided to evaluate pVET4m 
alongside pORFl. pVET4m was also unstable and so would be administered with antibiotic.
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It produces a product which varies in both size and cellular location to pORFl PA and so 
would act as a useful comparison to pORFl.
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8J. Introduction
Having selected S. typhimurium SL 3261 /  pORFl and S. typhimurium SL  3261 /  
pVET4m as the candidate recombinants for animal testing, experiments were designed to 
evaluate their protective potential. Neither of these recombinants were ideal as a candidate 
vaccine, but it was hoped to show that PA delivered to the immune system in 
S. typhimurium could induce protective immune responses. If the principle of vaccination 
using this system can be established then further work to stably express PA in 
S. typhimurium would be justified.
Firstly, it was necessary to confirm that mice vaccinated with an aro S. typhimurium 
could be successfully protected from wild type 5. typhimurium challenge. This would show 
that the culturing, storage and inoculation procedures were effective. Secondly, as it was 
known that the PA expressing constructs were unstable in vitro, a strategy was devised to 
enhance the possibility o f an immune response to the PA. Suitable positive and negative 
controls were included. Although serum anti-PA antibodies would indicate an immune 
response, it is known that they are not necessarily predictive of protection. There is no 
immunological test which is known to correlate with protection and so the vaccinated mice 
were challenged with B. anthracis in order to assess protective immunity.
8.2 Establishing the animal model
The animal model and vaccination techniques were established using two groups of 
10 BALB/c female mice aged 8-10 weeks. Prior to inoculations, the animals were lightly 
anaesthetized with halothane. All inoculations were given into the lower oesophagus 
(referred to as an 'intragastric inoculation') using a blunt-ended needle. The control group 
of animals was administered two doses o f 0.2 ml of PBS. 3 days apart. The other group was 
given 0.2 ml PBS containing 6 x l0 9 viable 5. typhimurium SL 3261 and 3 days later a second 
inoculation containing 4 x l0 9 S. typhimurium SL 3261. Viable counts were obtained 
retrospectively by serial dilutions o f the bacterial suspension and plating on appropriate 
media.
After 41 days both groups of mice were challenged with 0.2 ml of S. typhimurium 
SL 1344 resuspended in PBS, administered intragastrically. Assuming that the intragastric 
LD*, for BALB/c mice is 1.6 x 106 bacteria (O'Callaghan et at., 1988), serial dilutions and 
platings showed that the dose given contained 10* viable bacteria and so was equivalent to
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6TxLD5o. This challenge dose was smaller than the 250 LD*, intended. The mice were 
monitored for 14 days. Moribund animals were humanely euthanised and deaths were 
recorded twice a day.
4 o f the ten control animals died 6-7 days after challenge. None o f the vaccinated 
group died.
8 3  Mouse protection experiment
As the phagemid constructs are known to be unstable m vitro, two strategies were 
used to increase the possibility of inducing an immune response to the PA. Firstly, the IV 
route was used for administration o f the 5. typhimurium strains expressing PA as this 
delivers the bacteria to the reticulo-endothelial system by a more direct route and has given 
immune responses when oral administration has not (pers. comm. Prof. G. Dougan). 
Secondly, ampicillin was administered to some groups to stabilise the plasmid. This method 
has been reported by Tarkka et al. (1989) when 20 mg o f ampicilltn administered IP once 
a day was shown to stabilise an unstable plasmid. In preliminary experiments this dose was 
found to debilitate the mice and so the regimen used was to administer 7.5 mg ampicillin 
(50 p\ o f 150 mg/ml 'Penbriten' injectable) SC once a day for 7 days. With this regimen 
some mice developed soft swellings at the site o f injection by the end of the 7 day 
administration period but otherwise remained healthy. The efficacy o f this treatment in 
stabilising the constructs was assessed in suitable control groups.
The experimental groups are summarised in Table 8.1 and described below.
8.3.1 Group A - Negative controls
Group A were administered two IV doses of 5x10s S. typhimurium SL 3261 14 days 
apart and challenged with B. amhracis 45 days later. This penod o f time should allow  
clearance of the S. typhimurium from the mice and also allow non-specific immune responses 
to wane. Strugnell et al. (1992) with a P.69 antigen of Bordetella pertussis model showed 
that non-specific immunity affect protection at day 14 but not at day 28.
8.3x2 Groups B and C - Positive controls
It is known that vaccination o f  mice with PA mixed with adjuvant can protect 
against challenge with B. anthracis (Ivins et al., 1992). There is however great variation in
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Table 8.1 Mouse protection experiment - Groups
8-10 week old female BALB/c mice were assigned to one of ten groups designated 
by the letters A through J. Further details o f the treatments given to each group are 
contained in the text.
PA = Protective Antigen (from B. anthracis)
rPA = recombinant PA purified from E. coli /  pORFl
FIA = Freunds Incomplete Adjuvant
IV = intravenous
/
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Group Summary No.
mice
Procedures
A Negative controls,
S. typhimurium SL 3261
8 2 IV doses days 1 and 14
B PA vaccinated 8 3 doses IP PA + FIA (10-14 days 
apart)
C rPA vaccinated 8 3 doses IP rPA + FIA (10-14 days 
apart)
D S. typhimurium SL 3261 
/  pORFl + ampicillin
12 2 doses IV days 1 and 14. 
Ampicillin days 1-7 and 14-21
E S. typhimurium SL 3261 
/  pORFl
12 2 doses IV days 1 and 14
F S. typhimurium SL 3261 
/  pVET4m + ampicillin
12 2 doses IV days 1 and 14. 
Ampicillin days 1-7 and 14-21
G Stability after IV 
S. typhimurium SL 3261 
/pORFl + ampicillin
10 one dose IV and euthamse 3 mice on 
days 3, 8 and 14; with ampicillin 
days 1-7.
H Stability after IV 
S. typhimurium SL 3261 
/  pORFl without 
ampicillin
10 one dose IV and euthanise 3 mice on 
days 3, 8 and 14. 1
'
Stability after IV 
S. typhimurium SL 3261 
/  pVET4m + ampicillin
10 one dose IV and euthanise 3 mice on 
days 3, 8 and 14; with ampicillin j 
days 1-7.
J Stability after IV S. typhimurium SL 3261
10 one dose IV and euthanise 3 mice on 
days 3, 8 and 14.
Tabic 8.1 Mouse protection experiment - Groups
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the susceptibility o f different mice types to different strains o f  B. anthracis (Welkos et al., 
1986) and the adjuvant used can markedly alter the protective response (Ivins et al., 1992). 
It was not possible to find a literature report o f the amount of purified PA mixed with 
Freunds Incomplete Adjuvant (FIA) that would protect BALB/c mice against a specific 
B. anthracis Vollum challenge. From discussions w ith Dr ED Williamson (CBDE) it was 
decided to use an amount o f  PA/FIA that was known to produce a strong antibody response 
in BALB/c mice. Therefore Group B was inoculated with 3 IP doses o f 10 fig PA (purified 
from B. anthracis) mixed 50:50 with FIA, given 14 days apart. The PA expressed by the 
recombinant clones should be immunologically identical to the PA purified from 
B. anthracis. To verify this, recombinant PA (rPA) was purified from the periplasm o f  
E. coli containing phagemid pORFl. Group C were vaccinated in an identical manner to 
Group B but using 10 fig o f  rPA. Both groups were challenged with B. anthracis 18 days 
after the third vaccination.
The rPA was purified from the periplasm o f  E. coli JM 109 / pORFl. E. coli were 
used as, with IPTG induction, higher amounts o f rPA could be produced. By comparing 
bands on a Western blot with known amounts of PA, it was estimated that 7-12 mg of rPA 
could be recovered from one litre o f  culture medium. This equated to recovery o f about 
85% o f the rPA released from the cells by the lysozyme/EGTA treatment with 13% being 
left in solution after the ammonium sulphate precipitation step, and 2 % being lost in the 
ultracentrifugation step to remove LPS. The total expressed was therefore about 8-14 mg 
rPA/litre of induced culture.
8.3.3 Groups D. E and F - Vaccinated groups
In a similar manner to Group A  mice were inoculated IV on days 1 and 14 with 
5x10s S. typhimurium containing either pORFl or pVET4m. Inoculation doses were 
prepared as described in Chapter 2 from seed stocks o f  bacteria which had their aro and 
smooth LPS phenotypes confirmed. Groups D and E were inoculated with bacteria 
containing pORFl, and Group F was inoculated with pVET4m. Ampicillin was 
administered to Groups D and F. M ice were given 7.5 fig ampicillin SC for two periods o f  
seven days starting 4 hours before each of the IV inoculations. Space limitations prohibited 
the use of a non-ampicillin treated pVET4m group.
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8-3.4 Groups G, H. I and J - Stability in vivo
In order to assess the effect o f ampicillin in stabilising the plasmids in vivo. Groups 
G. H and I were inoculated once with S. lyphimurium containing the plasmids to parallel 
Groups D, E and F. Ampicillin was administered to Groups G and I (to parallel Groups D 
and F) for 7 days. Group J was inoculated with S. typhimurium SL 3261 without a construct 
to act as a control group. Three mice from each group were euthanised on days 3, 8 and 14 
and the livers and spleens removed and organ counts determined. At day 14, 10 ampicillin 
resistant colonies from Groups G and I were picked, grown overnight in L-broth 
supplemented with ampicillin and Western blotted to check for expression.
The organ counts for the S. typhimurium recombinants were lower than expected 
(10-102 instead o f  lOMO6, (O'Callaghan el al.. 1988)) and so few colonies were counted and 
the variation between the three mice at each sampling point was large. The data is presented 
as means without standard errors so that the trends can be identified. The mean total organ 
counts are shown in Figure 8.1. The percentage which were ampicillin resistant (amp1)  at 
each time point are shown below:
Percentage o f total organ count still ampicillin resistant
Day Group G. Group H. Group I.
Liver Spleen Liver Spleen Liver Spleen
3 30 70 10 30 100 100
8 70 40 1 2 80 80
14 40 30 0 0 20 20
At day 14, 9 out o f 10 amp' clones in group G and 8 o f 10 in Group I were still 
expressing PA.
From Figure 8.1 it can be seen that all the constructs (Groups G, H and 1) have 
lower organ counts than the S. typhimurium SL 3261 control group (Group J) by a factor o f 
102 to 105. The Group H count appears to be increasing faster than the other ampicillin 
treated groups and this may be correlated with the loss o f amp' (and by implication the 
plasmid) in this group. The ampicillin treatment seem s to have increased the percentage of
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Figure 8.1 Liver and Spleen counts for Groups G, H, I, and J.
Groups G, H, I and J were inoculated with 5x10s efu on day 0 as shown below.
Group No. in Group Vaccinated IV with:
G 10 S. typhimurium SL 3261 /  pORFl + ampicillin
H 10 S. typhimurium SL 3261 /  pORFl
I 10 S. typhimurium SL 3261 /  pVET4m + ampicillin
J 10 5. typhimurium SL 3261
Ampicillin was given to Groups G and I between day 0  and 7.
On days 3, 8 and 14 three mice in Groups G, H, I and J were euthanised and their 
livers and spleens removed ascptically and placed in ice-cold PBS. The organs were 
homogenised in 10 ml o f PBS for 2 minutes in a Stomacher. Aliquots o f the homogenised 
organs were plated on L-agar plates and L-agar plates supplemented with ampicillin (except 
for Group J). The plates were incubated overnight at 37°C and the colonies on each plate 
counted. From the plate counts the total organ count was determined. The log of the total 
organ count was plotted against time.
/
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UVER CO U N TS
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Figure 8.1 Liver and Spleen counts for Groups G, H, I. and J.
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amp' bacteria present. If Groups G and H are compared. Group G has 40-70% o f colonies 
amp' at day 8 , but only 1-2% o f the non-ampicillin treated Group H are amp'. Group I 
parallels the ampicillin treated group G, although there is no specific matched control group. 
The majority o f the amp' colonies are still expressing PA.
It was possible that the lower colonization rates seen could be the result o f the 
presence of the phagemid vector pBluescripl. To test if  this phagemid alone caused lower 
colonization, 4 mice were inoculated IV with 4 x 103 S. typhimurium SL 3261 / pBluescript 
II. They were not given ampicillin. After 7 days they were euthanised and total organ 
counts of both amp' and amp* S. typhimurium determined. The mean liver count was 1.95 
x 103 and the mean spleen count was 2.95 x 103. By day 7 all the bacteria had become 
ampicillin sensitive.
From Figure 8.1 it can be seen that this colonisation level lies above the PA 
expressing clones but falls short o f the S. typhimurium without a phagemid. This result 
suggests that either the presence o f  pBlucscript can cause a decrease in colonization or that 
the procedure o f electroporating the bacteria and selecting for recombinants has affected their 
ability to colonise. For instance electroporation and in vitro growth on agar plates could 
select for LPS mutants with reduced virulence, although the smooth phenotype o f the 
inoculating cultures was confirmed before use. All the bacteria recovered at day 7 were 
amp* which suggests that the in vivo instability of the PA expressing constructs may be due 
to the phagemid vector. This also indicates that the in vitro results showing that pBluescript 
was stable (Table 7.1) were not predictive o f in vivo results.
8.4 Antibody response
2 days before the challenge with B. anthracis, all mice in Groups A through F were 
tail bled and their sera pooled by groups. The level of anti-PA antibodies was determined 
by ELISA. Plates were coated with PA and the pooled serum double diluted across the plate 
starting at an initial dilution of 1/10. Anti-PA antibody was detected with HRP conjugated 
sheep anti-mouse IgG antibody developed with ABTS. Only groups B and C had detectable 
levels o f  anti-PA antibodies, and these groups had high litres o f 1/5,120 and 1/10,240 
respectively.
Each group's pooled sera were also used to probe Western blot strips containing 3 
lanes o f MW markers, PA and a whole cell lysate of S. typhimurium SL 3261 (results not
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shown). Groups B and C reacted with the PA as expected. Group C  also reacted with 
proteins in the S. typhimurium SL 3261 lane, possibly due to cross-reacting antibodies 
generated to the E. coli proteins contaminating the rPA preparation used in the group C 
immunisations. Groups D, E and F reacted strongly with the 5. typhimurium SL  3261 lane 
with a smeared appearance. This may be due to antibodies reacting with lipopolysaccharide. 
The serum from these three groups reacted faintly with PA suggesting that a low level o f  
anti-PA antibodies might be present, but presumably this level was below the detection limit 
of the ELISA.
8.5 Protective responses
The mice in Groups A through F were challenged with B. anthracis. The LDj,, for 
B. anthracis Vollum IB spores injected SC in BALB/cJ mice (Jackson Laboratory strain o f  
BALB/c mice) has been given as 6.6 spores (Welkos et al., 1986). It was assumed that 
BALB/c mice would behave in a similar manner. From previous experience at CBDE, it 
was expected that 10-20 LD% should lead to the death o f  all susceptible mice. A  
preliminary experiment was carried out to verify this.
8.5.1 Determination of B. anthracis challenge dose
B. anthracis Vollum IB spore stock was prepared as described and stored at 4°C  
To try to evaluate what the challenge dose would be in mice o f a similar weight to that o f  
the vaccinated mice at the time of their challenge (8 -10  weeks at the start and challenged 8 
weeks later, therefore age 16-18 weeks at challenge), 28 older mice were ordered. The only 
older mice that were available were ex-breeders which were potentially much older. 8 o f  
these mice were challenged SC with 0.25 ml of a diluted spore preparation which was 
subsequently determined to contain 341 cfu/ml. Thus the dose given was 85 cfu/mouse. 
This equates to approximately 13 LDW. All o f the mice died between 3V4 and 6 days after 
challenge with a mean time to death (ltd) o f 5.4 days. This is shown graphically in 
Figure 8.2.
The time to death was similar to the 4.1-6.7 days described by Welkos et al., (1986) 
for a dose of 60 spores. Two other doses were also evaluated; 10 mice were challenged with 
0.125 ml (38 efu, approximately equivalent to 6 LDW) and another 10 mice with 0.5 ml (150  
efu, approximately equivalent to 23 LDy,). In the low dose group two mice survived until
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Figure 8.2 Time to death o f mice challenged with three doses o f B. anthracis Vollum spores.
Old breeder BALB/c mice were obtained as the nearest approximation to the weight 
that the vaccinated mice would have achieved by the time o f the B. anthracis challenge. 8 
mice were given 85 efu SC (0.25 ml of a diluted B. anthracis Vollum IB spore preparation 
containing 341 cfu/ml) equivalent to 13 LD,0 (Welkos et a 1986). Subsequently, two 
groups of 10 mice were given .38 and 150 efu SC (0.125 ml and 0.5 ml o f a preparation 
containing .300 cfu/ml) equivalent to 6  LDM and 26 LD^. Deaths were recorded every 12 
hours and are plotted against time, thus for each day there are AM and PM data points.
Facing page 164
Chapter 8. Testing o f candidate recombinants
DAYS A FTE R  CHALLENGE CAM AND OV}
□  30  CFU 4- 0 5  CPU O 1 5 0  CFu
Figure 8.2 Time to death of mice challenged with three doses o f B. anthracis Vollum spores
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day nine when the experiment was terminated. In the high dose group, all the animals died 
with a time to death approximately 24 hours less than for the middle dose group. From this 
result, it was concluded that the dose required to kill all mice was between 38 and 85 cfu. 
It was decided to challenge the vaccinated and control mice with approximately 85 cfu.
S.5.2 Challenge of Groups A through F with B. anthracis
Mice in groups A through F were challenged with a SC injection of 0.25 ml of a 
B anthracis Vollum IB  spore preparation (369 cfu/ml). Thus each mouse was administered 
approximately 92 cfu (14 LD^). The percentage of mice surviving at each 12 hour interval 
after challenge is shown in the graph in Figure 8.3. The table in Figure 8.3 shows the mean 
time to death (ttd) for those animals dying in each Group and the percentage that died in 
each Group. As a protective response may be indicated by either animals surviving the 
challenge or an increase in the ttd, a protection index (PI) was derived that takes both factors 
into account. This data is also presented as separate group histograms o f  deaths occurring 
in each 12 hour period between days 3 and 8 after challenge in Figure 8.4.
Group A all died between 4 and 6 days after challenge with a mean time to death 
of 4.6 days and a PI o f  4.6. The ttd was less than the 5.4 day ttd of the group given 13 
LDm to determine the challenge dose. This may be due to the older ex-breeder mice used 
in the determination o f  challenge dose experiment having an age related immunity.
In Group B, 2 out o f 8  animals (25%) survived with 6 deaths occurring between 
days 4 and 7. The ttd was 5.2 and the PI was increased to 6.9.
In Group C, 3 out o f 8  animals (37.5%) survived with deaths between 3 and 6 days. 
Some animals in this group died earlier than other groups, but only by a maximum of 24 
hours. The ttd was 4.5 and the PI 7.2. Groups B and C give a similar picture of deaths and 
partial protection which suggests that the PA and rPA behave in a similar manner in 
inducing the same level o f protective immunity.
In Group D, 3 out o f 10 mice (30%) survived showing that this vaccine was able to 
protect some animals. Deaths occurred from 4 to 8 days with a ttd of 6 .2  and a PI of 8.9. 
This Group had the highest PI o f the Groups. The increased ttd may represent a partially 
protective immune response which subsequently became overwhelmed.
In group E, all 10 animals died with a mean ttd o f 5.5 days and a PI of 5.5, one 
greater than the PI for the control Group A. This lengthening o f the ttd from 4.6 days in
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Figure 8.3 Challenge with B. anthracis.
Groups o f  8-10 mice were challenged on day 0 with a SC injection of 0.25 ml of  
a diluted B. anthracis Vollum IB spore preparation (369 cfu/ml). Thus each mouse was 
administered approximately 92 efu which is equivalent to 14 L D ^ The mice were checked 
every 12 hours for 14 days.
The table opposite shows the mean time to death (ltd) for those animals which died 
in each Group and the percentage that died in each Group (%). A "protection index" (PI) 
was derived by the formula:
a d
% dead
*100
The percentage of mice surviving in each group at each 12 hour interval after 
challenge are shown in the graph.
Group No. in Group Vaccinated with:
A 8 5. typhimurium SL 3261 ||
B 8 PA + FIA I
C 8 rPA + FIA j
D 10 S. typhimurium SL 3261 / pORFl + ampicillin
E 10 S. typhimurium SL 3261 / pORFl
F 10 S. typhimurium SL 3261 / pVET4m + ampicillin
/
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Anthrax Challenge
A B C D E F
ttd 4.6 5.2 4.5 6 . 2 5.5 6.4
% 1 0 0 75 62.5 70 1 0 0 90
PI 4.6 6.9 7.2 8.9 5.5 7.1
Figure 8.3 Challenge with B. anthracis
166
Figure 8.4 Histograms of deaths occurring in each challenged group per 12 hour period.
A B. anthracis Vollum IB  spore stock was prepared as described. All mice in 
groups A through F were challenged with a SC injection of 0.25 ml o f a diluted spore 
preparation which was determined to contain 369 cfu/ml. Thus each mouse was 
administered approximately 92 cfu which is equivalent to 14 LD^. There were 8 mice in 
Groups A, B and C and 10 mice in Groups D, E and F.
From the data in Figure 8.3 the number o f mice which died in a given 12 hour 
period are plotted against time. There arc two time points for each day to reflect the two 
12 hour periods. All histograms show the same 3 to 8 day interval; no deaths occurred 
outside this interval.
Group No. in Group Vaccinated with:
A 8 S. typhimurium SL 3261
B 8 PA + FIA
C 8 rPA + FIA
D 10 S. typhimurium SL 3261 /  pORFl + ampicillin I
E
10 S. typhimurium SL 3261 /  pORFl
F
10 S. typhimurium SL 3261 /  pVET4m + ampicillin
/
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Figure 8.4 Histograms o f deaths occurring in each challenged group per 12 hour period.
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Group A may reflect a partial response. Although it is difficult to draw conclusions from 
limited numbers of animals, Group E may show a biphasic response (see Group E histogram. 
Figure 8.4) w ith  30% o f animals dying on day 4 and the other 70% dying between days 5 
to 7. This m ay reflect a non-responding group that dies early and a partially protected 
group.
In Group F, 1 animal (10%) survived with the deaths occurring between days 5 
and 7. As with Group D, the ttd was lengthened at 6.4 and the PI was 7.1.
8.5.3 Mouse passage of 5. tvphimurium /  pORFl to increase colonisation level
Section 8.3.4 describes the colonisation levels o f the clones in vivo. These were 
lower than expected compared to 5. typhimurium SL 3261 and an experiment was conducted 
to assess if mouse-passaging the recombinant strains would increase the colonization level. 
In Group G, at day 14, an ampicillin resistant colony was isolated that was shown to still be 
expressing PA. This colony was designated 'G3c' and was grown in L-broth supplemented 
with ampicillin to make a seed culture. When this was used to inoculate 2 mice IV with 
5x10s bacteria (and with 7 days of SC ampicillin injections) it was found that at day 7 the 
organ count for the livers and spleens o f these two mice were lOMO5 S. typhimurium and 
most bacteria were still ampr. O f the bacteria recovered, 20 o f  20 colonies were still aro' 
and 9 of 9  w ere still expressing full-length PA. It is therefore possible to enhance the 
colonization level and this clone could be used in further animal experiments.
&6 Conclusions
The initial experiment to establish the animal model was only partially successful 
as the wild-type S. typhimurium SL 1344 challenge dose was too low. It should have been 
greater so that all the control group died. The vaccinated group appeared to be protected 
from this challenge.
5. typhimurium infection can stimulate short-lived non-specific immune responses 
which can give protection against other infections such as Listeria but this protection is not 
apparent after 2 8  days (Killar & Eiscnstcin, 1985). It was not known if  S. typhimurium 
infection could provide non-specific protection against B. anthracis, but precautions were 
taken to limit this possibility. Thus the mice were not challenged until 6  weeks after 
vaccination to allow  the S. typhimurium to dear from the animals and non-specific immune
168
Chapter 8. Testing o f candidate recombinants
responses to diminish. The control animals (Group A), vaccinated with S. typhimurium SL 
3261 alone, did not show any protective response to B. anthracis challenge at this time.
PA is produced by B. anthracis and secreted into the medium. The full-length rPA 
produced in E. coli containing pORFl is exported into the periplasm. Western blotting 
suggested that denatured rPA behaved similarly to PA when reacting with both polyclonal 
and monoclonal antibodies. If antibody plays a role in protective immunity, neutralising 
antibody might only be induced when the PA was configured in the natural form so that 
conformational epitopes are present (Laver et al., 1990). If rPA did not configure in this 
manner then the epitopes required to induce neutralising antibody might not be present. The 
results from Groups B and C show that both PA and rPA produce the same level o f partial 
protective immunity. Although it is possible that the mechanism of the protective responses 
differ with the two antigens, it seems more likely that this result reflects the immunogenic 
similarity between the PA and rPA. The partial protection occurred in the presence of high 
anti-PA titres and confirms once again the antibody levels are not predictive o f  protection. 
If, as discussed below, protection can be T-cell mediated then the tertiary structure o f the 
antigen may not be so critical anyway as only short peptides o f PA would be presented on 
the surface o f antigen presenting cells.
When S. typhimurium expressing PA are used to vaccinate mice they are partially 
protected against B. anthracLs challenge. The 5. typhimurium SL 3261 / pORFl construct 
is very unstable and the phagemid is quickly lost. Phagcmid instability is a problem 
identified by many workers (Charles & Dougan, 1990; Curtiss, 1990). Ampicillin treatment 
can stabilise pORFl (Group D versus Group E) and this increases the level o f  protective 
immunity. The presence o f pORFl also leads to a much lower colonisation rate than 
S. typhimurium SL 3261 alone. This occurs even without selective pressure (Group E), and 
also with pBluescript alone and so it is not caused by PA expression. It may reflect a 
decreased ability o f the bacteria carrying the phagemids to survive the initial clearance 
mechanisms o f  the body and to adapt to intracellular life. The initial inactivation or 
clearance of S. typhimurium is by macrophages (Collins, 1974) and to survive within the 
macrophage the S. typhimurium must activate gene transcription. This activation involves 
many proteins and can be detected within 30-60 minutes after macrophage infection 
(Buchmcier & Hcffron, 1990; Alpuchc Aranda et at., 1992). It is possible that the presence 
of a high copy number plasmid could subvert cellular synthetic mechanisms from the rapid
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induction o f protein synthesis required for survival in the macrophage. In Section 7.3.1 it 
was shown that S. typhimurium SL 3261 containing pBluescript grew more slowly than 
S. typhimurium alone suggesting that the phagemid inhibited the bacteria in some way. An 
alternative possibility is that the manipulations (electroporation and selection in vitro) 
required to transform the bacteria with the phagemid select for strains of reduced virulence. 
This might involve changes in the LPS. Further work is needed to evaluate the mechanism 
of this effect. The LPS from the different strains could be examined for differences, also 
S. typhimurium /  pBluescript could be cured o f the phagemid and the in vivo colonisation 
of these two strains compared. This would show if  the host S. typhimurium was altered by 
the manipulations used to transform it or whether the presence o f the phagemid was required. 
If the manipulations to transform the bacteria lead to reduced virulence, then presumably this 
would be seen with all recombinant strains produced by these methods. This is not the case 
and so it seems more likely that it is an effect o f  the phagemid itself.
The immune responses occurred with a small number o f  bacteria and presumably 
with only a small amount o f  PA antigen being present. The fact that any immune response 
is produced with such a small antigen load reflects the effectiveness o f this system o f antigen 
presentation. The low level of organ colonization might be responsible for the production 
of only partial protection. It was possible to increase the colonization level o f the 
recombinant by animal passage. 5. typhimurium SL  3261 has been reported to have acquired 
additional attenuating lesions during laboratory passage as this strain still has reduced mouse 
virulence to its parent strain when the aroA lesion is complemented with a plasmid-borne 
aroA gene (Curtiss, 1990). If the process of electroporating any plasmid into S. typhimurium 
can select for attenuating lesions, such as LPS mutants, this process might be reversed by 
animal passage. Tarkka el al. (1989) have shown that the colonization rate of 
5. typhimurium SL 3261 containing a plasmid expressing an outer membrane protein of 
Neisseria meningitidis can be increased form 102 to 10s-106 by a single mouse passage. 
Although the mutations that arc acquired (or reversed) by this process are undefined, as long 
as the antigen is still expressed at the same level by the bacteria, then presumably more of  
the antigen is available to act as an immunogen. If protective responses are stronger this 
would suggest that research to increase the strain stability and level o f expression would be 
worthwhile. The recombinant organism designated 'G3c' (Section 8.5.3) colonises at the
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normal levels (103 times more bacteria), is stable with ampicillin selective pressure, and still 
produces PA. This might give significantly better immune responses.
The partial protection in Groups D and F occurs without ELISA detectable levels o f  
anti-PA antibody. It is possible that the mechanisms of protection varies between the 
methods o f  antigen presentation. Although anti-PA antibody levels may not be predictive 
o f protection, the antibody may have a role in protection when it is present. Titus in Groups 
B and C antibody and cell-mediated immunity (CMI) might combine to partially protect. 
It seems unlikely that the low levels o f anti-PA antibody that might be present in the 
S. typhimurium vaccinated Groups are capable of partially protecting and so another immune 
mechanism is probably responsible. S. typhimurium arc known to generate both CD4* and 
CD8* T-cells and these may play a role in protection against B. anthracis. To stimulate 
these cells the antigen is processed within antigen presenting cells (APC) into short peptides. 
These peptides are complexed with the major histocompatibility complex (MHC) I (for 
Tc-cells, CDS') and MHC II m olecules (for Th-cells, CD4*) and presented on the surface o f  
the APC where they are recognised by receptors on the appropriate T-cells (Germain, 1991). 
In this case the conformational structure o f the antigen is not important and fragments of the 
antigen, that contain relevant T-cell epitopes, can induce protective responses. The 
cytoplasmic 63 kDa fragment o f PA fused to a fragment o f /3-galactosidase expressed by 
pVET4m may not have the expected tertiary structure o f PA, yet it can induce protective 
responses (Group F).
Further work would be needed to investigate the cells responsible for protective 
immunity and T-cell activation studies may elucidate the mechanisms o f  protection.
In conclusion, recombinant PA behaves in an immunologically similar manner to 
B. anthracis PA when used as an immunogen. Both can induce high anti-PA antibody titres 
but these titres do not correlate with protection and the animals are only partially protected. 
S. typhimurium containing pBluescript and phagemids derived from this vector colonise the 
liver and spleen at lower levels that S. typhimurium SL 3261 alone. These phagemids arc 
unstable in vivo but can be partially stabilised by the concurrent administration o f ampicillin. 
The level o f  colonisation can be improved by mouse-passage. Even at low colonisation 
levels 5. typhimurium SL  3261 expressing PA can partially protect mice against SC 
challenge with a lethal dose of B. anthracis Vollum IB. This protection occurs in the 
absence o f  ELISA detectable anti-PA antibody and may be due to the induction of
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cell-mediated immune responses. S. typhimurium SL 3261 alone does not protect. These 
results demonstrate that PA expressed by S. typhimurium can induce protective immune 
responses in mice.
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Chapter 9. Discussion
9.1 Discussion
Anthrax is still a significant animal and human pathogen. Current methods of 
control and vaccination are expensive and time-consuming and the vaccines used in humans 
are reactogenic and of limited efficacy. Experimental work has shown that a strong immune 
response to one component o f the anthrax toxin. Protective Antigen, can protect against 
challenge (Ivins & Welkos, 1988). This allows a directed vaccine effort; with some diseases 
the protective antigens have not been identified, or a response to a number o f antigens are 
required to stimulate protective immunity. Adjuvanis that are approved for human use, when 
mixed with PA, are not able to stimulate strong protective immune responses even with 
multiple injections. The mechanism of protection against anthrax is not well understood, but 
cell-mediated responses are probably important (Ivins et al., 1992). The aluminium 
adjuvants used in the current human vaccines do not stimulate strong CMI (Gupta el al., 
1993) and this may account for the lack o f  effectiveness o f the human vaccines. If CMI is 
required, PA must be delivered in such a way as to generate this type of immunity. New  
adjuvants with the required capabilities are being developed but it is difficult to separate the 
adujvanting properties from the toxic side-effects (Gupta et al., 1993). Live vaccine vectors 
are capable o f  delivering antigens to the immune system and stimulating various immune 
responses including CMI. Attenuated salmoncllac are one such vector which offers this 
capability with the advantage o f  being orally active. PA could be expressed in this vector 
using recombinant DNA technology. The aim of this project was to develop a recombinant 
S. typhimurium that expressed PA and to evaluate the immune responses generated by this 
strain.
PA is poorly expressed from the native B. anthracis DNA sequences when these arc 
cloned into E. coli (Vodkin & Lcppla, 1983) and so the initial work concentrated on trying 
to improve expression. The effect on expression o f moving the B. anthracis DNA insert 
from the intermediate copy number pBR322 vector into the high copy number pBlucscript 
II was evaluated. It was found that there was a small increase in expression that was o f the 
same order o f  magnitude as the increase in plasmid copy number between the two clones. 
Next the B. anthracis promoter was replaced with the lac promoter. This increased 
expression to some extent and suggested that the B. anthracis promoter had been limiting 
expression, but that another factor might now be limiting. An analysis o f the promoter, RBS 
and predicted secondary mRNA structure failed to identify a problem, but an analysis o f the
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codon usage in the PA gene showed that this might be limiting translation. It was 
considered impractical to modify codon usage and so an alternative means to increase 
expression was considered. Although much is known about the regulation of transcription 
and translation the complexity o f  the interactions makes it difficult to predict the effect o f  
changes in the DNA sequences. Until a more rigorous method of evaluating the interwoven 
effects o f the DNA sequence is produced, constructs need to be made and tested.
The use o f  fusion proteins may increase expression as this uses the TIR of a 
characterised system. The 63 kDa C-terminal fragment of PA was selected as a candidate 
for expression as a fusion protein with part o f /3-galactosidase. /9-galactosidase has been 
used as an antigen in S. typhimurium and generates appropriate responses (Brown et aL, 
1987). The fusion protein was expressed at reasonable levels but seemed prone to 
proteolytic degradation. This susceptibility to degradation was shown to not be due to 
changes made to the C-terminal amino acid sequence. As the lac promoter is not a high 
level promoter, the 63 kDa fragment was expressed from the tre promoter. This construct 
produced only a small amount o f  full-length 63 kDa protein which from the appearance o f 
smaller immunoreactive protein bands, appeared unstable. The full-length PA was not 
degraded in this fashion. This could be due to its cellular location or to the presence of the 
20 kDa N-terminal fragment. The full-length PA was expected to be periplasmically located. 
The 20 kDa fragment is not required for the biological activity o f PA, but presumably has 
another function (Leppla, 1991). It might stabilise the PA and prevent proteolytic 
degradation or it could be required for the correct secretion and folding o f PA. Gram­
positive secreted proteases have a similar propeptide sequence (Wandcrsman, 1989). It has 
also been postulated that it is required to keep the 63 kDa fragment in a soluble form and 
prevent this hydrophobic protein from interacting with cell membranes during processing 
(Lcppla, 1991). It was decided to investigate the cellular location of the expressed PA and 
the effect o f the 20  kDa fragment.
The cellular location o f the full-length PA expressed from phagemid pORFl (which 
followed the B. ant hr acts signal sequence) was primarily in the periplasm. The 63 kDa 
fusion protein from pVET4m was located cytoplasmically and was less stable. An attempt 
to secrete this 63 kDa fusion protein into the periplasm with the LT-B signal sequence did 
not work. This may have been due to the protein fragment failing to pass through the
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transport mechanism and becoming trapped in the membrane. This suggests that the 20 kDa 
fragment (or other fusion protein) may be needed for correct export o f the PA protein.
Although none o f the recombinant strains are suitable vaccine candidates, as they 
express low levels o f PA, arc unstable and contain an ampicillin marker, they were used to 
show if protective immune responses against B. anthracis challenge could be generated by 
PA expressed in 5. typhimurium. The recombinant organisms were evaluated to select the 
most suitable for study. Their stability in vitro was measured as an indicator of in vivo 
stability. It was found that many o f  the clones were unstable without ampicillin selection 
present. Subsequently it was found that the in vitro results did not correlate well with the 
in vivo results, as was also noted by Molina & Parker (1990). When Salmonella invade the 
host cells and subsequently enter macrophages, they must rapidly express many different 
bacterial proteins to survive in the changing environment (Finlay el al., 1989). This ability 
to rapidly respond to external conditions is not tested during in vitro growth. An attempt 
to stabilise one o f the phagemids with the cer region was not successful. There are many 
mechanisms that might lead to plasmid instability and the cer region would only effect 
stability if  formation o f multimers was the cause o f plasmid loss (Summers & Sherratt, 
1984). pBlucscript was probably an inappropriate vector to use; it contains the intergenic 
region o f the f l  phage which has no function in a S. typhimurium vaccine vector and may 
impose additional negative selection pressure on phagemid stability. High copy number 
vectors can be unstable and reducing the copy number can increase the stability (Salas-Vidal 
el al., 1990). Thus the use of a lower copy number vector, such as pBR322, could improve 
stability. From all the available data two constructs, pORFl and pVET4m, were chosen for 
animal work. The choice of two constructs allowed a comparison between a periplasmically 
located full-length product and a cytoplasmically located fusion between 0-galactosidasc and 
the 63 kDa C-terminal fragment.
The vaccination o f  mice with PA, rPA and with the two S. typhimurium recombinant 
strains and their subsequent challenge with virulent B. anthracis was described. 
Recombinant PA was shown to induce partial protection comparable to native PA when both 
were purified and administered with adjuvant. This showed that the expressed rPA behaved 
in a similar immunological fashion to native PA. As it was known that the plasmids were 
unstable they were given IV and with daily ampicillin injections. Ampicillin was shown to 
enhance stability of the plasmids in vivo. The PA cxpressingS. typhimurium only colonised
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mice at low levels. 5. typhimurium containing only pBluescript also colonised at 
intermediate levels and the possible reasons were discussed. In vitro growth curves 
suggested that pBluescript alone could slow the growth of S. typhimurium SL 3261.
A mouse passaged strain (Section 8.5.3) was shown to colonise at levels equivalent 
to S. typhimurium and could be used in future studies. The mechanism of this change is 
unclear and could reflect an alteration in the host bacteria or a mutation in the phagemid. 
This could be resolved by recovering the phagemid and electroporating it back into the 
original stock o f  5. typhimurium SL .3261 and also curing the mouse passaged strain of pG3c 
and electroporating pORFl into the host. Both constructs could then be tested to identify 
if the ability to colonise at the higher level is conferred by the phagemid or host.
Although the S. typhimurium expressing PA only colonised at low levels (Group G 
colonised below 103 efu/organ against 10s for the carrier strain) they still managed to induce 
partial protective responses (30% survived in Group D). These protective responses occurred 
without detectable anti-PA antibody. Protective responses in the absence of detectable 
antibody have also been reported forS. typhimurium expressing the Circumsporozoite protein 
of mouse malaria (Flynn et al., 1990) and the P.69 antigen o f Bordetella pertussis (Strugncll 
et al., 1992). Although it is possible that a small amount o f high affinity antibody could 
have been undetected yet responsible for protection, it seems more likely that CM1 was 
generated by the constructs and contributed to protection. Only partial protection was 
obtained but this may be due to the low colonisation levels failing to provide sufficient 
quantity o f antigen to the immune system to generate strong responses. Also ampicillin was 
only administered for 7 days after the two IV injections and this regimen was shown to only 
partially stabilise the phagemid and the phagemids were lost at a higher rate once the 
antibiotic was stopped. Without ampicillin (Groups E and H) the phagemid was rapidly lost 
and all mice died when challenged. A construct that colonised at high levels and produced 
a high level o f PA over the full period o f bacterial persistence would be expected to induce 
better protection. The mouse-passaged phagemid pG3c may induce a higher level o f  
protection by presenting a larger mass o f antigen by virtue o f its higher colonisation level.
In summary, this work has investigated the problems o f stable high-level expression 
of the PA of B. anthracis in 5. typhimurium. Although the expression level was increased 
by changing the promoter, it appeared that other factors were limiting expression. The 
importance o f the 20 kDa N-tcrminal fragment for export was shown and the problems of
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exporting fragments o f the PA identified. Although a candidate vaccine strain was not 
produced in this work it has shown where the problems are and provides a basis for further 
expression studies. It was shown that in principal PA expressed by S. typhimurium can 
induce protective responses, even when only low colonisation occurs. This system may also 
help identify the mechanism of protection against anthrax. These results show the potential 
for this approach and suggests that further work to stabilise and increase the expression of 
PA would be worthwhile.
Various general strategies are available for expression of toxic or unstable antigens 
and som e of these are shown in Table 9.1. An antigen can be expressed in an insoluble 
form within the cytoplasm or it can be exported from the cytoplasm where it may be more 
stable (Enfors, 1992). The host strain may influence stability and protease negative mutants 
may degrade foreign proteins less. Although the full-length native protein may be required 
for some expression studies, for vaccine work it may be possible to modify the antigen so 
that it is no longer toxic or unstable yet still immunogenic (Curtiss, 1990). Many different 
systems arc available for this type o f protein engineering and some have been discussed in 
Chapter 5.
Plasmid expression offers the-possibility o f multiple gene copies but the plasmids 
can be unstable and often contain antibiotic markers. The problem of antibiotic markers can 
be overcome to som e extent by the use o f  balanced lethal mutations and various systems 
have been described (Nakayama et al., 1988; Fulginiti et al., 1992). If plasmids are used 
they must be stable and this work has suggested that pBluescript was not suitable as it was 
found to impair colonisation levels itself. Other plasmids may be more successful. If 
plasmid expression is still unsuitable, the gene can be integrated into the chromosome and 
this can be coupled with the introduction o f  further attenuating lesions (Hone et al., 1988b; 
Strugnell et al., 1990). Only a single copy is usually chromosomally integrated and so a 
suitable promoter that produces sufficient protein must be used.
There arc many classes o f promoters that can be used in both plasmids and 
chromosomal integration. If a protein is toxic then high level constitutive expression may 
be impossible. Alternatively a promoter can be used which only induces expression in 
particular environments; especially the antigen presenting macrophage. This allows the 
bacteria to colonise at normal levels and only then is expression switched on. Even if 
bacterial death occurs, due to the toxic nature o f the antigen, the antigen will be presented
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System Comments References
Engineer antigen, or its 
form or location, so not 
toxic to the cell.
Express antigen as 
fragments or just express 
epitopes. Can alter 
cellular compartment of  
antigen or express as 
fusions or insoluble 
inclusions.
Charles & Dougan, 1990; 
Curtiss, 1990; Stocker, 
1990; Enfors, 1992.
Select different carrier 
strain.
Different strains may 
degrade antigens 
differently, eg htrA 
mutants.
Johnson et al., 1991; 
Chatfield et al., 1992; 
Strahan et al., 1992.
Chromosomal integration 
to stabilise inserted DNA.
Stabilises gene but single 
copy number.
Hone et al., 1988b; 
Strugnell et al., 1990; 
Flynn et al., 1990.
Inducible promoters 
express antigen in vivo.
Use o f anaerobic or 
macrophage inducible 
promoters to drive 
expression in particular 
environments.
Buchmeier & Heffron, 
1990; Oxer et al., 1991; 
Chatfield et al., 1992.
Balanced lethal mutations 
to stabilise plasmids.
asd or pur on plasmid 
complements deleted gene 
in chromosome.
Nakayama et al., 1988; 
Fulginiti et al., 1992.
Inverted promoters. Only a proportion o f cell 
switch on expression at 
any one time.
Yan et al., 1990.
Repressor on incompatible 
plasmid.
Repressor lost in vivo as 
plasmid free segregants 
occur and so only a 
proportion o f cells 
constitutively express 
antigen.
Ervin et al., 1992.
Table 9.1 Systems for stable expression of antigens
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to the immune system by the macrophage. Expression may result in the death o f the bacteria 
and so the persistence phase o f S. typhimurium colonisation may be lost. The level o f  the 
immune response generated is related to the persistence phase and so this may moderate the 
response. In this case the bacteria may function more as an antigen delivery vehicle than 
as a living vaccine with a persistence phase and long term antigen presentation. Alternative 
promoter systems achieve a similar effect by ensuring that only a proportion of the bacteria 
switch to expressing the antigen to high levels at any one time and so if this induces 
bacterial death the non-expressing bacteria survive and persist (Yan et al., 1990; Ervin et al.,
1992).
With regard to PA, the most successful expression was achieved by exporting the 
full-length product into the periplasm. The instability o f the phagemid and low colonisation 
levels o f  the bacteria may be due to the pBluescript vector used. The lac promoter could 
be replaced with a stronger promoter to identify if this is limiting expression in the full- 
length construct (the tre promoter was only used with the 63 kDa fragment). If this has little 
effect then other factors, such as codon usage, may be important. Replacing the coding 
sequence of the similarly AT rich tetanus toxin C-fragment with a sequence optimized for 
E. coli codon usage increased expression levels (Makoff et al., 1989). The level of 
expression could also be assessed in periplasmic protease mutants (such as htrA (Johnson et 
al., 1991; Chatfield et al., 1992)) as these may degrade secreted proteins less than wild-type 
strains. Alternatively, efforts could be made to express PA as an insoluble fusion protein 
within cytoplasmic inclusion bodies. This work suggests that the 63 kDa fragment o f  PA 
may not be a suitable candidate for expression, but other fragments might be both stably 
expressed and immunogenic. Protective epitopes have not yet been identified for PA and 
so it would be necessary to clone different fragments o f PA and assess both expression and 
their protective effect. Until the mechanism o f protection against B. anthracis is established, 
and a test devised which correlates with protection, it will be necessary to test such 
constructs for their ability to induce protective immunity. Inducible promoters, such as the 
anaerobic promoter nirB or macrophage inducible promoters, could help stabilise a plasmid 
as the protein would only be expressed after bacterial invasion in an immunogenic site. If 
the plasmids are still unstable, chromosomal integration could be considered although a 
suitable high level promoter will be needed.
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The results obtained in this study suggest that protection against challenge with 
B. anthracis can occur in the absence o f detectable anti-PA IgG antibody. S. typhimurium 
is known to induce CMI and the relevance o f this to protection could be studied. An initial 
approach would be to carry out T-cell proliferation assays on spleen cells from vaccinated 
animals. If it can be shown that T-cells proliferate in response to PA, then the cell class 
involved can be identified. Their relevance to protection could be shown by depleting the 
identified T-cell class in vaccinated mice using specific monoclonal antibodies and seeing 
if protection was impaired. Additionally it may be possible to show that a particular T-cell 
clone can adoptively protect unvaccinated mice.
In conclusion, this work has identified a promising approach to developing a new 
anthrax vaccine. S. typhimurium expressing PA  can induce protective responses against 
challenge with B. anthracis spores. Although work is needed to increase the expression level 
of PA, stabilise the inserted genetic material and ensure suitable colonisation levels these 
problems should not be insurmountable and various approaches to solving them have been 
identified. With further work, the goal o f developing an oral vaccine is achievable.
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ANNEX A - Reference Guide to plasmids
P ' -  prom oter
PA -  Native PA prom oter 
la c - E. coll p rom oter 
tre -  hybrid prom oter
slg  -  signal seq u en ce ,
Native PA signal sequence  In all but 
plasm id pSIG13 which h a s  the  E. coll 
LT-B signal sequence .
car-  part Ion Ing region from ColE1 
M -  modified C -term lnus
A - 1
Name Vector
/
01 PA ORFp 20kDa 63kDa
pPA26 pbm  - -
pCB1
pORF1
cer
p O R FIc
lac M
pVET4n pBluescript la c i;
pN IK Im PTrc99A - ---------- -----------------888888888888 M
oN IK In oTrc99A tr c
•
pUC19 la C
ala II
pSIG13
■9 $05588888888^ IVI
l
